document incorporate reference specify portion registrant proxy statement file commission pursuant regulation connection registrant annual meeting stockholder hold incorporate reference iii report base closing price share june exclude share registrant common stock hold executive officer director stockholder ownership exceed registrant common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registrantgilead sciences inc annual report table content item business item risk factor item unresolved staff comment item property item legal proceeding item safety disclosure item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service item exhibit financial statement schedule signature right trademark copyright trade name business include follow gilead gilead sciences sovaldi truvada harvoni complera eviplera stribild viread letairis ranexa ambisome zydelig emtriva tybost hepsera vitekta cayston volibris rapiscan atripla register trademark belong bristolmyer squibb gilead sciences llc lexiscan register trademark belong astella llc macugen register trademark belong eyetech inc sustiva register trademark bristolmyers squibb pharma company tamiflu register trademark belong hoffmannla roche inc report include trademark service mark trade name companiesthis annual report include section entitle management discussion analysis financial condition result operation contain forwardlooke statement future event future result subject safe harbor create security act amend securities act securities exchange act amended exchange act word expect anticipate target goal project hope intend plan believe seek estimate continue variation word similar expression intend identify forwardlooke statement addition statement statement historical fact forward look statement include statement overall trend operate cost revenue trend liquidity capital need statement expectation belief future plan strategy anticipate event trend similar expression base forwardlooke statement current expectation future event statement guarantee future performance involve risk uncertainty assumption difficult predict actual result differ materially suggest forwardlooke statement reason include identify risk factor beginning give risk uncertainty caution place undue reliance forward look statement forwardlooke statement include report date hereof require federal security law rule regulation securities exchange commission sec undertake specifically decline obligation update statement publicly announce result revision forwardlooke statement distribution report result new information future event change assumption item business overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world gilead primary area focus include human immunodeficiency virus hiv liver disease chronic hepatitis virus hcv infection chronic hepatitis virus hbv infection oncology inflammation cardiovascular respiratory condition operation country worldwide headquarters foster city california continue add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy highlight past year bring bestinclass drug market advanced standard care offering enhance mode delivery convenient treatment regimen improve resistance profile reduce effect great efficacy liver disease area receive approval food drug administration fda european commission harvoni oncedaily single tablet regimen treatment hcv genotype infection adult harvoni combine nsa inhibitor ledipasvir nucleotide analog polymerase inhibitor sofosbuvir approve tradename sovaldi december approval harvoni represent significant improvement treatment paradigm majority hcv genotype infect patient eliminate need pegylate interferon pegifn injection ribavirin rbv clinical study harvoni demonstrate high cure rate week hiv area submit new drug application nda oncedaily single tablet regimen contain elvitegravir cobicistat emtricitabine tenofovir alafenamide taf ecftaf treatment hiv infection adult receive approval united states tybost cobicistat vitekta elvitegravir component stribild oncology area receive approval zydelig idelalisib firstinclass target oral inhibitor pik delta combination rituximab treatment certain patient chronic lymphocytic leukemia cll small lymphocytic lymphoma sll follicular lymphoma common type indolent nonhodgkin lymphoma inhl advanced research development pipeline active clinical study end phase clinical trial addition advance treatment option therapeutic area enable access medication people need world sign nonexclusive license agreement seven indiabase generic drug company manufacture sovaldi harvoni distribution develop country announce agreement medicine patent pool mpp mpp sublicense taf generic drug company india china manufacturing distribution develop country effort extend ongoing program enable access people resourcelimite part world disease like hiv hcv affect high number individual hiv program goal ensure hiv patient choose single tablet regiman right single tablet regimen allow patient adhere fully suppressive course therapy easily consistently critical successful management disease focus development new hiv medicine coformulation product complete regimen launch stribild united states europe compleraeviplera emtricitabine mgrilpivirine mgtenofovir disoproxil fumarate atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate single tablet regimen available treatment hiv advance development new single tablet regimen ecftaf treatment hiv infection adult marketing application ecftaf pende united states european union fda establish target review date prescription drug user fee act november phase clinical study demonstrate patient take ecftaf experience favorable renal bone safety compare stribild patient conduct phase clinical trial fixeddose coformulation taf emtricitabine agreement janssen ireland janssen tibotec pharmaceutical evaluate single tablet regimen taf cobicistat darunavir emtricitabine treatment hiv infection amend agreement janssen collaborate single tablet regimen rilpivirine emtricitabine taf receive fda approval tybost pharmacokinetic enhancer boost blood level certain hiv medicine tybost indicate boost agent hiv protease inhibitor atazanavir daily darunavir daily antiretroviral combination therapy adult hiv infection fda approve vitekta integrase inhibitor treatment hiv infection adult know mutation associate resistance elvitegravir vitekta indicate use hiv treatment regimen include ritonavirbooste protease inhibitor liver disease goal advance treatment option standard care underserve hcv market receive approval sovaldi treatment hcv component combination antiviral treatment regimen sovaldi efficacy establish patient hcv genotype infection united states europe genotype infection europe include hepatocellular carcinoma meeting milan criterion await liver transplantation hcvhiv coinfection compare prior standard care week sovaldi shorten duration treatment week reduce completely eliminate need pegifn injection certain viral genotype population receive fda european commission approval harvoni oncedaily single tablet regimen treatment hcv genotype infect patient prevalent genotype united states harvoni combine nsa inhibitor ledipasvir sofosbuvir indicate week treatment duration depend prior treatment history cirrhosis status baseline viral load eliminate need pegifn rbv challenge tolerate marketing application sofosbuvir fixeddose combination ledipasvir sofosbuvir pende japan long term goal develop oral therapy hcv patient genotype fixeddose combination sofosbuvir pangenotypic nsa inhibitor currently phase clinical trial evaluate single tablet regimen sofosbuvir phase trial potential treatment hcv genotype infect patient week evaluate taf treatment hbv complete enrollment phase clinical trial conduct phase clinical study tarmogen cell immunity stimulator oral tlr agonist evaluate potential cure hbv evaluate simtuzumab nonalcoholic steatohepatitis nash phase clinical trial december enter agreement phenex pharmaceuticals phenex acquire phenexs farnesoid receptor fxr program comprise small molecule fxr agonist treatment liver disease include nash oncology inflammation oncology area receive fda european commission approval zydelig idelalisib firstinclass pik delta inhibitor combination rituximab treatment patient certain blood cancer fourth quarter initiate phase clinical study evaluate idelalisib treatment patient inhl frontline treatment patient cll december enter exclusive license agreement ono pharmaceutical ltd development commercialization ono know oral bruton tyrosine kinase inhibitor treatment bcell malignancy disease cardiovascular release positive result ambition study randomize doubleblind multicenter study firstline combination therapy letairis ambrisentan tadalafil patient pulmonary arterial hypertension conduct collaboration glaxosmithkline plc ambition firstline treatment pulmonary arterial hypertension combination ambrisentan tadalafil reduce risk clinical failure percent compare pooled ambrisentan tadalafil monotherapy arm combination statistically significant versus individual ambrisentan tadalafil monotherapy group primary endpoint file supplemental nda united states cover use ambrisentan combination tadalafil product hiv stribild oral formulation dose day treatment hiv infection treatmentnaive adult stribild complete single tablet regimen treatment hiv fixeddose combination antiretroviral medication vitekta tybost viread emtriva emtricitabine stribild approve fda august european commission compleraeviplera oral formulation dose day treatment hiv infection adult product market united states complera europe eviplera second complete single tablet regimen treatment hiv fixeddose combination antiretroviral medication viread emtriva janssen nonnucleoside reverse transcriptase inhibitor edurant rilpivirine atripla oral formulation dose day treatment hiv infection adult atripla single tablet regimen hiv intend standalone therapy combination antiretroviral fixeddose combination antiretroviral medication viread emtriva bristolmyers squibb company bms nonnucleoside reverse transcriptase inhibitor sustiva efavirenz truvada emtricitabine tenofovir disoproxil fumarate oral formulation dose day combination therapy treat hiv infection adult fixeddose combination antiretroviral medication viread emtriva fda approve truvada combination safe sex practice reduce risk sexually acquire hiv infection adult high risk strategy call preexposure prophylaxis prep viread oral formulation nucleotide analog reverse transcriptase inhibitor dose day combination therapy treat hiv infection patient year age old european commission approve use viread combination antiretroviral agent treatment hiv infect adolescent patient age year nucleoside reverse transcriptase inhibitor resistance toxicity precluding use firstline pediatric agent viread approve treatment chronic hbv emtriva oral formulation nucleoside analog reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult united states europe emtriva available oral solution approve combination therapy treat hiv infection child tybost pharmacokinetic enhancer dose day boost blood level certain hiv medicine tybost indicate boost agent hiv protease inhibitor atazanavir darunavir antiretroviral combination therapy adult hiv infection vitekta oral formulation integrase inhibitor dose day combination therapy treat hiv infection adult know mutation associate resistance elvitegravir active ingredient vitekta vitekta indicate use hiv treatment regimen include ritonavirbooste protease inhibitor liver disease harvoni oral formulation nsa inhibitor nucleotide analog polymerase inhibitor dose day treatment hcv genotype infection adult harvoni approve fda october european commission november europe harvoni indicate certain patient hcv genotype infection hcv genotype infection cirrhosis andor prior treatment failure hcvhiv coinfection sovaldi oral formulation nucleotide analog polymerase inhibitor dose day treatment hcv component combination antiviral treatment regiman sovaldi approve fda december european commission january sovaldis efficacy establish patient hcv genotype infection united states europe genotype infection europe include hepatocellular carcinoma meeting milan criterion await liver transplantation hcvhiv coinfection viread oral formulation nucleotide analog reverse transcriptase inhibitor dose day treatment chronic hbv adult compensate decompensate liver disease license glaxosmithkline inc gsk right commercialize viread treatment chronic hbv china japan saudi arabia european commission approve use viread treatment chronic hbv infection adolescent patient age year compensate liver disease evidence immune active disease viread approve treatment hiv infection hepsera adefovir dipivoxil oral formulation nucleotide analog polymerase inhibitor dose day treat chronic hbv patient year age old license gsk right commercialize hepsera treatment chronic hbv asia pacific latin america certain territory oncology zydelig firstinclass pik delta inhibitor combination rituximab treatment certain blood cancer july fda approve zydelig relapse cll sll september european commission approve zydelig cll cardiovascular letairis ambrisentan oral formulation endothelin receptor antagonist era indicate treatment pulmonary arterial hypertension pah world health organization group patients class iii symptom improve exercise capacity delay clinical worsen sublicense gsk right ambrisentan market gsk volibris ambrisentan pah territory outside united states ranexa ranolazine extendedrelease tablet treatment chronic angina licensed menarini international operation luxembourg rights ranexa territory outside united states lexiscanrapiscan regadenoson injection indicate use pharmacologic stress agent radionuclide myocardial perfusion image mpi test detect characterize coronary artery disease patient unable undergo adequate exercise stress astella llc astella exclusive right manufacture sell regadenoson lexiscan united states rapidscan pharma solutions inc rps hold exclusive right manufacture sell regadenoson rapiscan europe certain territory outside united states receive royalty astella rps sale territory respiratory cayston aztreonam inhalation solution inhale antibiotic treatment respiratory system cystic fibrosis patient seven year age old pseudomona aeruginosa aeruginosa tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza tamiflu approve treatment influenza child adult country include united states japan european union tamiflu approve prevention influenza child adults united states japan european union develop tamiflu hoffmannla roche ltd hoffmannla roche inc roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay royalty base percentage net sale tamiflu ambisome amphotericin liposome injection proprietary liposomal formulation amphotericin antifungal agent treat invasive fungal infection cause fungal specie adult corporate partner astella pharma inc promote sell ambisome united states canada promote sell ambisome europe australia new zealand macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelate macular degeneration macugen develop eyetech inc eyetech technology license promote united states valeant pharmaceuticals inc valeant acquire eyetech valeant hold exclusive right manufacture sell macugen united states pfizer inc pfizer hold exclusive right manufacture sell macugen rest world receive royalty valeant pfizer base worldwide sale macugen sale antiviral product include product hiv liver disease area describe billion billion billion represent total revenue total revenue total revenue sale product billion billion billion represent total revenue total revenue item management discussion analysis item note segment information consolidate financial statement include annual report commercialization distribution international commercial sale operation marketing subsidiary argentina australia austria belgium brazil canada czech republic denmark finland france germany greece hong kong india ireland israel italy japan malaysia mexico netherlands new zealand norway panama poland portugal russia singapore slovakia south africa south korea spain sweden switzerland taiwan turkey united arab emirates united kingdom united states product market commercial team andor conjunction thirdparty distributor corporate partner commercial team promote product direct field contact physician hospital clinic healthcare provider generally grant thirdparty distributor exclusive right promote product territory specify period time agreement distributor provide collaborative effort distributor gilead obtain maintain regulatory approval product specify territory sell distribute sovaldi atripla truvada harvoni complera stribild viread emtriva ranexa zydelig tybost hepsera united states exclusively wholesale channel product sale large wholesaler cardinal health inc mckesson corp amerisourcebergen corp account total revenue year end december combine basis wholesaler account approximately product sale united states approximately total worldwide revenue letairis cayston distribute exclusively specialty pharmacy specialty pharmacy dispense medication complex chronic condition require high level patient education ongoing counseling sell distribute stribild eviplera atripla truvada sovaldi harvoni viread hepsera emtriva vitekta tybost ambisome europe country outside united states product approve commercial team thirdparty distributor corporate partner patient access priority increase access medicine people benefit regardless ability pay united states patient assistance program help therapy accessible uninsured individual need financial assistance support program unable afford copayment associate health insurance program half patient take hiv medicine united states receive federal state program substantially discount price long history work state aids drug assistance program adap provide low pricing hiv medicine price freeze institute adap extend end provide important support critical program evolve change healthcare environment access develop world gilead access program establish certain product treatment hiv hbv hcv visceral leishmaniasis available substantially reduce price develop world deliver medicine country work regional business partner distribute brand truvada viread price base country ability pay represent little profit partnership indiabase company expand access generic version hiv hcv medication leastdevelope country world work closely world health organization nongovernmental organization provide ambisome treatment leishmaniasis preferential price resource limited setting support numerous clinical study investigate role ambisome treat visceral cutaneous leishmaniasis develop country collaboration organization drug neglect disease initiative mdecin san frontire support clinical research study aim identify good treatment course visceral leishmaniasis donate ambisome support clinical study assess combination therapy costeffectiveness multiple visceral leishmaniasis treatment intervention december sign partnership agreement world health organization donate vial ambisome year donation treat patient resource limited country support clinical study donation product help define good treatment strategy develop world country example donate tenofovir centre aids programme research south africa caprisa microbicide trial assess effectiveness safety tenofovirbase microbicide gel prevention hiv infection south african woman provide drug number innovative international study investigate viread truvada prevent hiv transmission atrisk uninfected adult hiv prevention strategy call preexposure prophylaxis prep fda approval prep truvada agent indicate uninfected individual reduce risk acquire hiv sex enter number collaboration relate access product develop world include pharmachem acquisition company ltd pharmachem pharmachem commercial manufacturing partner establish facility bahama manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread active pharmaceutical ingredient atripla truvada include resource limited country cooperative effort pharmachem grand bahama port authority aspen pharmacare holdings ltd aspen enter nonexclusive manufacturing distribution agreement aspen provide manufacture distribution truvada viread treatment hiv infection certain develop world country include gilead access program amend agreement aspen amend agreement aspen retain right manufacture distribute truvada viread treatment hiv infection develop world country aspen right purchase truvada viread unlabeled bottle distribution country right manufacture truvada viread active pharmaceutical ingredient purchase aspen supplier approve aspen grant right manufacture distribute generic version emtricitabine tenofovir disoproxil fumarate include version tenofovir disoproxil fumarate combination emtricitabine treatment hiv infection aspen require pay royalty net sale truvada viread royaltie net sale generic version tenofovir disoproxil fumarate include version tenofovir disoproxil fumarate combination generic version emtricitabine manufacture distribute aspen license generic manufacturer enter nonexclusive license agreement indian generic manufacturer grant right produce distribute generic version tenofovir disoproxil fumarate treatment hiv infection low income country world include india country gilead access program agreement require generic manufacturer meet certain national international regulatory quality standard include technology transfer enable expeditious production large volume high quality generic version tenofovir disoproxil fumarate addition agreement allow manufacture commercial quantity active pharmaceutical ingredient finish product expand nonexclusive license agreement increase number country include license include right cobicistat elvitegravir include generic version combination product contain active ingredient cobicistat elvitegravir tenofovir disoproxil fumarate emtricitabine include nonexclusive license agreement ability manufacture distribute generic version tenofovir disoproxil fumarate treatment hbv country authorize sell generic version tenofovir disoproxil fumarate hiv announce new collaboration indian partner produce distribute generic emtricitabine develop world include single tablet regimen contain emtricitabine fixeddose combination emtricitabine formulate hiv medicine grant certain indian partner direct license produce distribute generic tenofovir alafenamide develop world include single tablet regiment contain emtricitabine fixeddose combination tenofovir alafenamide emtricitabine coformulate hiv medicine enter new collaboration indian partner produce distribute generic version sofosbuvir fixeddose combination ledipasvirsofosbuvir distribution develop country early expand collaboration allow indian partner manufacture single tablet regimen sofosbuvirg approve merck inc merck enter agreement affiliate merck pursuant merck provide atripla substantially reduce price hiv infect patient develop country africa caribbean latin america southeast asia agreement manufacture atripla efavirenz supply merck merck handle distribution product country cover agreement enter agreement merck commercialize atripla lowmiddle income country include brazil egypt mexico international partnership microbicide ipm conrad enter agreement grant right ipm conrad cooperate agency agency international development commit improve reproductive health expand contraceptive choice woman man develop manufacture prove efficacious arrange distribution resource limited country certain formulation tenofovir use topical microbicide prevent hiv infection medicine patent pool mpp enter agreement mpp organization establish united nations increase global access highquality lowcost antiretroviral therapy sharing patent grant mpp nonexclusive license identify generic pharmaceutical manufacturer india specialize highquality production generic medicine grant sublicense indian manufacturer manufacture distribute generic version antiretroviral develop world sublicensee mpp free develop combination product pediatric formulation hiv medicine grant mpp right grant sublicense generic version single tablet regimen consist elvitegravir cobicistat tenofovir disoproxil fumarate emtricitabine product candidate elvitegravir cobicistat generic pharmaceutical manufacturer india distribution develop world enter new agreement mpp expand access taf hiv hbv develop country contingent medicine regulatory approval agreement mpp sublicense generic drug company india china right manufacture generic version product contain taf include fixeddose combination taf coformulate certain hiv medicine distribute generic version develop country janssen expand agreement janssen provide distribution compleraeviplera treatment hiv developed country agreement amend include product clinical development contain janssen rilpivirine emtricitabine taf competition market product target number area include viral cardiovascular respiratory fungal disease commercially available product treatment disease company institution make substantial investment develop additional product treat disease product compete available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing hiv product hiv landscape competitive complex treatment trend continue evolve grow number hiv drug currently sell advanced stage clinical development competition current expect competitor erode revenue receive sale hiv product brand hiv drug available united states product primarily compete fixeddose combination product nucleotidenucleoside reverse transcriptase inhibitor nrti class include combivir lamivudinezidovudine epzicomkivexa abacavirlamivudine trizivir abacavirlamivudinezidovudine sell viiv healthcare viiv product compete stribild compleraeviplera atripla truvada tybost compete ritonavir market abbvie inc abbvie hiv product compete broadly hiv product abbvie boehringer ingelheim gmbh merck roche janssen addition tivicay dolutegravir integrase inhibitor launch viiv triumeq dolutegravirabacavirlamivudine single tablet antiretroviral regimen launch quarter viiv adversely impact sale hiv product face competition generic hiv product bms videx didanosine ddi generic hiv product united states gsk retrovir zidovudine face competition united states result launch generic zidovudine bms zerit stavudine face competition united states result launch generic stavudine epivir lamivudine market viiv competitive emtricitabine active pharmaceutical ingredient emtriva component atripla truvada compleraeviplera stribild compound patent cover epivir lamivudine expire united states generic lamivudine available united states spain portugal italy expect generic version lamivudine launch country european union generic version combivir lamivudine zidovudine approve recently launch united states addition late generic tenofovir available turkey result increase rebate viread turkey generic efavirenz active pharmaceutical ingredient sustiva component atripla available canada europe expect competition generic efavirenz united states december pricing pressure hiv product liver disease product hcv product sovaldi harvoni compete abbvie viekira pak janssen olysio simeprevir united states hbv product viread hepsera face significant competition exist expect therapy treat patient hbv erode revenue receive sale hbv product hbv product face competition baraclude entecavir oral nucleoside analog develop bms generic entecavir hbv product compete tyzekasebivo telbivudine oral nucleoside analog develop novartis pharmaceutical corporation novartis epivirhbvzeffix lamivudine develop gsk collaboration shire plc viread hepsera treatment hbv compete establish immunomodulatory therapy include introna interferon alfab sell merck major country north south america europe asia pegasys pegylate interferon alfaa injectable drug similar introna sell roche treatment hbv cardiovascular product letairis compete directly tracleer bosentan opsumit macitentan drug sell actelion pharmaceutical inc letairis compete adcirca tadalafil united therapeutics corporation ranexa compete predominantly generic compound distinct class drug treatment chronic angina united states include generic andor brand betablocker calcium channel blocker longacte nitrate addition surgical treatment intervention coronary artery bypass graft percutaneous coronary intervention option angina patient perceive healthcare practitioner prefer method treat cardiovascular disease underlie cause angina numerous market generic andor brand pharmacologic stress agent compete lexiscanrapiscan respiratory product cayston compete primarily tobi tobramycin inhalation solution inhale medication sell novartis treatment patient lung contain aeruginosa bacterial infection tamiflu compete relenza zanamivir antiinfluenza drug sell gsk relenza neuraminidase inhibitor deliver orallyinhale dry powder generic competitor include amantadine rimantadine oral tablet inhibit replication influenza virus biocryst pharmaceuticals inc develop injectable formulation peramivir influenza neuraminidase inhibitor treatment influenza currently approve japan south korea product zydelig competes imbruvica ibrutinib market pharmacyclic inc treatment relapse cll ambisome face strong competition current expect competitor ambisome face competition vfend voriconazole develop pfizer caspofungin product develop merck market cancidas united states caspofungin ambisome compete lipidbase amphotericin product include abelcet amphotericin lipid complex injection sell enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin cholesteryl sulfate complex injection sell river pharmaceutical llc worldwide anfogen amphotericin liposomal sell genpharma argentina bms numerous generic manufacturer sell conventional amphotericin compete ambisome aware lipid formulation claim similarity ambisome available outside united state include possible entry formulation taiwan formulation reduce market demand ambisome manufacture lipid formulation amphotericin complex formulation find unsafe sale ambisome negatively impact association macugen compete primarily visudyne verteporfin injection sell novartis connection photodynamic therapy lucentis ranibizumab sell genentech inc united states novartis territory outside united states number company pursue development technology competitive research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program collaborative relationship business strategy establish collaboration company university medical research institution assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire product right product technology complementary business company university medical research institution information certain relationship include ongoing financial accounting impact business item note collaborative arrangement consolidate financial statement include annual report commercial collaboration currently number collaboration corporate partner manufacture sale distribution andor marketing product territory worldwide follow commercial collaboration significant financial statement perspective significant ongoing collaboration activity exist bms enter collaboration arrangement bms develop commercialize single tablet regimen contain truvada bms sustiva efavirenz united states combination approve use united states sell brand atripla bms structure collaboration joint venture operate limited liability company name bristolmyers squibb gilead sciences llc consolidate bms grant royaltyfree sublicense joint venture use respective company own technology return grant license joint venture use intellectual property result collaboration bms amend joint venture collaboration agreement allow joint venture sell atripla canada economic interest joint venture hold bms include share revenue outofpocket expense base portion net selling price atripla attributable efavirenz truvada net selling price truvada change time relative net selling price efavirenz bms respective economic interest joint venture vary annually bms share marketing sale effort start limited number activity jointly manage party long coordinate detail promotional activity united states party reduce joint promotional effort launch complera august stribild august agreement continue terminate mutual agreement party addition party terminate party participation collaboration day launch generic version party single agent product double agent product terminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination gilead sciences ireland unlimited company whollyowne subsidiary know gilead science limited bms enter collaboration agreement bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory party form limited liability company consolidate manufacture atripla distribution european territory efavirenz purchase bms bms estimate net selling price efavirenz european territory start limited number activity jointly manage party long coordinate detail promotional activity region december efavirenz purchase bms bms estimate net selling price efavirenz european territory include inventory consolidate balance sheet agreement terminate expiration lasttoexpire patent afford market exclusivity atripla component european territory addition start december party terminate agreement reason termination effective calendar quarter notice termination nonterminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination event continue party decide sell atripla effective date termination date atripla withdraw country date party assume distribution atripla whichever early janssen enter collaboration agreement janssen develop commercialize fixeddose combination truvada janssen rilpivirine agreement amend combination approve united states european union sell brand complera united states eviplera european union amendment expand collaboration include single tablet regimen contain janssen rilpivirine emtricitabine tenofovir alafenamide rftaf agreement janssen grant exclusive license compleraeviplera rftaf worldwide right distribute combination product country include mexico russia japan party restrict combine drug drug product similar component compleraeviplera rftaf december record million approximately million reimbursable research development expense incur janssen development rilpivirine represent maximum reimbursable term agreement responsible manufacturing compleraeviplera rftaf lead role registration distribution commercialization product country janssen distribute janssen exercise right codetail combination product country gilead sell party selling party set price product party share revenue base ratio net selling price party component subject certain restriction adjustment retain specify percentage janssen share revenue major market party terminate collaboration agreement respect product country product withdraw market country respect product country party materially breach agreement respect product agreement party obligation share revenue expire productbyproduct countrybycountry basis janssen patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement cause respect country sell product case janssen right sell party country product launch market few year japan tobacco enter licensing agreement japan tobacco japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right agreement responsible seek regulatory approval territory require use diligent effort commercialize elvitegravircontaine product treatment hiv infection bear cost expense associate commercialization effort term agreement pay upfront license fee million total milestone payment million achievement certain clinical regulatory commercial objective additionally obligate pay royalty base net sale product contain elvitegravir territory market agreement obligation pay royalty japan tobacco terminate productbyproduct basis patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement reason case license grant japan tobacco terminate party terminate agreement response material breach party research collaboration number collaboration partner certain compound drug candidate research collaboration rise level significant financial statement perspective significant ongoing collaboration activity exist research development philosophy strategy develop bestinclass drug improve safety efficacy unmet medical need intend continue commit significant resource opportunity business development activity product development effort cover wide range medical condition include hivaid liver disease hbv hcv inflammationoncology cardiovascular respiratory condition research scientist foster city fremont san dimas oceanside california branford connecticut seattle washington alberta canada engage discovery development new molecule technology hope lead approval new medicine address unmet need development product candidate subject risk uncertaintie risk uncertainty include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain regulatory approval result product candidate successfully commercialize drug development inherently risky product candidate fail drug development process summary key product candidate correspond current stage development additional information development pipeline visit website wwwgileadcom product candidate treatment hiv product candidate description marketing application pende single tablet regimen elvitegravir cobicistat single tablet regimen elvitegravir cobicistat emtricitabine taf evaluate treatment emtricitabine taf hiv infection product phase fixeddose coformulation emtricitabine fixeddose coformulation emtricitabine taf evaluate treatment hiv infection taf single tablet regimen emtricitabine rilpivirine agreement janssen single tablet regimen emtricitabine rilpivirine taf evaluate taf treatment hiv infection product candidate treatment liver disease product candidate description product phase fixeddose combination sofosbuvir fixeddose combination sofosbuvir nucleotide nsb inhibitorpangenotypic nsa inhibitor evaluate treatment hcv taf taf nucleotide reverse transcriptase inhibitor evaluate treatment hbv product phase fixeddose combination sofosbuvir pangenotypic protease inhibitor evaluate combination sofosbuvir treatment hcv tarmogen cell immunity stimulator evaluate treatment hbv oral tlr agonist evaluate potential cure hbv simtuzumab simtuzumab monoclonal antibody evaluate treatment liver fibrosis nash primary sclerose cholangitis product phase ask inhibitor evaluate treatment diabetic nephropathy nash aldh inhibitor evaluate treatment drug addiction product candidate treatment oncology inflammation product candidate description product phase idelalisib idelalisib pik delta inhibitor evaluate treatment inhl frontline relapse refractory cll momelotinib momelotinib jak inhibitor evaluate treatment myelofibrosis product phase spleen tyrosine kinase syk inhibitor evaluate hematological malignancy idelalisib idelalisib evaluate treatment frontline inhl momelotinib momelotinib evaluate treatment pancreatic cancer product phase bruton tyrosine kinase inhibitor evaluate bcell malignancy mmp mab inhibitor evaluate treatment solid tumor ulcerative colitis pik delta inhibitor evaluate treatment hematological malignancy product candidate treatment cardiovascular disease product candidate description product phase ranolazine ranolazine late sodium current inhibitor approve treatment chronic angina evaluate treatment incomplete revascularization postpercutaneous coronary intervention late sodium current inhibitor evaluate treatment lqt syndrome product phase fixeddose combination ranolazine fixeddose combination ranolazine dronedarone evaluate treatment paroxysmal atrial dronedarone fibrillation evaluate treatment pulmonary arterial hypertension late sodium current inhibitor evaluate treatment lqt syndrome hypertrophic cardiomyopathy product candidate treatment respiratory disease product candidate description product phase inhalable small molecule antiviral fusion inhibitor evaluate treatment respiratory syncytial virus simtuzumab simtuzumab evaluate treatment idiopathic pulmonary fibrosis total expense billion compare billion billion addition internal discovery clinical development program seek add portfolio product product acquisition license collaboration december enter exclusive license agreement ono pharmaceutical ltd development commercialization ono know oral bruton tyrosine kinase inhibitor treatment bcell malignancy disease december enter agreement phenex pharmaceuticals phenex acquire phenexs farnesoid receptor program comprise small molecule fxr agonist treatment liver disease include nash patent proprietary right european patent expiration number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states europe primary typically compound patent phase product candidate patent cover ranolazine compound active ingredient ranexa instead discover sustainedrelease formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve product candidate single tablet regimen estimate patent expiration date provide correspond late expiring compound patent active ingredient single tablet regimen phase product candidate patent expiration product candidate treatment hiv single tablet regimen elvitegravir cobicistat emtricitabine taf single tablet regimen emtricitabine taf single tablet regimen darunavir cobicistat emtricitabine taf single tablet regimen emtricitabine rilpivirine taf product candidate treatment liver disease single tablet regimen sofosbuvir treatment hcv single agent taf treatment hbv product candidate treatment oncologyinflammation idelalisib treatment inhl frontline relapse refractory cll momelotinib treatment myelofibrosis product candidate treatment cardiovascular disease ranolazine treatment incomplete revascularization postpercutaneous coronary intervention treatment type diabetes treatment lqt syndrome date parenthesis reflect estimate expiration date patent issue currently pende application estimate expiration date include potential additional exclusivity patent term extension supplementary protection certificate pediatric exclusivity grant follow table show actual estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states europe primary typically compound patent market product product single tablet regimen truvada atripla compleraeviplera stribild estimate patent expiration date provide correspond late expiring compound patent active ingredient single tablet regimen product patent expiration hepsera ambisome macugen tamiflu letairis viread ranexa atripla cayston emtriva truvada lexiscan compleraeviplera vitekta zydelig sovaldi stribild tybost harvoni date parenthesis reflect estimate expiration date patent issue currently pende application estimate expiration date include potential additional exclusivity patent term extension supplementary protection certificate pediatric exclusivity grant gilead teva pharmaceutical teva reach agreement principle settle ongoing patent litigation concern patent protect tenofovir disoproxil fumarate viread truvada atripla product agreement teva allow launch generic version viread december gilead lupin limited lupin reach agreement settle patent litigation prior issuance court decision agreement lupin allow launch generic version ranexa february patent protection certain challenge patent proprietary right important business properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology patent cover certain active pharmaceutical ingredient atripla truvada compleraeviplera stribild letairis emtriva hepsera vitekta hold party acquire exclusive right patent agreement party patent cover ranolazine compound active ingredient ranexa instead discover sustainedrelease formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve patent cover active ingredient ambisome obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension supplementary protection certificate country example extension patent supplementary protection certificate product grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain country important infringe valid patent party infringe valid patent party prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware body patent relate operation letairis education access program leap restrict distribution program design support letairis aware patent patent application own party claim cover use sofosbuvir use combination sofosbuvir ledipasvir patent application confidential period time patent issue know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete product addition competitor file patent application cover technology participate interferencederivation proceeding litigation determine right patent litigation interferencederivation proceeding unpredictable expensive ultimately successful result operation adversely affect event patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation proceeding enforcement validity exist patent future patent result invalidation patent substantially reduce protection time time certain individual entity challenge patent pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product closely relate developed develop addition certain country south america africa asia include brazil china provide effective enforcement patent thirdparty manufacturer able sell generic version product country litigation sofosbuvir january acquire pharmasset inc pharmasset acquisition acquire sofosbuvir nucleotide analog act inhibit replication hcv december receive fda approval sofosbuvir know commercially sovaldi october receive approval fixeddose combination ledipasvir sofosbuvir know commercially harvoni receive number intellectual property claim sofosbuvir carefully consider claim prior follow acquisition believe merit patent patent application claim sofosbuvir sovaldi chemical entity metabolite fixeddose combination ledipasvir sofosbuvir harvoni party obtain right patent allegedly prevent attempt prevent commercialize sovaldi harvoni example aware patent patent application own party allege party cover use sovaldi harvoni predict ultimate outcome intellectual property claim relate sovaldi harvoni spend continue spend significant resource defend claim party successfully obtain valid enforceable patent successfully prove infringement patent sovaldi andor harvoni prevent sell product able obtain license patent license available commercially reasonable term interference proceeding litigation idenix pharmaceuticals inc idenix february receive notice patent trademark office uspto declare interference idenix interference patent patent idenix pende patent application interference administrative proceeding uspto design determine invent subject matter claim party patent cover metabolite sofosbuvir idenix attempt patent class compound include metabolite purpose idenix interference determine invent compound entitle patent claim compound march uspto patent trial appeal board board determine idenix entitle benefit early application filing date patent application include application grant idenixs patent patent teach compound dispute board determine entitle filing date early application file patent application compound dispute senior party idenix interference january board determine pharmasset idenix invent compound dispute accordingly gilead prevail idenix interference decision board hold idenix fail prove conceive compound dispute specifically idenix fail prove idenix inventor identify structure method make use dispute compound board go conclude idenix fail work diligently make testing compound dispute relevant time period idenix appeal board decision district court district delaware december receive request uspto declare interference second idenix interference pende patent application patent patent include claim direct method treat hcv nucleoside compound similar involved idenix interference second idenix interference determine invent claim method treat hcv january board issue decision favor gilead phase second idenix interference board decide file patent application dispute method treat hcv designate gilead senior party second idenix interference invalidated patent claim idenix patent involve second idenix interference senior party presume invent dispute method treat hcv idenix fail teach use invention patent board invalidate idenix claim involve second idenix interference lack enablement board place idenix order cause require idenix explain judgment enter second idenix interference base decision board idenix interference decision second idenix interference consistent board early ruling march january idenix interference gilead declare senior party invent certain fluoro methyl nucleoside compound compound relevant method treat hcv issue second idenix interference believe idenix claim involve second idenix interference similar foreign patent claim compound metabolite use thereof invalid result file impeachment action federal court canada invalidate idenix canadian patent patent canadian patent correspond patent idenix patent application subject idenix interference idenix assert commercialization sovaldi canada infringe patent canadian patent correspond patent involve idenix interference invalid trial issue commence january file similar legal action norway oslo district court seek invalidate idenix norwegian patent correspond patent september idenix file invalidation action norwegian proceeding norwegian patent patent correspond patent march norwegian court find claim idenix norwegian patent invalid upheld validity claim challenge gilead patent april idenix appeal march decision norwegian court appeal idenixs obligation pay attorney fee stay pendency appeal appeal march decision schedule commence february august april idenix file separate request invalidation chinese patent office chinese patent correspond patent august idenix withdraw invalidation request chinese proceeding terminate challenge patent remain valid enforceable january file legal action federal court australia seek invalidate idenixs australian patent correspond patent april idenix assert commercialization sovaldi australia infringe australian patent correspond patent trial issue schedule commence september sydney march european patent office epo grant idenix european patent patent correspond patent day patent grant file opposition epo seek revoke patent day idenix initiate infringement proceeding gilead united kingdom germany france allege commercialization sovaldi country infringe respective national counterparts patent united kingdom trial hold october determine issue infringement validity idenix patent december high court justice england wale court invalidate claim patent multiple ground specifically court hold patent lack novelty early file patent application teaching compound patent lack inventive step add knowledge exist time disclosure idenixs patent application insufficient teach compound claim compound activity virus like hepatitis virus january court hold hearing court order idenix pay gilead cost interim payment day hear court grant idenix permission appeal december judgment february german court dsseldorf hold hearing determine issue infringement idenix german patent expect decision mid march trial date french lawsuit idenix award patent correspond patent japan china event patent issue expect challenge proceeding similar invoke country december idenix universita degli studi cagliari udsg centre national recherche scientifique luniversit montpellier sue district court district delaware allege commercialization sofosbuvir infringe patent interference exist patent patent december idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos june court massachusetts grant request transfer massachusetts litigation district court district delaware believe idenixs patent invalid infringe commercialization sofosbuvir sole right commercialize sofosbuvir district court set trial date october december resolution issue decision district court appeal party court appeal federal circuit cafc idenix acquire merck august acquisition change view lack merit claim idenix merck great resource idenix choose fund litigation high level idenix litigation merck august merck contact request pay royalty sale sofosbuvir obtain license patent nos coown isis pharmaceuticals inc believe merck patent invalid infringe commercialization sofosbuvir sole right commercialize sofosbuvir august file lawsuit district court northern district california seek declaratory judgment merck patent invalid infringe merck patent nos cover compound include relate sofosbuvir patent prosecution merck amend patent application attempt cover compound relate sofosbuvir apparent goal ultimately extract royalty payment sofosbuvir commercialization eliminate competition exclude market court determine merck patent valid infringe claim require obtain license pay royalty merck commercialize sofosbuvir party appeal decision district court cafc court set trial date march lawsuit litigation abbvie inc abbvie abbvie obtain patent nos abbvie patent purport cover use combination ledipasvirsofosbuvir harvoni treatment hcv gilead aware abbvie pende patent application united states country publish pende patent application direct use combination treatment hcv specifically combination ledipasvir sofosbuvir certain application file abbvie patent reason believe abbvie patent invalid accordingly december file lawsuit district court district delaware seek declaratory judgment abbvie patent invalid unenforceable relief believe abbott laboratories inc abbvie conspire eliminate competition hcv market falsely represent uspto gilead invent method treat hcv combination ledipasvirsofosbuvir february march abbvie respond lawsuit file lawsuit district court district delaware allege fixeddose combination ledipasvirsofosbuvir infringe patent lawsuit consolidate single action united states party appeal decision district court cafc abbvie patent block delayed commercialization combination product united states europe expect foreign patent block delay commercialization world court determine abbvie patent valid infringe claim require obtain license pay royalties abbvie commercialize sofosbuvir combination product litigation generic manufacturer approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug tenofovir disoproxil fumarate emtricitabine fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz receive notice teva pharmaceutical teva submit anda fda request permission manufacture market generic version truvada april teva reach agreement settle ongoing patent litigation concern patent protect tenofovir disoproxil fumarate atripla truvada viread agreement teva allow launch generic version viread december april teva enter agreement settle ongoing patent litigation concern emtricitabine patent protect atripla truvada term settlement confidential november receive notice teva submit and canadian minister health request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate notice teva allege patent associate truvada invalid unenforceable andor infringe teva manufacture use sale generic version truvada january file lawsuit teva federal court canada seek order prohibition approval and december receive notice teva submit and canadian minister health request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva allege patent associate atripla merck patent associate atripla invalid unenforceable andor infringe teva manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz february file lawsuit teva federal court canada seek order prohibition approval and august receive notice teva submit and canadian minister health request permission manufacture market generic version viread notice teva allege patent associate tenofovir disoproxil fumarate invalid unenforceable andor infringe teva manufacture use sale generic version viread truvada atripla september file lawsuit teva federal court canada seek order prohibition approval and august teva file impeachment action federal court canada seek invalidation canadian patent associate viread currently defend impeachment action request order prohibition connection tevas and filing tevas generic version viread truvada atripla consolidated december court issue request order prohibit canadian minister health issuing notice compliance tevas generic version viread truvada atripla product expiry patent july teva appeal decision decision rule validity patent accordingly issue appeal minister health prohibit issue notice compliance tevas product separately court determine validity patent pende impeachment action trial impeachment action schedule september teva successful invalidating patent teva able launch generic version viread truvada atripla products canada prior expiry patent receive notice lupin limited lupin submit anda fda request permission manufacture market generic version truvada viread lupin amend anda certify long seek approval market generic version truvada viread prior expiration patent associate tenofovir disoproxil fumarate january include pediatric exclusivity september reach agreement lupin settle lawsuit related emtricitabine patent protect truvada atripla term settlement confidential july receive notice cipla ltd cipla submit anda fda request permission manufacture market generic version emtriva viread july cipla reach agreement settle lawsuit term settlement confidential april received notice mylan inc mylan submit anda fda request permission manufacture market generic version truvada notice mylan allege patent associate emtricitabine patent associate fixeddose combination emtricitabine tenofovir disoproxil fumarate invalid unenforceable andor infringe mylan manufacture use sale generic version truvada june file lawsuit mylan district court northern district west virginia infringement patent june receive notice mylan inc submit petition inter parte review ipr board allege patent associate tenofovir disoproxil fumarate invalid oppose mylan petition december uspto patent trial appeal board ptab issue decision deny mylan petition ipr tenofovir disoproxil fumarateassociate patent ground mylan establish reasonable likelihood success prevail challenge patent mylan request rehear basis believe ptab decision wrong june receive notice apotex inc apotex submit and canadian minister health request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate separate and request permission manufacture market generic version viread notice apotex allege patent associate truvada patent associate viread invalid unenforceable andor infringe apotex manufacture use sale generic version truvada viread august file lawsuit apotex federal court canada seek order prohibition approval ands ranolazine receive notice lupin submit anda fda request permission manufacture market generic version sustainedrelease ranolazine august party reach agreement settle patent litigation prior issuance court decision agreement lupin allow launch generic version ranexa february tamiflu february receive notice natco pharma ltd natco submit anda fda request permission manufacture market generic version tamiflu notice natco allege patent associate oseltamivir phosphate invalid unenforceable andor infringe natco manufacture use sale generic version tamiflu march roche file lawsuit natco district court district new jersey infringement patent associate tamiflu december court issue rule favor gilead roche patent invalid reason state natco notice letter natco appeal decision cafc issue decision april allow natcos patent invalidity challenge proceed remand district court new jersey trial merit june file petition rehear banc cafc subsequently deny file petition certiorari supreme court united states concurrently proceed district court letairis august natco file complaint district court district minnesota gilead express script hold specialty pharmacy distribute letairis product distribute letairis pursuant fdamandate risk evaluation mitigation strategy rem program natco allege gilead independently express script deny natco access sample letairis natco claim need order conduct bioequivalence testing file anda accord natco conduct violate antitrust law natco seek damage order restrain gilead limit distribution letairis natco use rem program november zydus pharmaceuticals usa inc zydus cadila healthcare limited cadila file complaint district court district new jersey relate letairis sale distribute letairis pursuant rem program zydus cadila allege deny access sample letairis claim need order conduct bioequivalence testing file anda accord zydus cadila conduct violate antitrust law zydus cadila seek damage order enjoin gilead provide zydus sample letairis february receive notice watson laboratories inc watson submit anda fda request permission manufacture market generic version letairis notice watson allege patent associate ambrisentan tablet invalid unenforceable andor infringed watson manufacture use sale generic version letairis currently evaluate watson notice file patent infringement lawsuit necessary protect exclusivity product lexiscan december astellas inform receive notice apotex submit anda fda request permission manufacture market generic version lexiscan notice apotex allege patent associate regadenoson invalid unenforceable andor infringe apotexs manufacture use sale generic version lexiscan apotex challenge patent associate regadenoson apotex product eligible final approval expiry patent challenge astella opportunity file patent infringement lawsuit apotex future decide necessary protect exclusivity product predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit claim patent narrow invalidated patent protection truvada viread lexiscan tamiflu united states atripla truvada viread canada substantially shorten patent cover product invalidate fda canadian minister health approve request manufacture generic version products united states canada respectively prior expiration date patent sale generic version product early patent expiration significant negative effect revenue result operation trade secret rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention manufacture raw material manufacturing strategy contract party manufacture majority active pharmaceutical ingredient solid dose product rely corporate partner manufacture certain product additionally lease manufacturing facility foster city san dimas oceanside california edmonton alberta canada cork ireland manufacture certain product active pharmaceutical ingredient clinical commercial use manufacturing product contract party manufacture certain product clinical commercial purpose include sovaldi atripla truvada harvoni compleraeviplera stribild viread emtriva hepsera tybost vitekta ranexa ambisome zydelig cayston generally use multiple thirdparty contract manufacturer manufacture active pharmaceutical ingredient product exclusive manufacturer idelalisib active pharmaceutical ingredient zydelig ambrisentan active pharmaceutical ingredient letairis supplier qualify active pharmaceutical ingredient letairis rely thirdparty contract manufacturer manufacture tablet capsule product example use multiple thirdparty contract manufacturers tablet sovaldi atripla truvada harvoni compleraeviplera stribild viread hepsera tybost vitekta letairis zydelig ranexa emtriva encapsulation complete thirdparty contract manufacturer manufacture agreement corporate partner roche party responsible manufacturing tamiflu agreement roche joint manufacturing committee compose representative roche gilead opportunity review roche exist manufacturing capacity tamiflu global plan manufacture tamiflu astella llc corporate partner lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan future product continue develop additional manufacturing capability establish additional thirdparty supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale unable develop manufacturing capability internally contract large scale manufacturing party acceptable term future product ability conduct large scale clinical trial meet customer demand commercial product adversely affect addition rely thirdparty contract manufacturer manufacture aseptic product ambisome cayston manufacturing facility san dimas california manufacturing facility package label solid dosage oral form product include sovaldi atripla truvada harvoni compleraeviplera stribild viread ranexa zydelig emtriva label hepsera facilities san dimas manufacture ambisome cayston san dimas facility depend single supplier high quality cholesterol active pharmaceutical ingredient manufacture ambisome exclusive supplier key drug product intermediate ambisome event disaster include earthquake equipment failure difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome meet market need utilize cork ireland facility primarily solid dose tablet manufacturing certain antiviral product product packaging activity package label drug product sovaldi atripla truvada harvoni compleraeviplera stribild viread tybost vitekta label hepsera emtriva facilities cork ireland perform quality control testing final labeling secondary packaging ambisome cayston final release product european union facility distribute product european union international market dublin ireland site edmonton alberta facility canada carry process research scaleup clinical development candidate manufacture active pharmaceutical ingredient investigational commercial product conduct chemical development activity improve exist commercial manufacturing process manufacture active pharmaceutical ingredient letairis hepsera exclusively edmonton site supplier qualify active pharmaceutical ingredient letairis oceanside california facility design equip produce biologic compound toxicological phase phase clinical study use facility process development manufacture simtuzumab investigational monoclonal antibody candidate development treatment certain cancer respiratory disease biologic thirdparty manufacturer thirdparty manufacturer corporate partner independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval writeoff cost manufacturing batch fail pass quality inspection meet regulatory approval extent risk materialize affect performance obligation financial result adversely affect addition thirdparty manufacturer corporate partner able produce product limit number facility limited manufacturing capacity certain product example unexpected delay qualify new external site expand cayston manufacturing san dimas unable supply cayston fulfill project demand february september suspend access patient new prescription cayston subject certain exception specific medical need exist result inability manufacture sufficient cayston meet demand revenue receive sale cayston reduce believe technology use manufacture product proprietary product manufacture thirdparty contract manufacturer disclose necessary aspect technology enable manufacture product agreement thirdparty manufacturer intend restrict manufacturer reveal technology certain thirdparty manufacturer comply restriction addition thirdparty manufacturer develop technology relate work perform need manufacture product required enter additional agreement thirdparty manufacturer want use technology allow manufacturer use technology thirdparty manufacturer refuse allow use technology demand term use technology acceptable regulation manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation thirdparty manufacturer corporate partner subject current good manufacturing practice extensive regulation govern manufacturing process stability testing record keep quality standard define fda european medicine agency ema similar regulation effect country manufacture operation subject routine inspection regulatory agency example april fda conduct inspection foster city facility issue form inspectional observation note deficiency documentation validation certain quality testing procedure method result observation fda deliver complete response letter notify unable approve nda elvitegravir cobicistat standalone agent midoctober fda complete sofosbuvir preapproval inspection foster city facility follow inspection fda issue additional form inspectional observation cite deficiency relate testing reconciliation stability sample test protocol test shipping sample procedure calibrate test equipment complete file response observation fda receive letter fda relate extent method revalidation conduct stability program oversight audit trail reviewdata management quality management system gap file response observation fda unable remedy deficiency cite fda inspection currently market product time regulatory approval product development adversely affect risk regulatory agency country marketing application pende undertake similar additional review apply heighten standard review delay regulatory approval product country approval product candidate delay production market product interrupt anticipate revenue stock price adversely affect access supply material need access certain supply product manufacture product unable purchase sufficient quantity material find suitable alternate material timely manner development effort product candidate delay ability manufacture product limit limit ability generate revenue example significant portion raw material intermediate manufacture antiviral product sovaldi atripla truvada harvoni compleraeviplera stribild viread emtriva tybost vitekta supply chinabased company result international trade dispute china united states action chinese government limit prevent chinese company supply material adversely affect ability manufacture supply hiv hcv product meet market need material adverse effect operating result seasonal operation backlog worldwide product sale reflect significant degree seasonality operate market characterize short lead time absence significant backlog believe backlog information material business government regulation operation activity subject extensive regulation numerous government authority united states countries united states drug subject rigorous fda regulation federal food drug cosmetic act federal state statute regulation govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume fda approve drug sell united states general process approval follow preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug candidate potential benefit safety submit datum fda investigational new drug ind application seek approval test compound human clinical trial fda accept ind drug candidate study human clinical trial determine drug candidate safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug candidate give small number healthy human control subject patient suffer indicate disease test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug candidate give limited patient population determine effect drug candidate treat disease good dose drug candidate possible effect safety risk drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous phase clinical trial phase drug candidate appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial conduct long term involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous extensive phase clinical trial fda approval process believe datum clinical trial adequate level safety efficacy submit appropriate filing usually form nda supplemental nda fda seek approval sell drug candidate particular use fda hold public hear independent advisory committee expert advisor ask additional question make recommendation drug candidate committee make recommendation fda binding generally follow fda fda agree compound meet require level safety efficacy particular use allow sell drug candidate united states use unusual fda reject application believe drug candidate safe efficacious believe datum submit reliable conclusive point process development drug candidate stop number reason include safety concern lack treatment benefit certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require phase nonregistrational study explore scientific question characterize safety efficacy commercial use drug fda require provide additional data information improve manufacturing process procedure facility require extensive surveillance monitor safety benefit product candidate determine file contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory inspection manufacturing facility locate california include oceanside san dimas facility license state california compliance local regulatory requirement manufacture facility locate canada include edmonton alberta facility facility locate near dublin cork ireland obtain local license permit compliance local regulatory requirement drug treat life threaten disease condition adequately address exist drug development program design address unmet medical need designate fast track candidate fda eligible accelerate priority review drug treatment hiv infection designate use president emergency plan aid relief qualify expedite priority review sovaldi atripla truvada harvoni viread complera stribild viread zydelig receive accelerate approval priority review drug receive accelerated approval monitor postmarkete clinical trial order confirm safety benefit drug drug subject extensive regulation outside united states european union centralize approval procedure authorize marketing product country european union include major country europe centralize approval procedure approval country european union obtain approval country european union simplified application process mutual recognition procedure decentralize procedure rely principle mutual recognition receive regulatory approval european registration procedure separate pricing reimbursement approval require country european union requirement approval manufacturing facility product approve sale european regulatory authority price reimbursement successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service result low average selling price united states significant portion sale majority product subject significant discount list price rebate obligation hcv area experience increase pricing pressure certain case provide significant discount rebate private public payer order obtain formulary status change formulary coverage reimbursement level discount rebate offer hcv product payer impact anticipate revenue expect pricing pressure hcv market continue addition state adap purchase significant portion hiv product rely federal supplemental federal state funding help fund purchase product past experienced shift payer mix hiv patient previously cover private insurance public reimbursement program require rebate discount patient previously cover public reimbursement program public reimbursement program require great rebate discount federal state fund available amount sufficient support number patient rely adap sale hiv product negatively impact reduce revenue prior quarter insufficiency federal state fund state reduce eligibility criterion see increase number patient state adap waitlist similar increase future period result reduction federal state adap support result sequestration patient enrol adap generally receive product industrysupporte patient assistance program unable access treatment increase emphasis manage healthcare united states additional pressure product pricing reimbursement usage adversely affect product sale profitability pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid healthcare reform pharmaceutical reimbursement policy price general july receive letter senate committee finance request information support documentation related sovaldi pricing sovaldi united states letter raise concern approach pricing sovaldi affordability impact federal government spend public health cooperating inquiry costly timeconsume comply inquiry predict outcome possible inquiry result negative publicity negative action harm reputation reduce demand sovaldi harvoni sofosbuvir contain product andor reduce coverage sovaldi harvoni sofosbuvir contain product include federal health care program medicare medicaid event occur business stock price materially adversely affect country outside united states success commercialize product product candidate develop depend largely obtain maintain government reimbursement country patient unlikely use prescription drug reimburse government addition negotiate price certain governmental authority delay commercialization month reimbursement policy adversely affect ability sell product profitable basis international market government control price prescription pharmaceutical include implementation reference pricing price cut rebate revenuerelate taxis tender profit control expect price prescription pharmaceutical decline life product volume increase recently country european union increase level discount require product effort continue country attempt manage healthcare expenditure especially light severe fiscal debt crisis experience country european union country institute clawback enact taxis specific product generic drug come market face price decrease product country european union cost containment pressure european union especially southern europe lead delay treatment patient delay pricing approval negatively impact commercialization new product government agency issue regulation guideline directly applicable product addition time time professional society practice management group private healthscience foundation organization publish guideline recommendation direct certain health care patient community recommendation guideline relate matter product usage dosage route administration use related compete therapy consequently result increase decrease usage product united states healthcare reform legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction march healthcare reform legislation adopt united states require rebate discount product reimburse pay public payer include medicaid entity eligible purchase discount product drug pricing program public health service act adap result legislation discount rebate fee impact include minimum base rebate owe medicaid product reimburse medicaid increase discount rebate owe adap public health service entity reimburse purchase product increase require extend rebate patient receive product medicaid manage care organization require provide discount product sell patient medicare donut hole pharmaceutical manufacturer brand drug product require pay portion new industry fee know brand prescription drug fee bpd fee billion calculate base select government sale calendar year percentage total industry government sale annual industry fee impose pharmaceutical industry billion increase billion increase peak billion decrease billion expect portion bpd fee increase revenue grow annual industry fee increase drug patent expire major drug company addition quarter internal revenue service irs issue final regulation indicate manufacturer obligation pay portion bpd fee give calendar year trigger qualifying sale previous year instead qualify sale current calendar year result final irs regulation require recognize fee million fee million consolidated statement income bpd fee approximately million million million respectively bpd fee tax deductible address healthcare reform legislation discussion continue federal level legislation allow require federal government directly negotiate price concession pharmaceutical manufacturer set minimum requirement medicare pricing addition state medicaid program request additional supplemental rebate product result increase federal base medicaid rebate private insurer use enactment increase rebate exert pricing pressure product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule health care fraud abuse law antibribery law subject federal state law pertain health care fraud abuse include antikickback law false claim law antikickback law illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business include purchase prescription particular drug breadth statutory provision increase attention give law enforcement authority possible certain practice challenge antikickback similar law false claim law generally prohibit knowingly present cause present false fraudulent claim payment federal certain state payer include medicare medicaid knowingly make cause false record statement material false fraudulent claim sale marketing medical activity subject scrutiny law addition foreign corrupt practice act similar worldwide antibribery law generally prohibit company intermediary make improper payment purpose obtain retain business policy mandate compliance antibribery law operate part world experience governmental corruption degree certain circumstance strict compliance antibribery law conflict local custom practice require interact doctor hospital state control manner different local custom despite train compliance program internal control policy procedure protect reckless criminal act commit employee agent violation fraud abuse law antibribery law punishable criminal andor civil sanction include fine civil monetary penalty possibility exclusion federal health care program include medicare medicaid violation lead imposition corporate integrity agreement similar government oversight program government allege convict violate law disruption business material adverse effect result operation compulsory license number develop country government official interested group suggest pharmaceutical company drug hcv hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example grow attention availability hcv therapy activist advocate increase availability hcv therapy mean include compulsory license past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread addition concern cost availability tamiflu relate potential avian flu pandemic influenza generate international discussion compulsory licensing tamiflu patent example canadian government consider allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop develop country canada access medicine regime furthermore roche issue voluntary license permit thirdparty manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group ltd china sublicense india hetero drug limited india certain develop country compulsory license permit generic manufacturing override product patent sovaldi harvoni hiv product tamiflu require grant compulsory license product reduce earning cash flow harm business addition certain country permit enforcement patent thirdparty manufacturer able sell generic version product country compulsory license sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale employee january approximately fulltime employee believe good relation employee environment health safety evaluate current level environmental impact identify way reduce energy consumption factor contribute environmental impact include greenhouse gas emission produce employee commute energy water consume facility use hazardous material chemical viruse radioactive compound facility pursuant evaluation take initial measure address impact example establish employee commuter program evaluate energy efficiency building instal lowflow water fixture implement proactive program minimize occurrence hazardous material incident reduce risk accidental environmental contamination worker injury subject number law regulation require compliance federal state local regulation workplace safety protection environment anticipate additional regulation near future law regulation implement consideration mitigate effect climate change mainly cause greenhouse gas emission business energy intensive anticipate subject cap trade system mitigation measure materially impact capital expenditure operation competitive position base current information subject finalization propose regulation believe primary risk relate climate change increase energy cost use hazardous material chemical viruse radioactive compound activity eliminate risk accidental contamination injury material misuse accident involve hazardous material lead significant litigation fine penalty information subject information requirement exchange act file periodic report proxy statement information sec report proxy statement information obtain visit public reference room sec street washington call sec sec send electronic message sec publicinfosecgov send fax sec addition sec maintain website wwwsecgov contain report proxy information statement information issuer file electronically mail address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section available follow filing soon reasonably practicable electronically file furnished sec annual report quarterly report form current report form amendment report file furnish pursuant section exchange act filing available free charge request transaction iran transaction iran require disclosure annual report item risk factor evaluate business carefully consider follow risk addition information annual report manifestation follow risk materially adversely affect business result operation financial condition note factor investor permit private security litigation reform act possible predict identify factor consider follow risk complete statement potential risk uncertainty face substantial portion revenue derive sale product treat hcv hiv unable maintain continue increase sale product result operation adversely affect year end december sale sovaldi harvoni treatment hcv account approximately total product sale sovaldi harvoni recently launch certain sale hcv product indicative future sale approval competitor hcv product december potential entry competitive product predict extent hcv revenue adversely affect future result launch compete regiman experience continue experience increase pricing pressure certain case provide significant discount rebate public private payer order obtain formulary status expand access patient hcv product addition future sale sovaldi harvoni difficult estimate demand depend extent reimbursement hcv product private public payer united states country outside united states light continued fiscal debt crisis experience country european union government announce implement measure manage healthcare expenditure continue experience pricing pressure increase discount require product delay reimbursement negatively impact future product sale result operation private public payer choose exclude sovaldi harvoni formulary limit type patient coverage provide negatively impact demand revenue sovaldi harvoni change formulary coverage reimbursement level discount rebate offer hcv product payer impact anticipate revenue expect pricing pressure hcv market continue unable maintain current expect future sale level sovaldi harvoni obtain approval reimbursement hcv product candidate currently anticipate timeline result operation stock price negatively affect receive substantial portion revenue sale product treatment hiv infection particularly single tablet regimen product atripla compleraeviplera stribild year end december sale hiv product account total product sale hiv product contain tenofovir disoproxil fumarate andor emtricitabine belong nucleoside class antiviral therapeutic treatment paradigm hiv change cause nucleosidebase therapeutic fall favor unable maintain continue increase hiv product sale result operation likely suffer likely need scale operation include spend research development effort able sustain increase growth rate sale hiv product especially atripla compleraeviplera stribild number reason include limited follow hiv product long period time patient combination product additional study conduct new issue respect safety resistance interaction drug arise cause provide additional warning contraindication label narrow approve indication halt sale product reduce revenue hiv product mature private insurer government payer reduce reimburse patient product increase pressure reduce price large market hiv product consist patient take hiv drug physicians benefit hiv product sale hiv product limit generic hiv product introduce major market ability maintain pricing market share affect example generic version sustiva efavirenz component atripla available canada europe anticipate competition generic efavirenz united states december observe pricing pressure relate sustiva component atripla sale fail commercialize new product expand indication exist product prospect future revenue adversely affect introduce new product market increase sale exist product able increase maintain total revenue continue expand effort drug development inherently risky product candidate fail drug development process example recently announce result phase study simtuzumab treatment pancreatic cancer myelofibrosis colorectal cancer show product candidate provide clinical benefit june submit nda japans pharmaceutical medical devices agency pmda approval sofosbuvir treatment hcv september submit nda pmda approval fixeddose combination ledipasvir sofosbuvir fourth quarter file marketing application approval single tablet regimen elvitegravir cobicistat emtricitabine taf treatment hiv infection adult united states european union marketing application approve regulatory authority timely basis marketing approval grant product significant limitation use unable file marketing application new product inability accurately predict demand product uptake new product time fluctuation inventory maintain customer make difficult accurately forecast sale cause revenue earning fluctuate adversely affect financial result stock price unable accurately predict demand product include uptake new product demand dependent number factor example hcv product sovaldi harvoni represent significant change treatment paradigm hcvinfecte patient shorten duration treatment reduction elimination need pegylate interferon injection ribavirin certain patient population product new therapeutic area product demand dependent number factor revenue product difficult investor estimate demand sovaldi harvoni depend extent reimbursement hcv product private public payer united states country outside united states private public payer choose exclude sovaldi harvoni formulary limit type patient coverage provide negatively impact demand revenue sovaldi harvoni hcv product represent significant change treatment paradigm hcv infection light launch competitor regimen sale level prescription growth rate early launch indicative future sale result launch compete regiman experience increase pricing pressure united states certain case provide significant discount private public payer order obtain formulary status expand access patient hcv product change formulary coverage reimbursement level discount rebate offer hcv product payer negatively impact anticipate revenue expect pricing pressure hcv market continue hcvrelate revenue difficult predict investor widely vary expectation materially higher low actual revenue extent hcv product revenue exceed fall short expectation stock price experience significant volatility year end december approximately product sale united states wholesaler amerisourcebergen corp mckesson corp cardinal health inc wholesaler enter inventory management agreement estimate determine end user demand completely effective match inventory level actual end user demand result change inventory level hold wholesaler cause operating result fluctuate unexpectedly sale wholesaler match end user demand addition inventory hold retail pharmacy nonwholesaler location inventory management agreement control buy pattern adverse change economic condition factor cause retail pharmacy reduce inventory product reduce order wholesaler consequently wholesaler order end user demand change example fourth quarter strong wholesaler subwholesaler purchase hiv product result inventory drawdown wholesaler subwholesaler quarter inventory distribution channel fluctuate quarter quarter continue fluctuation earning mismatch prescription demand product revenue addition nonretail sector united states include government institution include state aids drug assistance program adap correctional facility large health maintenance organization tend consistent term buy pattern cause quarter quarter fluctuation necessarily mirror patient demand product federal state budget pressure include sequestration annual grant cycle federal state adap fund cause adap purchasing pattern reflect patient demand hiv product example quarter certain prior year observe large nonretail purchase hiv product number state adap exceed patient demand believe purchase drive grant cycle federal adap fund expect continue experience fluctuation purchase pattern nonretail customer result fluctuation product sale revenue earning future light global economic downturn budget crisis face european country observe variation purchase pattern induce cost containment measure europe believe measure cause government agency purchaser reduce inventory product distribution channel decrease revenue cause fluctuation product sale earning continue trend future result operation adversely affect current potential future healthcare reform legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction march healthcare reform legislation adopt united states require rebate discount product reimburse pay public payer include medicaid entity eligible purchase discount product drug pricing program public health service act adap result legislation discount rebate fee impact include minimum base rebate owe medicaid product reimburse medicaid increase discount rebate owe adap public health service entity reimburse purchase product increase require extend rebate patient receive product medicaid manage care organization require provide discount product sell patient medicare donut hole pharmaceutical manufacturer brand drug product require pay portion new industry fee know brand prescription drug bpd fee billion calculate base select government sale calendar year percentage total industry government sale annual industry fee impose pharmaceutical industry billion increase billion increase peak billion decrease billion expect portion bpd fee increase revenue grow annual industry fee increase drug patent expire major drug company addition quarter internal revenue service irs issue final regulation indicate manufacturer obligation pay portion bpd fee give calendar year trigger qualifying sale previous year instead qualify sale current calendar year result final irs regulation require recognize fee million fee million consolidated statement income bpd fee approximately million million million respectively bpd fee tax deductible address healthcare reform legislation discussion continue federal level legislation allow require federal government directly negotiate price concession pharmaceutical manufacturer set minimum requirement medicare pricing addition state medicaid program request additional supplemental rebate product result increase federal base medicaid rebate private insurer use enactment increase rebate exert pricing pressure product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service result low average selling price significant portion sale majority product subject significant discount list price rebate obligations united states state adap purchase significant portion hiv product rely federal supplemental federal state funding help fund purchase product past experienced shift payer mix hiv patient previously cover private insurance public reimbursement program require rebate discount patient previously cover public reimbursement program public reimbursement program require great rebate discount federal state fund available amount sufficient support number patient rely adap sale hiv product negatively impact reduce revenue prior quarter insufficiency federal state fund state reduce eligibility criterion see increase number patient state adap waitlist similar increase future period result reduction federal state adap support result sequestration patient enrol adap generally receive product industrysupporte patient assistance program unable access treatment increase emphasis manage healthcare united states country regional pricing reimbursement control european union additional pressure product pricing reimbursement usage adversely affect product sale profitability pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid healthcare reform pharmaceutical reimbursement policy pricing general experience increase pricing pressure united states certain case provide discount private payer order obtain formulary status expand access patient hcv product risk factor substantial portion revenue derive sale product treat hcv hiv unable maintain continue increase sale product result operation adversely affect july receive letter senate committee finance request information support documentation related sovaldi pricing sovaldi united states letter raise concern approach pricing sovaldi affordability impact federal government spend public health cooperating inquiry costly timeconsume comply inquiry predict outcome possible inquiry result negative publicity negative action harm reputation reduce demand sovaldi harvoni sofosbuvir contain product andor reduce coverage sovaldi harvoni sofosbuvir contain product include federal health care program medicare medicaid event occur business stock price materially adversely affect country outside united states success commercialize product product candidate develop depend largely obtain maintain government reimbursement country patient unlikely use prescription drug reimburse government addition negotiate price certain governmental authority delay commercialization month reimbursement policy adversely affect ability sell product profitable basis international market government control price prescription pharmaceutical include implementation reference pricing price cut rebate revenuerelate taxis tender profit control expect price prescription pharmaceutical decline life product volume increase recently country european union increase level discount require product effort continue country attempt manage healthcare expenditure especially light severe fiscal debt crisis experience country european union country institute clawback enact taxis specific product generic drug come market face price decrease product country european union cost containment pressure european union especially southern europe lead delay treatment patient delay pricing approval negatively impact commercialization new product government agency issue regulation guideline directly applicable product addition time time professional society practice management group private healthscience foundation organization publish guideline recommendation direct certain health care patient community recommendation guideline relate matter product usage dosage route administration use related compete therapy consequently result increase decrease usage product approximately product sale occur outside united states currency fluctuation hedging expense cause earning fluctuate adversely affect stock price significant percentage product sale denominate foreign currency primarily euro face exposure adverse movement foreign currency exchange rate dollar strengthen foreign currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative value sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business use foreign currency exchange forward option contract hedge percentage forecast international sale primarily denominate euro hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay predict future fluctuation foreign currency exchange rate dollar dollar appreciate significantly certain currency hedge program sufficiently offset effect appreciation result operation adversely affect stock price decline additionally expense recognize relation hedging activity cause earning fluctuate level hedging expense recognize particular period impact change interest rate spread foreign currency hedge dollar face significant competition face significant competition large global pharmaceutical biotechnology company specialize pharmaceutical firm generic drug manufacturer hcv product sovaldi harvoni compete product market abbvie inc abbvie janssen ireland olysio simeprevir united states hiv product compete primarily product viiv healthcare viiv market fixeddose combination product compete stribild compleraeviplera atripla truvada example lamivudine market joint venture compete emtricitabine active pharmaceutical ingredient emtriva component compleraeviplera atripla truvada tybost compete ritonavir market abbvie addition tivicay dolutegravir integrase inhibitor launch fourth quarter viiv triumeq singletablet triplecombination antiretroviral regimen launch quarter viiv adversely impact sale hiv product face competition generic hiv product compound patent cover epivir lamivudine expire united states generic lamivudine available united states spain portugal italy expect generic version lamivudine launch country european union generic version combivir lamivudine zidovudine approve recently launch united states addition late generic tenofovir available turkey result increase rebate viread turkey generic version sustiva efavirenz component atripla available canada europe anticipate competition generic efavirenz united states december observe pricing pressure relate sustiva component atripla sale viread hepsera treatment chronic hepatitis virus hbv infection face competition baraclude entecavir market bristolmyer squibb company generic entecavir hbv product compete tyzekasebivo telbivudine market novartis pharmaceutical corporation novartis ambisome compete predominantly vfend voriconazole develop pfizer caspofungin product develop merck market cancidas united states caspofungin addition aware lipid formulation claim similarity ambisome available outside united state include possible entry formulation taiwan formulation reduce market demand ambisome furthermore manufacture lipid formulation amphotericin complex formulation find unsafe sale ambisome negatively impact association letairis compete directly tracleer bosentan opsumit macitentan produce actelion pharmaceutical inc adcirca tadalafil united therapeutics corporation pfizer ranexa compete predominantly generic compound distinct class drug betablocker calcium channel blocker longacte nitrate treatment chronic angina united states cayston competes tobi tobramycin inhalation solution market novartis tamiflu compete relenza zanamivir sell gsk product sell generic competitor relapse chronic lymphocytic leukemia zydelig competes imbruvica ibrutinib market pharmacyclic inc addition number company pursue development technology competitive exist product research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program competitor gain market share product adversely affect result operation stock price significant safety issue arise market product product candidate future sale reduce adversely affect result operation datum support marketing approval product form basis safety warning product label obtain control clinical trial limit duration case postapproval use product long period time patient underlie health problem take numerous medicine expect continue find new issue safety resistance drug interaction issue require provide additional warning contraindication label narrow approve indication reduce market acceptance product product letairis approve food drug administration fda june member class compound call endothelin receptor antagonist pose specific risk include risk birth defect risk letairis available letairis education access program leap restrict distribution program intend help physician patient learn risk associate product assure appropriate use product product additional patient discover new risk associate letairis result change distribution program additional restriction use letairis decrease demand product regulatory authority move active transparent pharmacovigilance make great amount standalone safety information clinical trial datum directly available public website mean periodic safety update report summarie risk management plan summarie adverse event datum safety information appropriate context expertise misinterpret lead misperception legal action potentially cause product sale stock price decline safety resistance drug interaction issue arise market product sale product limit halt regulatory authority result operation adversely affect operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis maintain compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation fda ema comparable regulatory agency country continue clinical trial sovaldi atripla truvada harvoni compleraeviplera stribild viread emtriva hepsera tybost vitekta letairis ranexa cayston zydelig currently approve additional use anticipate file marketing approval additional country additional indication product year product fail receive marketing approval timely basis market product manufacture sell product subject extensive regulation review discovery previously unknown problem market product problem manufacture promotional activity result restriction product include withdrawal product market fail comply applicable regulatory requirement include related promotion manufacturing subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution example fda rule require conduct postapproval clinical study assess know risk signal risk identify unexpected risk implement risk evaluation mitigation strategy product include medication guide patient package insert communication plan healthcare provider element fda deem necessary assure safe use drug include impose certain restriction distribution use product failure comply requirement impose sponsor fda result significant civil monetary penalty operating result adversely affect result anticipate timeline clinical trial uncertain support continue development product candidate adversely affect prospect future revenue growth require demonstrate safety efficacy product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product product candidate fails achieve primary endpoint clinical trial safety issue arise result clinical trial inadequate support regulatory approval product candidate commercialization product candidate delay halt example recently announce result phase study simtuzumab treatment pancreatic cancer myelofibrosis colorectal cancer show product candidate provide clinical benefit addition face challenge clinical trial protocol design clinical trial product candidate pipeline delay terminate prospect future revenue growth adversely impact example face numerous risk uncertaintie product candidate include fixeddose combination sofosbuvir hcv fixeddose combination emtricitabine taf hiv idelalisib treatment indolent nonhodgkin lymphoma frontline relapse refractory chronic lymphocytic leukemia momelotinib treatment myelofibrosis ranolazine treatment incomplete revascularization post percutaneous coronary intervention treatment lqt taf standalone agent currently phase clinical trial prevent completion development product candidate risk include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain fda regulatory body approval result product candidate successfully commercialize strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline program pipeline complete timely basis prospect future revenue growth adversely impact addition clinical trial involve commercial product raise new safety issue exist product turn decrease revenue harm business reliance thirdparty contract research organization conduct clinical trial unable directly control timing conduct expense quality clinical trial extensively outsource clinical trial activity usually perform small portion startup activity inhouse rely independent party contract research organization cro perform clinical study include document preparation site identification screen preparation prestudy visit training program management bioanalytical analysis important aspect service perform cros direct control dispute disruption relationship cro clinical trial delay regulatory submission rely quality validity clinical work perform thirdparty cro cro process methodology result determine invalid inadequate clinical data result relate regulatory approval adversely affect depend relationship company sale marketing performance development commercialization product candidate revenue failure maintain relationship poor performance company dispute company negatively impact business rely number significant collaborative relationship major pharmaceutical company sale marketing performance certain territory include collaboration bms atripla united states europe canada hoffmannla roche ltd hoffmannla roche inc roche tamiflu worldwide gsk ambrisentan territory outside united states country rely international distributor sale truvada viread hepsera emtriva ambisome relationship involve clinical development product partner reliance collaborative relationship pose number risk include risk unable control resource corporate partner devote program product dispute arise respect ownership right technology develop corporate partner disagreement corporate partner cause delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose pursue compete technology devote few resource marketing product product development distributor corporate partner unable pay particularly light current economic condition give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue product decline addition letairis cayston distribute thirdparty specialty pharmacy pharmacie specialize dispense medication complex chronic condition require high level patient education ongoing counseling use specialty pharmacy require significant coordination sale marketing medical affair regulatory affair legal finance organization involve risk include limited risk specialty pharmacy provide accurate timely information inventory patient data safety complaint effectively sell support letairis cayston devote resource necessary sell letairis cayston volume time frame expect able satisfy financial obligation cease operation rely party administer leap restrict distribution program design support letairis party provide information education prescriber patient risk letairis confirm insurance coverage investigate alternative source reimbursement assistance ensure fulfillment risk management requirement mandate letairis fda coordinates control dispense patient party specialty pharmacy failure party specialty pharmacy distribute letairis perform expect result regulatory action fda decrease letairis sale harm business cayston take patient specific inhalation device deliver drug lung patient ongoing distribution cayston entirely reliant manufacturer device manufacturer encounter issue regulatory agency relate device unable supply sufficient quantity device addition manufacturer able provide adequate warranty support device distribute patient respect distribution drug device patient reliant capability specialty pharmacy example distribution channel drug device complicated require coordination reimbursement approval process associate drug device similarly complex device manufacturer unable obtain reimbursement approval receive approval lowerthanexpecte price sale cayston adversely affect previously describe issue limit sale cayston adversely affect financial result success depend significant degree ability defend patent intellectual property right domestically internationally able obtain effective patent protect technology use competitor patent company require stop pay use require technology patent proprietary right important business success depend significant degree ability obtain patent license patent right preserve trade secret defend infringement effort invalidate patent operate infringe intellectual property properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent patent application confidential period time patent issue result know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete product addition competitor file patent application cover technology participate litigation interference proceeding determine right patent litigation interference proceeding unpredictable expensive ultimately successful result operation adversely affect event patent cover ranolazine compound active ingredient ranexa instead discover sustainedrelease formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve patent cover active ingredient ambisome addition patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera asia major market therapie hbv indication hepsera develop obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension supplementary protection certificate country generic manufacturer seek continue seek fda approval market generic version product abbreviate new drug application anda application form typically manufacturer seek approval generic drug description anda litigation legal proceeding begin risk factor entitle litigation generic manufacturer increase expense continue reduce earning unsuccessful lawsuit claim patent narrow invalidated generic version product launch prior patent expiry begin success depend large ability operate infringe patent proprietary right party infringe valid patent party prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware patent relate operation leap restrict distribution program design support letairis aware patent patent application own party claim cover use sofosbuvir description litigation sofosbuvir risk factor entitle party successful establish exclusive right sovaldi andor harvoni expect revenue earning sale sovaldi andor harvoni adversely affect beginning furthermore rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention trade secret confidential information know independently discover competitor enter dispute ownership invention business result operation adversely affect party successful establish exclusive right sovaldi andor harvoni expect revenue earning sale sovaldi andor harvoni adversely affect patent patent application claim sofosbuvir sovaldi chemical entity metabolite fixeddose combination ledipasvir sofosbuvir harvoni party obtain right patent allegedly prevent attempt prevent commercialize sovaldi harvoni example aware patent patent application own party allege party cover use sovaldi harvoni predict ultimate outcome intellectual property claim relate sovaldi harvoni spend continue spend significant resource defend claim party successfully obtain valid enforceable patent successfully prove infringement patent sovaldi andor harvoni prevent sell sofosbuvir able obtain license patent license available commercially reasonable term interference proceeding litigation idenix pharmaceuticals inc idenix february receive notice patent trademark office uspto declare interference idenix interference patent patent idenix pende patent application interference administrative proceeding uspto design determine invent subject matter claim party patent cover metabolite sofosbuvir idenix attempt patent class compound include metabolite purpose idenix interference determine invent compound entitle patent claim compound march uspto patent trial appeal board board determine idenix entitle benefit early application filing date patent application include application grant idenixs patent patent teach compound dispute board determine entitle filing date early application file patent application compound dispute senior party idenix interference january board determine pharmasset idenix invent compound dispute accordingly gilead prevail idenix interference decision board hold idenix fail prove conceive compound dispute specifically idenix fail prove idenix inventor identify structure method make use dispute compound board go conclude idenix fail work diligently make testing compound dispute relevant time period idenix appeal board decision district court district delaware december receive request uspto declare interference second idenix interference pende patent application patent patent include claim direct method treat hcv nucleoside compound similar involved idenix interference second idenix interference determine invent claim method treat hcv january board issue decision favor gilead phase second idenix interference board decide file patent application dispute method treat hcv designate gilead senior party second idenix interference invalidated patent claim idenix patent involve second idenix interference senior party presume invent dispute method treat hcv idenix fail teach use invention patent board invalidate idenix claim involve second idenix interference lack enablement board place idenix order cause require idenix explain judgment enter second idenix interference base decision board idenix interference decision second idenix interference consistent board early ruling march january idenix interference gilead declare senior party invent certain fluoro methyl nucleoside compound compound relevant method treat hcv issue second idenix interference believe idenix claim involve second idenix interference similar foreign patent claim compound metabolite use thereof invalid result file impeachment action federal court canada invalidate idenix canadian patent patent canadian patent correspond patent idenix patent application subject idenix interference idenix assert commercialization sovaldi canada infringe patent canadian patent correspond patent involve idenix interference invalid trial issue commence january file similar legal action norway oslo district court seek invalidate idenix norwegian patent correspond patent september idenix file invalidation action norwegian proceeding norwegian patent patent correspond patent march norwegian court find claim idenix norwegian patent invalid upheld validity claim challenge gilead patent april idenix appeal march decision norwegian court appeal idenixs obligation pay attorney fee stay pendency appeal appeal march decision schedule commence february august april idenix file separate request invalidation chinese patent office chinese patent correspond patent august idenix withdraw invalidation request chinese proceeding terminate challenge patent remain valid enforceable january file legal action federal court australia seek invalidate idenixs australian patent correspond patent april idenix assert commercialization sovaldi australia infringe australian patent correspond patent trial issue schedule commence september sydney march european patent office epo grant idenix european patent patent correspond patent day patent grant file opposition epo seek revoke patent day idenix initiate infringement proceeding gilead united kingdom germany france allege commercialization sovaldi country infringe respective national counterparts patent united kingdom trial hold october determine issue infringement validity idenix patent december high court justice england wale court invalidate claim patent multiple ground specifically court hold patent lack novelty early file patent application teaching compound patent lack inventive step add knowledge exist time disclosure idenixs patent application insufficient teach compound claim compound activity virus like hepatitis virus january court hold hearing court order idenix pay gilead cost interim payment day hear court grant idenix permission appeal december judgment february german court dsseldorf hold hearing determine issue infringement idenix german patent trial date french lawsuit idenix award patent correspond patent japan china event patent issue expect challenge proceeding similar invoke country december idenix universita degli studi cagliari udsg centre national recherche scientifique luniversit montpellier sue district court district delaware allege commercialization sofosbuvir infringe patent interference exist patent patent december idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos june court massachusetts grant request transfer massachusetts litigation district court district delaware believe idenixs patent invalid infringe commercialization sofosbuvir sole right commercialize sofosbuvir district court set trial date october december resolution issue decision district court appeal party court appeal federal circuit cafc idenix acquire merck august acquisition change view lack merit claim idenix merck great resource idenix choose fund litigation high level idenix litigation merck august merck contact request pay royalty sale sofosbuvir obtain license patent nos coown isis pharmaceuticals inc believe merck patent invalid infringe commercialization sofosbuvir sole right commercialize sofosbuvir accordingly august file lawsuit district court northern district california seek declaratory judgment merck patent invalid infringe merck patent nos cover compound include relate sofosbuvir patent prosecution merck amend patent application attempt cover compound relate sofosbuvir ultimately extract royalty payment sofosbuvir commercialization exclude market court determine merck patent valid infringe claim require obtain license pay royalty merck commercialize sofosbuvir party appeal decision district court cafc court set trial date march litigation litigation abbvie abbvie obtain patent nos abbvie patent purport cover use combination ledipasvirsofosbuvir harvoni treatment hcv aware abbvie pende patent application country publish pende patent application direct use combination treatment hcv specifically combination ledipasvir sofosbuvir certain application file abbvie patent reason believe abbvie patent invalid accordingly december file lawsuit district court district delaware seek declaratory judgment abbvie patent invalid unenforceable relief believe abbott laboratories inc abbvie conspire eliminate competition hcv market falsely represent uspto gilead invent method treat hcv combination ledipasvirsofosbuvir february march abbvie respond lawsuit file lawsuit district court district delaware allege fixeddose combination ledipasvirsofosbuvir infringe patent lawsuit consolidate single action party appeal decision district court cafc abbvie patent block delayed commercialization combination product united states expect foreign patent block delay commercialization world court determine abbvie patent valid infringe claim require obtain license pay royalties abbvie commercialize sofosbuvir combination product manufacturing problem include thirdparty manufacturer corporate partner cause inventory shortage delay product shipment regulatory approval adversely affect result operation order generate revenue product able produce sufficient quantity product satisfy demand product result complex manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation product manufacture facility thirdparty manufacturer corporate partner depend party perform manufacturing activity effectively timely basis majority solid dose product addition roche party responsible manufacturing tamiflu thirdparty manufacturer corporate partner subject good manufacturing practice gmp extensive regulation govern manufacturing process stability testing record keep quality standard define fda ema similar regulation effect country thirdparty manufacturer corporate partner independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval writeoff cost manufacturing batch fail pass quality inspection meet regulatory approval extent risk materialize affect performance obligation financial result adversely affect addition thirdparty manufacturer corporate partner able produce product limit number facility limited manufacturing capacity certain product example unexpected delay qualify new external site expand cayston manufacturing san dimas unable supply cayston fulfill project demand february september suspend access patient new prescription cayston subject certain exception specific medical need exist result inability manufacture sufficient cayston meet demand revenue receive sale cayston reduce manufacturing operation subject routine inspection regulatory agency example april fda conduct inspection foster city facility issue form inspectional observation note deficiency documentation validation certain quality testing procedure method result observation fda deliver complete response letter notify unable approve nda elvitegravir cobicistat standalone agent midoctober fda complete sofosbuvir preapproval inspection foster city facility follow inspection fda issue additional form inspectional observation cite deficiency relate testing reconciliation stability sample test protocol test shipping sample procedure calibrate test equipment complete file response observation fda receive letter fda relate extent method revalidation conduct stability program oversight audit trail reviewdata management quality management system gap file response observation fda unable remedy deficiency cite fda inspection currently market product time regulatory approval product development adversely affect risk regulatory agency country marketing application pende undertake similar additional review apply heighten standard review delay regulatory approval product country approval product candidate delay production market product interrupt anticipate revenue stock price adversely affect able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue need access certain supply product conduct clinical trial manufacture product unable purchase sufficient quantity material find suitable alternate material timely manner development effort product candidate delay ability manufacture product limit limit ability generate revenue supplier key component material name nda file fda ema regulatory authority product candidate seek marketing approval significant delay occur qualification new supplier require manufacturer qualified regulatory authority manufacturer continue expend time money effort area production quality control ensure compliance gmp manufacturer subject regular periodic inspection regulatory authority follow initial approval result inspection regulatory authority determine equipment facility laboratory process comply applicable regulation condition product approval regulatory authority suspend manufacturing operation manufacture operation single supplier product suspend unable generate sufficient quantity commercial clinical supply product meet market demand turn decrease revenue harm business addition delivery material supplier interrupt reason unable ship certain product commercial supply supply product development clinical trial addition product material utilize operation facility example manufacture certain drug product intermediate utilize ambisome exclusively facility san dimas california event disaster include earthquake equipment failure difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome meet market need addition depend single supplier highquality cholesterol active pharmaceutical ingredient manufacture ambisome rely single source active pharmaceutical ingredient zydelig letairis astellas llc markets lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan problem single supplier depend negatively impact development commercialization effort significant portion raw material intermediate manufacture antiviral product sovaldi atripla truvada harvoni compleraeviplera stribild viread emtriva tybost supply chinabased company result international trade dispute china united states action chinese government limit prevent chinese company supply material adversely affect ability manufacture supply antiviral product meet market need material adverse effect operating result litigation generic manufacturer increase expense continue reduce earning unsuccessful lawsuit claim patent narrow invalidated generic version product launch prior patent expiry approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug anda application form typically manufacturer seek approval generic drug current legal proceeding significance generic manufacturer include mylan april receive notice mylan inc mylan submit anda fda request permission manufacture market generic version truvada notice mylan allege patent associate emtricitabine patent associate fixeddose combination emtricitabine tenofovir disoproxil fumarate invalid unenforceable andor infringe mylan manufacture use sale generic version truvada june file lawsuit mylan district court northern district west virginia infringement patent june receive notice mylan inc submit petition inter parte review ipr board allege patent associate tenofovir disoproxil fumarate invalid oppose mylan petition december ptab issue decision deny mylan petition ipr tenofovir disoproxil fumarateassociate patent ground mylan establish reasonable likelihood success prevail challenge patent mylan request rehear basis believe ptab decision wrong apotex june receive notice apotex inc apotex submit abbreviate new drug submission and canadian minister health request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate separate and request permission manufacture market generic version viread notice apotex allege patent associate truvada patent associate viread invalid unenforceable andor infringe apotex manufacture use sale generic version truvada viread august file lawsuit apotex federal court canada seek order prohibition approval ands natco march hoffmannla roche ltd roche file lawsuit natco pharma ltd natco district court district new jersey infringement patent associate tamiflu december court issue rule favor gilead roche patent invalid reason state natcos notice letter natco appeal decision cafc april cafc issue decision allow natcos patent invalidity challenge procee case remand district court trial merit june file petition rehear banc cafc subsequently deny submit request extension time submit petition certiorari supreme court united states concurrently proceed district court teva august teva pharmaceutical teva file impeachment action federal court canada seek invalidation canadian patent associate viread september hearing consolidated request order prohibition connection tevas and filing canadian minister health tevas generic version viread truvada atripla take place december court issue request order prohibit canadian ministry health issue notice compliance tevas generic version viread truvada atripla product expiry patent july teva appeal decision court prohibit minister heath issuing notice compliance expiry patent july decision rule validity patent accordingly issue appeal minister health prohibit issue notice compliance tevas product separately court determine validity patent pende impeachment action trial impeachment action schedule september teva successful invalidating patent teva able launch generic version viread truvada atripla products canada prior expiry patents watson february receive notice watson laboratories inc watson submit anda fda request permission manufacture market generic version letairis notice watson allege patent associate ambrisentan tablet invalid unenforceable andor infringed watson manufacture use sale generic version letairis currently evaluate watson notice file patent infringement lawsuit necessary protect exclusivity product astellasapotex december astellas inform receive notice apotex submit anda fda request permission manufacture market generic version lexiscan notice apotex allege patent associate regadenoson invalid unenforceable andor infringe apotexs manufacture use sale generic version lexiscan apotex challenge patent associate regadenoson apotex product eligible final approval expiry patent challenge astella opportunity file patent infringement lawsuit apotex future decide necessary protect exclusivity product predict ultimate outcome forego action litigation generic manufacturer spend significant resource enforce defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection truvada viread tamiflu united states atripla truvada viread canada substantially shorten patent cover product invalidate fda canadian minister health approve request manufacture generic version products united states canada respectively prior expiration date patent sale generic version product early patent expiration significant negative effect revenue result operation face credit risk emerge market southern european customer adversely affect result operation exposure customer credit risk emerge market southern europe southern european product sale governmentowne support customer southern europe specifically spain italy portugal greece historically continue subject significant payment delay government funding reimbursement practice result continue result day sale outstanding significantly high country average length time account receivable remain outstanding december account receivable country total approximately million million past great day million past great day historically receivable balance certain publiclyowne hospital accumulate period time subsequently settle large lump sum payment pattern experience pharmaceutical company sell directly hospital significant change occur reimbursement practice european government government funding unavailable able collect amount customer result operation adversely affect revenue gross margin reduce import country product available low price price product base local market economic competition differ country country sale country relatively high price reduce product import country low price market case pharmaceutical product sell steeply discount price develop world reexporte european country resold high price happen product particularly truvada viread agree available substantially reduce price country participate gilead access program atripla merck distribute substantially reduce price hiv infect patient develop country agreement revenue adversely affect addition establish partnership indiabase generic manufacturer distribute generic version tenofovir disoproxil fumarate develop world country include india expand agreement include right stribild tybost vitekta enter agreement certain indiabase generic manufacturer produce distribute generic emtricitabine develop world include single tablet regimen contain emtricitabine fixeddose combination emtricitabine coformulate hiv medicine september enter licensing agreement indiabase generic manufacturer produce distribute generic sofosbuvir fixeddose combination ledipasvirsofosbuvir develop country generic version hiv hcv medication license reexporte united states europe market outside country revenue adversely affect commitment sovaldi available develop world discount price enter agreement sovaldi available egypt country high hcv prevalence world discount sovaldi reexporte develop country united states high price market revenue adversely affect addition purchase product country sell price relatively low resale country sell price relatively high adversely impact revenue gross margin cause sale fluctuate quarter quarter example european union require permit product purchase country sell country purchase product country sell price relatively low resale country sell price relatively high affect inventory level hold wholesaler cause relative sale level country fluctuate quarter quarter reflect actual consumer demand give quarter quarterly fluctuation impact earning adversely affect stock price harm business expensive litigation government investigation increase expense continue reduce earning involve number litigation investigation disputerelate matter require expend substantial internal financial resource expect matter continue require high level internal financial resource foreseeable future matter reduce continue reduce earning description litigation sofosbuvir litigation generic manufacturer legal proceeding begin outcome lawsuit lawsuit brought investigation investigation initiate inherently uncertain adverse development outcome result significant expense monetary damage penalty injunctive relief significantly reduce earning cash flow harm business country require grant compulsory license product patent enforce number develop country government official interested group suggest pharmaceutical company drug hcv hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example grow attention availability hcv therapy activist advocate increase availability hcv therapy mean include compulsory license past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread addition concern cost availability tamiflu relate potential avian flu pandemic influenza generate international discussion compulsory licensing tamiflu patent example canadian government consider allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop develop country canada access medicine regime furthermore roche issue voluntary license permit thirdparty manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group ltd china sublicense india hetero drug limited india certain develop country compulsory license permit generic manufacturing override product patent sovaldi harvoni hiv product tamiflu require grant compulsory license product reduce earning cash flow harm business addition certain country permit enforcement patent thirdparty manufacturer able sell generic version product country example july brazilian patent authority reject patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread high level appeal available brazilian patent authority currently patent brazil brazilian government purchase supply tenofovir disoproxil fumarate generic manufacturer sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale face significant liability result product cover insurance successful claim materially reduce earning testing manufacturing marketing use commercial product product candidate development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company recent year coverage availability costeffective product liability insurance decrease unable maintain sufficient coverage product liability arise addition cost defend lawsuit pay damage product liability claim exceed coverage unable maintain adequate coverage claim exceed coverage financial condition ability clinically test product candidate market product adversely affect addition negative publicity associate claim regardless merit decrease future demand product impair financial condition business disruption natural manmade disaster harm future revenue worldwide operation subject business interruption stem natural manmade disaster selfinsure corporate headquarters fremont location house majority activity san dima oceanside manufacture facility locate california seismically active region carry earthquake insurance significant recovery time require resume operation financial condition operating result materially adversely affect event major earthquake dependent information technology system infrastructure datum dependent information technology system infrastructure datum multitude complexity computer system inherently vulnerable service interruption destruction malicious intrusion random attack likewise datum privacy security breach employee pose risk sensitive datum include intellectual property trade secret personal information employee patient customer business partner expose unauthorized person public cyberattack increase frequency sophistication intensity cyberattack include deployment harmful malware denialofservice social engineering mean affect service reliability threaten datum confidentiality integrity availability business partner face similar risk security breach system adversely affect security posture invest continue invest protection datum information technology infrastructure assurance effort prevent service interruption identify breach system adversely affect business operation andor result loss critical sensitive information result financial legal business reputational harm addition liability insurance sufficient type cover claim relate security breach cyberattack relate breach change effective income tax rate reduce earning subject income taxis unite states foreign jurisdiction include ireland economic political condition country actively consider change exist tax law predict form time potential legislative change material adverse impact result operation addition significant judgment require determine worldwide provision income taxis factor favorable unfavorable effect income tax rate include limited change forecast demand hcv product portion nontax deductible bpd fee know pharmaceutical excise tax accounting stock option sharebase award merger acquisition ability manufacture product cork ireland facility amortization certain acquisition relate intangible receive tax benefit expiration federal research tax credit future level spending change mix earning tax jurisdiction operate change overall level pretax earning resolution federal state foreign income tax audits impact income tax provision result mention factor significant negative impact consolidate result operation income tax return audit federal state foreign tax authority currently examination internal revenue service tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction resolution exposure report period material impact result operation period fail attract retain highly qualified personnel unable successfully develop new product candidate conduct clinical trial commercialize product candidate future success depend large continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical testing governmental regulation commercialization face competition personnel company university public private research institution government entity organization competition qualified personnel biopharmaceutical field intense limited pool qualified potential employee recruit able attract retain quality personnel acceptable term unsuccessful recruitment retention effort business harm assurance pay dividend continue repurchase stock february announce board director authorize dividend program intend pay quarterly dividend share begin second quarter subject quarterly declaration board director board director approved repurchase additional billion common stock declaration time dividend andor time stock repurchase subject capital availability determination board director cash dividend andor stock repurchase good interest stockholder compliance respective law agreement applicable declaration payment cash dividend repurchase stock ability pay dividend andor repurchase stock depend factor cash balance potential future capital requirement strategic transaction include acquisition debt service requirement result operation financial condition factor control board director deem relevant reduction elimination dividend payment dividend program andor stock repurchase negative effect stock price item unresolved staff comment applicable item property corporate headquarters locate foster city california house administrative manufacturing activity facility oceanside fremont california seattle washington branford connecticut alberta canada manufacturing facilities san dimas california cork ireland global commercial operation include office europe seven asia south america north america believe exist property include own lease site good condition suitable conduct business believe capital resource sufficient purchase lease construct additional facility require meet expect longterm growth need item legal proceeding litigation sofosbuvir january acquire pharmasset inc pharmasset acquisition acquire sofosbuvir nucleotide analog act inhibit replication hcv december receive fda approval sofosbuvir know commercially sovaldi october receive approval fixeddose combination ledipasvir sofosbuvir know commercially harvoni receive number contractual intellectual property claim sofosbuvir carefully consider claim prior follow acquisition believe merit patent patent application claim sofosbuvir sovaldi chemical entity metabolite fixeddose combination ledipasvir sofosbuvir harvoni party obtain right patent allegedly prevent attempt prevent commercialize sovaldi harvoni example aware patent patent application own party allege party cover use sovaldi harvoni predict ultimate outcome intellectual property claim relate sovaldi harvoni spend continue spend significant resource defend claim party successfully obtain valid enforceable patent successfully prove infringement patent sovaldi andor harvoni prevent sell product able obtain license patent license available commercially reasonable term interference proceeding litigation idenix pharmaceuticals inc idenix february receive notice patent trademark office uspto declare interference idenix interference patent patent idenix pende patent application interference administrative proceeding uspto design determine invent subject matter claim party patent cover metabolite sofosbuvir idenix attempt patent class compound include metabolite purpose idenix interference determine invent compound entitle patent claim compound march uspto patent trial appeal board board determine idenix entitle benefit early application filing date patent application include application grant idenixs patent patent teach compound dispute board determine entitle filing date early application file patent application compound dispute senior party idenix interference january board determine pharmasset idenix invent compound dispute accordingly gilead prevail idenix interference decision board hold idenix fail prove conceive compound dispute specifically idenix fail prove idenix inventor identify structure method make use dispute compound board go conclude idenix fail work diligently make testing compound dispute relevant time period idenix appeal board decision district court district delaware december receive request uspto declare interference second idenix interference pende patent application patent patent include claim direct method treat hcv nucleoside compound similar involved idenix interference second idenix interference determine invent claim method treat hcv january board issue decision favor gilead phase second idenix interference board decide file patent application dispute method treat hcv designate gilead senior party second idenix interference invalidated patent claim idenix patent involve second idenix interference senior party presume invent dispute method treat hcv idenix fail teach use invention patent board invalidate idenix claim involve second idenix interference lack enablement board place idenix order cause require idenix explain judgment enter second idenix interference base decision board idenix interference decision second idenix interference consistent board early ruling march january idenix interference gilead declare senior party invent certain fluoro methyl nucleoside compound compound relevant method treat hcv issue second idenix interference believe idenix claim involve second idenix interference similar foreign patent claim compound metabolite use thereof invalid result file impeachment action federal court canada invalidate idenix canadian patent patent canadian patent correspond patent idenix patent application subject idenix interference idenix assert commercialization sovaldi canada infringe patent canadian patent correspond patent involve idenix interference invalid trial issue commence january file similar legal action norway oslo district court seek invalidate idenix norwegian patent correspond patent september idenix file invalidation action norwegian proceeding norwegian patent patent correspond patent march norwegian court find claim idenix norwegian patent invalid upheld validity claim challenge gilead patent april idenix appeal march decision norwegian court appeal idenixs obligation pay attorney fee stay pendency appeal appeal march decision schedule commence february august april idenix file separate request invalidation chinese patent office chinese patent correspond patent august idenix withdraw invalidation request chinese proceeding terminate challenge patent remain valid enforceable january file legal action federal court australia seek invalidate idenixs australian patent correspond patent april idenix assert commercialization sovaldi australia infringe australian patent correspond patent trial issue schedule commence september sydney march european patent office epo grant idenix european patent patent correspond patent day patent grant file opposition epo seek revoke patent day idenix initiate infringement proceeding gilead united kingdom germany france allege commercialization sovaldi country infringe respective national counterparts patent united kingdom trial hold october determine issue infringement validity idenix patent december high court justice england wale court invalidate claim patent multiple ground specifically court hold patent lack novelty early file patent application teaching compound patent lack inventive step add knowledge exist time disclosure idenixs patent application insufficient teach compound claim compound activity virus like hepatitis virus january court hold hearing court order idenix pay gilead cost interim payment day hear court grant idenix permission appeal december judgment february german court dsseldorf hold hearing determine issue infringement idenix german patent trial date french lawsuit idenix award patent correspond patent japan china event patent issue expect challenge proceeding similar invoke country december idenix universita degli studi cagliari udsg centre national recherche scientifique luniversit montpellier sue district court district delaware allege commercialization sofosbuvir infringe patent interference exist patent patent december idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos june court massachusetts grant request transfer massachusetts litigation district court district delaware believe idenixs patent invalid infringe commercialization sofosbuvir sole right commercialize sofosbuvir district court set trial date october december resolution issue decision district court appeal party court appeal federal circuit cafc idenix acquire merck august acquisition change view lack merit claim idenix merck great resource idenix choose fund litigation high level idenix litigation merck inc merck august merck contact request pay royalty sale sofosbuvir obtain license patent nos coown isis pharmaceuticals inc believe merck patent invalid infringe commercialization sofosbuvir sole right commercialize sofosbuvir august file lawsuit district court northern district california seek declaratory judgment merck patent invalid infringe merck patent nos cover compound include relate sofosbuvir patent prosecution merck amend patent application attempt cover compound relate sofosbuvir apparent goal ultimately extract royalty payment sofosbuvir commercialization eliminate competition exclude market court determine merck patent valid infringe claim require obtain license pay royalty merck commercialize sofosbuvir party appeal decision district court cafc court set trial date march lawsuit litigation abbvie inc abbvie abbvie obtain patent nos abbvie patent purport cover use combination ledipasvirsofosbuvir harvoni treatment hcv gilead aware abbvie pende patent application united states country publish pende patent application direct use combination treatment hcv specifically combination ledipasvir sofosbuvir certain application file abbvie patent reason believe abbvie patent invalid accordingly december file lawsuit district court district delaware seek declaratory judgment abbvie patent invalid unenforceable relief believe abbott laboratories inc abbvie conspire eliminate competition hcv market falsely represent uspto gilead invent method treat hcv combination ledipasvirsofosbuvir february march abbvie respond lawsuit file lawsuit district court district delaware allege fixeddose combination ledipasvirsofosbuvir infringe patent lawsuit consolidate single action united states party appeal decision district court cafc abbvie patent block delayed commercialization combination product united states europe expect foreign patent block delay commercialization world court determine abbvie patent valid infringe claim require obtain license pay royalties abbvie commercialize sofosbuvir combination product litigation generic manufacturer approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug tenofovir disoproxil fumarate emtricitabine fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz receive notice teva pharmaceutical teva submit anda fda request permission manufacture market generic version truvada april teva reach agreement settle ongoing patent litigation concern patent protect tenofovir disoproxil fumarate atripla truvada viread agreement teva allow launch generic version viread december april teva enter agreement settle ongoing patent litigation concern emtricitabine patent protect atripla truvada term settlement confidential november receive notice teva submit and canadian minister health request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate notice teva allege patent associate truvada invalid unenforceable andor infringe teva manufacture use sale generic version truvada january file lawsuit teva federal court canada seek order prohibition approval and december receive notice teva submit and canadian minister health request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva allege patent associate atripla merck patent associate atripla invalid unenforceable andor infringe teva manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz february file lawsuit teva federal court canada seek order prohibition approval and august receive notice teva submit and canadian minister health request permission manufacture market generic version viread notice teva allege patent associate tenofovir disoproxil fumarate invalid unenforceable andor infringe teva manufacture use sale generic version viread truvada atripla september file lawsuit teva federal court canada seek order prohibition approval and august teva file impeachment action federal court canada seek invalidation canadian patent associate viread currently defend impeachment action request order prohibition connection tevas and filing tevas generic version viread truvada atripla consolidated december court issue request order prohibit canadian minister health issuing notice compliance tevas generic version viread truvada atripla product expiry patent july teva appeal decision decision rule validity patent accordingly issue appeal minister health prohibit issue notice compliance tevas product separately court determine validity patent pende impeachment action trial impeachment action schedule september teva successful invalidating patent teva able launch generic version viread truvada atripla products canada prior expiry patent receive notice lupin limited lupin submit anda fda request permission manufacture market generic version truvada viread lupin amend anda certify long seek approval market generic version truvada viread prior expiration patent associate tenofovir disoproxil fumarate january include pediatric exclusivity september reach agreement lupin settle lawsuit related emtricitabine patent protect truvada atripla term settlement confidential july receive notice cipla ltd cipla submit anda fda request permission manufacture market generic version emtriva viread july cipla reach agreement settle lawsuit term settlement confidential april received notice mylan inc mylan submit anda fda request permission manufacture market generic version truvada notice mylan allege patent associate emtricitabine patent associate fixeddose combination emtricitabine tenofovir disoproxil fumarate invalid unenforceable andor infringe mylan manufacture use sale generic version truvada june file lawsuit mylan district court northern district west virginia infringement patent june receive notice mylan inc submit petition inter parte review ipr board allege patent associate tenofovir disoproxil fumarate invalid oppose mylan petition december uspto patent trial appeal board ptab issue decision deny mylan petition ipr tenofovir disoproxil fumarateassociate patent ground mylan establish reasonable likelihood success prevail challenge patent mylan request rehear basis believe ptab decision wrong june receive notice apotex inc apotex submit and canadian minister health request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate separate and request permission manufacture market generic version viread notice apotex allege patent associate truvada patent associate viread invalid unenforceable andor infringe apotex manufacture use sale generic version truvada viread august file lawsuit apotex federal court canada seek order prohibition approval ands ranolazine receive notice lupin submit anda fda request permission manufacture market generic version sustainedrelease ranolazine august party reach agreement settle patent litigation prior issuance court decision agreement lupin allow launch generic version ranexa february tamiflu february receive notice natco pharma ltd natco submit anda fda request permission manufacture market generic version tamiflu notice natco allege patent associate oseltamivir phosphate invalid unenforceable andor infringe natco manufacture use sale generic version tamiflu march roche file lawsuit natco district court district new jersey infringement patent associate tamiflu december court issue rule favor gilead roche patent invalid reason state natco notice letter natco appeal decision cafc issue decision april allow natcos patent invalidity challenge proceed remand district court new jersey trial merit june file petition rehear banc cafc subsequently deny file petition certiorari supreme court united states concurrently proceed district court letairis august natco file complaint district court district minnesota gilead express script hold specialty pharmacy distribute letairis product distribute letairis pursuant fdamandate risk evaluation mitigation strategy rem program natco allege gilead independently express script deny natco access sample letairis natco claim need order conduct bioequivalence testing file anda accord natco conduct violate antitrust law natco seek damage order restrain gilead limit distribution letairis natco use rem program november zydus pharmaceuticals usa inc zydus cadila healthcare limited cadila file complaint district court district new jersey relate letairis sale distribute letairis pursuant rem program zydus cadila allege deny access sample letairis claim need order conduct bioequivalence testing file anda accord zydus cadila conduct violate antitrust law zydus cadila seek damage order enjoin gilead provide zydus sample letairis february receive notice watson laboratories inc watson submit anda fda request permission manufacture market generic version letairis notice watson allege patent associate ambrisentan tablet invalid unenforceable andor infringed watson manufacture use sale generic version letairis currently evaluate watson notice file patent infringement lawsuit necessary protect exclusivity product lexiscan december astellas inform receive notice apotex submit anda fda request permission manufacture market generic version lexiscan notice apotex allege patent associate regadenoson invalid unenforceable andor infringe apotexs manufacture use sale generic version lexiscan apotex challenge patent associate regadenoson apotex product eligible final approval expiry patent challenge astella opportunity file patent infringement lawsuit apotex future decide necessary protect exclusivity product predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit claim patent narrow invalidated patent protection truvada viread lexiscan tamiflu united states atripla truvada viread canada substantially shorten patent cover product invalidate fda canadian minister health approve request manufacture generic version products united states canada respectively prior expiration date patent sale generic version product early patent expiration significant negative effect revenue result operation department justice investigation june receive subpoena attorney office northern district california request document relate manufacture relate quality distribution practice complera atripla truvada viread emtriva hepsera letairis cooperate government inquiry april united states department justice inform follow investigation decline intervene false claim act lawsuit file employee april employee serve amend complaint january federal district court issue order grant entirety prejudice motion dismiss amend complaint february employee serve second amend complaint dismiss second amend complaint matter party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation item safety disclosure applicable item market registrant common equity relate stockholder matter issuer purchase equity security common stock trade nasdaq global select market symbol gild follow table set forth high low intraday sale price share common stock nasdaq global select market period indicate price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low quarter second quarter quarter fourth quarter quarter second quarter quarter fourth quarter february share common stock outstanding hold approximately stockholder record include share hold broker bank nominee pay cash dividend common stock inception february announce initiation quarterly dividend share begin second quarter subject declaration board director quarterly dividend equivalent share annual basis performance graph follow graph compare total stockholder return past year index standard poor stock index label index nasdaq biotechnology index label nbi index total return index assume reinvestment dividend pay company include index calculate december year composite member index nbi index intend use indice comparator stock performance purpose follow graph go forward composite member index require applicable regulation use index comparator believe nbi index relevant comparator compose peer company linesofbusiness similar stockholder return show graph necessarily indicative future performance endorse prediction future stockholder return comparison cumulative total return investment past year section soliciting material deem file sec incorporate reference filing securities act exchange act date hereof irrespective general incorporation language filing show cumulative return investment assume investment common stock nbi index index december issuer purchase equity security quarter complete billion stock repurchase program announce program repurchase billion program board director authorize new threeyear billion stock repurchase program program program expire september december repurchase billion common stock program february announce board director authorize new billion fiveyear share repurchase program initiate completion program spend total billion repurchase retire approximately million share common stock average purchase price share item note stockholder equity consolidated financial statement include annual report information stock repurchase program table summarize stock repurchase activity month end december total number share purchase maximum fair publicly value share total number average price announce purchase share purchase pay share program program thousand dollar thousand million october october november november december december total stock repurchase program difference total number share purchase total number share purchase publicly announce program share common stock withhold employee restrict stock award order satisfy applicable tax withholding obligation item select financial datum gilead sciences inc select consolidated financial datum million share datum year end december consolidated statement income datum total revenue total cost expense income operation provision income taxis net income attributable gilead net income share attributable gilead common stockholder basic share share calculationbasic net income share attributable gilead common stockholder dilute share share calculationdilute december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm obligation convertible senior note senior unsecured note credit facility retain earning total stockholder equity item management discussion analysis description result operation complete acquisition pharmasset recognize consideration transfer billion primarily record intangible asset finance transaction approximately billion cash hand billion bank debt issue january billion senior unsecured note issue december issue senior unsecured note total aggregate principal billion repay million principal balance convertible senior note billion cash relate conversion spread note million senior unsecured note million revolve credit facility repay billion principal balance convertible senior note repay million fiveyear revolve credit facility credit agreement fiveyear revolve credit agreement borrow million fiveyear revolve credit agreement issue billion principal senior unsecured note register offering issue billion principal convertible senior note private placement item management discussion analysis financial condition result operation follow management discussion analysis financial condition result operation mda intend help reader understand result operation financial condition mda provide supplement read conjunction audit consolidated financial statement accompany note consolidated financial statement disclosure include annual report include disclosure item risk factor consolidate financial statement prepare accordance generally accept accounting principle present dollar management overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world gilead primary area focus include human immunodeficiency virus hiv liver disease chronic hepatitis virus hcv infection chronic hepatitis virus hbv infection oncology inflammation cardiovascular respiratory condition operation country worldwide headquarters foster city california continue add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy portfolio market product include sovaldi atripla truvada harvoni compleraeviplera stribild viread letairis ranexa ambisome zydelig cayston hepsera emtriva tybost vitekta tamiflu international commercial sale operation marketing subsidiary north south america europe asiapacific sell distribute certain product corporate partner royaltypaye collaborative agreement business highlight continue advance product pipeline therapeutic area goal deliver bestinclass drug advance current standard care andor address unmet medical need highlight announcement include antiviral program receive approval food drug administration fda october european commission november harvoni ledipasvir mgsofosbuvir oncedaily single tablet regimen treatment hcv genotype infection adult receive approval european commission sovaldi combination antiviral agent ribavirin pegylate interferon alpha country european union january submit new drug application nda japans pharmaceutical medical device agency approval sofosbuvir single tablet regimen ledipasvirsofosbuvir treatment chronic genotype hcv infection adult receive approval fda tybost pharmacokinetic enhancer boost blood level certain hiv medicines vitekta integrase inhibitor treatment hiv infection adult know mutation associate resistance elvitegravir submit nda fda approval single tablet regimen contain elvitegravir cobicistat emtricitabine tenofovir alafenamide ecftaf treatment hiv infection adult announce expansion agreement janssen ireland limited janssen development commercialization new single tablet regimen contain taf emtricitabine janssen rilpivirine rftaf amend agreement janssen collaborate single tablet regimen hiv infection contain taf emtricitabine cobicistat janssen darunavir enter agreement phenex pharmaceuticals phenex december acquire phenexs farnesoid receptor fxr program comprise small molecule fxr agonist treatment liver disease include nonalcoholic steatohepatitis nash announce nonexclusive licensing agreement indiabase generic pharmaceutical manufacturer expand access chronic hcv medicine develop country announce new agreement medicine patent pool expand access taf hiv hbv contingent fda approval oncology program receive approval fda july european commission september zydelig treatment bcell blood cancer zydelig indicate combination rituximab patient relapse chronic lymphocytic leukemia monotherapy patient relapse follicular lymphoma small lymphocytic lymphoma enter exclusive license agreement ono pharmaceutical ltd ono development commercialization ono oral bruton tyrosine kinase inhibitor treatment bcell malignancy disease cardiovascular program announce positive result ambition study randomize doubleblind multicenter study firstline combination therapy letairis ambrisentan tadalafil patient pulmonary arterial hypertension conduct collaboration glaxosmithkline plc file supplemental nda united states cover use ambrisentan combination tadalafil outlook continue focus key operating objective include progression product pipeline continue uptake commercial product research development perspective continue invest conduct new ongoing clinical study support exist product product candidate expect forward number latestage clinical study new product candidate plan file marketing application product candidate therapeutic area commercial perspective continue focus support uptake single tablet regimen treatment hiv prepare launch new single tablet regimen contain taf united states continue promote use sovaldi harvoni zydelig united states europe plan buildout expand international commercial infrastructure asia particular japan international market support anticipate launch sovaldi harvoni region result launch sovaldi harvoni united states sovaldi parts europe business double expect level growth anticipate overall net product sale growth expect expand access sovaldi harvoni united states launch harvoni additional european union country international market growth subject number uncertainty uncertainty include continuation challenge macroeconomic environment europe inclusive potential adoption additional pricing measure reduce healthcare spend particularly hcv potential continue volatility foreign currency exchange rate number hcv patient treat increase discount chargeback rebate ongoing private public payer negotiation large anticipate shift payer mix highly discount payer segment regulatory approval commercial launches sovaldi harvoni japan expect product pipeline investment expand commercial infrastructure enable execute operating objective financial highlight total revenue increase billion total product sale increase billion compare billion billion respectively drive primarily sale sovaldi harvoni increase sale hiv single tablet regimen product stribild compleraeviplera sovaldi approve united states december european union january sovaldi available countries harvoni approve united states october european union november expense increase billion compare continue investment progression expansion product pipeline sell general administrative sga expense increase billion compare increase cost support business expansion relate primarily liver disease oncology increase brand prescription drug fee bpd fee net income attributable gilead billion diluted share compare billion diluted share primarily launch sovaldi harvoni partially offset increase operating expense december cash cash equivalent marketable security total billion generate billion operating cash flow issue billion senior unsecured note repay billion debt result operation total revenue total revenue include product sale royalty contract revenue total revenue billion compare billion billion product sale represent total revenue respectively product sale total product sale billion compare billion billion drive primarily increase antiviral product sale antiviral product sale billion billion billion increase antiviral product sale drive primarily sale sovaldi harvoni drive primarily continued uptake hiv single tablet regimen product primarily stribild compleraeviplera product sale include letairis ranexa ambisome zydelig oncology product launch billion increase compare billion increase product sale billion approximately product sale generate outside united states face exposure adverse movement foreign currency exchange rate primarily euro foreign currency exchange contract hedge percentage foreign currency exposure foreign currency exchange net hedge favorable impact million revenue compare unfavorable impact million revenue compare record product sale net estimate mandatory supplemental discount government payer addition discount private payer relate cost deduction generally refer grosstonet deduction total billion billion billion percentage gross product sale grosstonet deduction decline grosstonet deduction percentage gross product sale compare primarily change payer mix reflect high proportion private payer compare prior year give launch sovaldi december harvoni october increase grosstonet deduction percentage gross product sale compare result primarily change payer mix dollar increase result payer mix high level gross product sale product sale united states increase billion compare billion primarily sale sovaldi harvoni increase sale stribild complera product sale united states increase compare billion drive sale growth single tablet regimen product specifically stribild complera launch sovaldi fourth quarter note inventory level high end inventory management agreement range see year past believe inventory draw quarter track normally demand rest product sale europe increase billion compare billion primarily sale sovaldi increase sale stribild eviplera product sale europe increase billion compare billion drive primarily high underlying demand antiviral product specifically eviplera partially offset decrease average net selling price hiv product foreign currency exchange net hedge favorable impact million european product sale compare unfavorable impact million european product sale compare follow table summarize period period change product sale million percentage change change antiviral product sovaldi atripla truvada harvoni compleraeviplera stribild viread antiviral total antiviral product product letairis ranexa ambisome zydelig total product sale percentage meaningful antiviral product antiviral product sale increase compare compare follow additional discussion result product hcv product sale sovaldi harvoni hcv product billion hcv product sale account total antiviral product sale year hcv product sale billion united states billion europe launch sovaldi december harvoni october patient world treat sofosbuvirbase regimen atripla atripla sale account total antiviral product sale respectively decrease compare primarily decline volume doctor prescribe new treatment compleraeviplera stribild efavirenz component atripla gross margin zero comprise billion billion billion atripla sale respectively generic version bristolmyers squibb company sustiva efavirenz component atripla available canada europe available united states observe pricing pressure relate efavirenz component atripla sale observe meaningful splitting atripla single tablet regimen truvada truvada sales increase compare primarily increase average net selling price sale volume growth united states decrease truvada sale low sale volume partially offset increase average net selling price truvada sale account total antiviral product sale respectively compleraeviplera sale compleraeviplera billion increase compare increase sale compleraeviplera drive primarily sale volume growth europe united states compleraeviplera sale increase primarily sale volume growth united states stribild sale stribild billion increase compare primarily increase sale volume united states europe increase sale stribild drive primarily sale volume growth united states product product include letairis ranexa ambisome zydelig oncology product launch billion compare billion increase product sale primarily increase sale volume royalty contract revenue follow table summarize period period change royalty contract revenue million percentage change change royalty contract revenue royalty contract revenue include royalty revenue hoffmanla roche ltd roche sale tamiflu majority royalty recognize quarter follow quarter correspond product sale occur cost good sell product gross margin follow table summarize period period change product sale cost good sell product gross margin million percentage change change total product sale cost good sell product gross margin product gross margin increase compare primarily change product mix result launch sovaldi harvoni product gross margin consistent product gross margin research development expense follow table summarize period period change expense million percentage change change research development expense summarize consist primarily clinical study perform contract research organization material supply license fee milestone payment collaboration arrangement personnel cost include salary benefit stockbase compensation overhead allocation consist support facilitiesrelate cost track total expense product candidate therapeutic area development phase manage expense identify activity anticipate perform give period prioritize effort base scientific datum probability successful development market potential available human capital resource consideration continually review pipeline status development necessary reallocate resource portfolio believe good support future growth business follow table provide breakout expense major cost type million percentage clinical study outside service personnel infrastructure expense facility cost total expense increase million compare primarily increase clinical study outside service increase clinical study outside service include onetime item million collaboration acquisition relate expense purchase fda priority review voucher million expense relate progression clinical study activity primarily oncology hiv area personnel infrastructure expense increase million support ongoing clinical study activity geographic expansion market product support expense increase million compare primarily million increase clinical study million increase personnel infrastructure expense support continue progression clinical study particularly phase study oncology liver disease hiv increase partially offset million decrease stockbase compensation expense acceleration vest stock option relate acquisition pharmasset inc pharmasset january clinical study outside service increase million compare progression expansion phase study particularly liver disease oncology additionally personnel expense increase million high headcount support product pipeline study progression expect expense increase support expansion clinical study therapeutic area include liver disease hiv oncology sell general administrative expense follow table summarize period period change sga expense million percentage change change sell general administrative sga expense relate sale marketing finance human resource legal administrative activity expense primarily comprise facility overhead cost outside marketing advertising legal expense general administrative cost sga expense increase billion compare primarily increase headcountrelate expense million support ongoing growth expansion business include commercial expansion relate launch sovaldi harvoni increase bpd fee quarter internal revenue service irs issue final regulation indicate manufacturer obligation pay portion bpd fee give calendar year trigger qualifying sale previous year instead qualify sale current calendar year result final irs regulation require recognize fee million fee million consolidated statement income bpd fee approximately million million million respectively bpd fee tax deductible sga expense increase million compare increase primarily million increase headcountrelate expense support ongoing growth business legal expense bpd fee increase partially offset million decrease stock base compensation acceleration vest stock option relate acquisition pharmasset january expect sga expense increase compare support continue buildout expansion commercial infrastructure europe asia support product interest expense interest expense increase million compare million increase primarily result issuance senior unsecured note register offering march november offset repayment senior unsecured note december december note conversion maturity convertible senior note note partial conversion convertible senior note note interest expense decrease million compare million decrease primarily repayment convertible senior note note conversion note partial conversion note repayment revolve credit facility income expense net income expense net significant compare change income expense net primarily million loss greek bond relate greece restructure sovereign debt quarter provision income taxis provision income tax billion billion billion respectively effective tax rate differ federal statutory rate primarily certain operating earning nonus subsidiary consider indefinitely reinveste tax credit partially offset state taxis portion nontax deductible bpd fee amortization expense intangible asset relate sofosbuvir receive tax benefit provide income taxis undistribute earning foreign operation intend indefinitely reinveste foreign subsidiary effective tax rate differ federal statutory rate primarily retroactive extension federal research tax credit january federal research tax credit certain operating earning nonus subsidiary consider indefinitely reinveste partially offset state taxis portion nontax deductible bpd fee amortization expense intangible asset relate sofosbuvir contingent consideration expense relate certain acquisition receive tax benefit effective tax rate differ federal statutory rate primarily tax credit certain operating earning nonus subsidiary consider indefinitely reinveste partially offset state taxis stockbase compensation expense relate pharmasset acquisition contingent consideration expense relate certain acquisition receive tax benefit acquisition biosciences inc complete acquisition biosciences inc base canada total consideration transfer million february time whollyowne subsidiary gilead drug development company primarily focus advance momelotinib orally administer oncedaily candidate hematologic cancer fair value acquire asset assume liability include primarily inprocess research development iprd million goodwill million defer tax asset million unrecognized tax benefit defer tax liability million cash acquire million pro forma result operation acquisition present acquisition material consolidated result operation item note intangible asset goodwill consolidated financial statement include annual report description iprd acquire pharmasset inc january complete acquisition pharmasset publiclyheld clinicalstage pharmaceutical company commit discover develop commercialize novel drug treat viral infection pharmasset primary focus development oral therapeutic treatment hcv infection pharmasset lead compound sofosbuvir refer nucleotide analog december approve fda sovaldi oncedaily oral regimen treatment hcv patient genotype infection include hepatocellular carcinoma meeting milan criterion await liver transplantation hcvhiv coinfection october harvoni combine nsa inhibitor ledipasvir sofosbuvir receive approval fda treatment chronic hcv genotype infection adult acquisition pharmasset allow advance effort develop alloral regimen treatment hcv acquire outstanding share common stock pharmasset share cash tender offer subsequent merger term agreement plan merger enter november aggregate cash payment acquire outstanding share common stock billion finance transaction approximately billion cash hand billion senior unsecured note issue december billion bank debt issue january pharmasset acquisition account business combination result operation pharmasset include consolidated statement income january date acquire approximately outstanding share common stock pharmasset cash consideration transfer result obtain effective control pharmasset acquisition complete january time pharmasset whollyowne subsidiary gilead integrate operation track earning result product candidate therapeutic area maintain separate earning result acquire pharmasset business follow table summarize component cash pay acquire pharmasset millions total consideration transfer stockbase compensation expense total cash pay billion cash payment consist billion cash payment outstanding common stockholder million cash payment option holder pharmasset stock option plan billion cash payment outstanding common stockholder million cash payment vested option holder pharmasset stock option plan account consideration transfer remain million cash payment account stockbase compensation expense result accelerate vest pharmasset employee option immediately prior acquisition follow table summarize acquisition date fair value asset acquire liability assume consideration transfer million identifiable intangible asset cash cash equivalent asset acquire liability assume net total identifiable net asset goodwill total consideration transfer refer item note acquisition consolidated financial statement include annual report detailed information liquidity capital resource believe exist capital resource supplement cash flow generate operating activity adequate satisfy capital need foreseeable future cash cash equivalent marketable security working capital increase significantly compare issue total billion senior unsecured note register offering march november follow table summarize cash cash equivalent marketable security work capital cash flow activity end period present million december cash cash equivalent marketable security working capital year end december cash provide operating activity invest activity financing activity certain prior period amount reclassify conform current presentation cash cash equivalent marketable security cash cash equivalent marketable security total billion december increase billion compare billion december generate billion cash flow operation receive billion issuance senior unsecured note register offering march november repay billion debt net convertible note hedge repurchase billion common stock pay approximately billion settle warrant expire warrant relate note retire cash cash equivalent marketable security remain relatively flat billion december compare billion december generate billion operating cash flow pay billion warrant relate note settle august repay billion debt net proceed convertible note hedge utilize million acquisition net cash acquire total cash cash equivalent marketable security december approximately billion generate operation foreign jurisdiction intend use foreign operation rely unrepatriate earning source fund domestic business expect sufficient cash flow borrowing capacity united states fund domestic operational strategic need work capital work capital billion december increase billion work capital december drive primarily positive cash flow operation increase cash cash equivalent issuance senior unsecured note march november partially offset cash pay settle convertible senior note warrant repayment bank debt repurchase common stock work capital million december decrease billion work capital december increase current portion longterm debt accrue liability partially offset increase account receivable inventory cash cash equivalent cash provide operating activity cash provide operating activity billion consist primarily net income billion adjust noncash item billion depreciation amortization expense million stockbase compensation expense million net cash outflow relate change operate asset liability cash provide operating activity billion consist primarily net income billion adjust noncash item million depreciation amortization expense million stockbase compensation expense partially offset million net cash outflow relate change operate asset liability cash provide operating activity billion consist primarily net income billion adjust noncash item million depreciation amortization expense million stockbase compensation expense million net cash inflow relate change operate asset liability cash investing activity cash investing activity billion consist primarily billion net purchase marketable security million capital expenditure relate expansion business cash investing activity million consist primarily million acquisition net cash acquire million capital expenditure primarily relate construction progress associate new facility headquarters support ongoing growth business partially offset million net proceed sale marketable security cash investing activity billion consist primarily billion acquisition pharmasset net stockbase compensation expense cash acquire million net purchase marketable security million capital expenditure relate primarily purchase office building million million increase construction progress associate new facility headquarters support ongoing growth business cash provide financing activity cash financing activity billion consist primarily billion repay debt net convertible note hedge billion repurchase common stock stock repurchase program billion settle warrant relate note payment primarily offset billion net proceed issuance senior unsecured note april april note senior unsecured note april april note senior unsecured note april april note april note april notes april note register offering total aggregate principal billion issuance senior unsecured note february february note senior unsecured note february february note senior unsecured note february february note february note february note february note register offer aggregate principal billion cash financing activity billion consist primarily billion repay debt financing include maturity note conversion note note billion settle warrant relate note settle august million repurchase common stock stock repurchase program cash outflow partially offset proceed billion relate convertible note hedges cash provide financing activity million drive primarily net proceed billion issuance bank debt conjunction pharmasset acquisition proceed million issuance common stock employee stock plan million proceed receive related convertible note hedge cash proceed partially offset billion repay debt financing year million repurchase common stock stock repurchase program debt credit facility debt financing march issue senior unsecured note register offering total aggregate principal billion issue april note million pay interest fix annual rate april note billion pay interest fix annual rate april note billion pay interest fix annual rate november issue senior unsecured note register offering total aggregate principal billion issue february note million pay interest fix annual rate february note billion pay interest fix annual rate february note billion pay interest fix annual rate bank debt january conjunction acquisition pharmasset enter fiveyear billion revolve credit facility credit agreement year revolve credit agreement borrow million fiveyear revolve credit agreement close acquisition year revolve credit agreement contain customary representation warranty affirmative negative financial maintenance covenant event default loan bear interest eurodollar rate plus applicable margin base rate plus applicable margin define credit agreement reduce commitment prepay loan time premium penalty require comply certain covenant credit agreement note indenture december violation covenant repay million fiveyear revolve credit agreement repay remain balance million outstanding fiveyear revolve credit agreement fiveyear revolve credit agreement terminate amount owe agreement shall payable january convertible senior note note mature portion note note convert repay million principal balance relate note pay billion cash relate conversion spread note represent conversion value excess principal receive billion cash convertible note hedge relate note year end december exercise option settle cash warrant result pay billion settle warrant market value common stock time exercise warrant exceed strike price million share common stock underlie warrant strike price share expire tradingday period commence august end september warrant settle option cash share common stock relate contract meet applicable criterion equity classification settlement record reduction additional paidin capital consolidate balance sheet december note classify current give conversion criterion meet result relate unamortized discount million classified equity component currently redeemable convertible note consolidated balance sheet million share common stock underlie warrant expire warrant warrant strike price share exercisable expiration date market value common stock time exercise warrant exceed strike price require net settle cash share common stock option value warrant excess warrant strike price stock repurchase programs stock repurchase program authorize january program repurchase total billion million share common stock board director authorize new billion stock repurchase program program open market private block transaction pursuant rule plan privately negotiate transaction mean new program expire year completion program begin repurchase program october repurchase total billion million share intend use additional authorization repurchase share opportunistically offset dilution create share issue employee stock plan february announce board director authorize new billion fiveyear share repurchase program initiate completion program longterm obligation summary borrowing financing arrangement include item note debt credit facility consolidate financial statement include annual report believe exist capital resource supplement cash flow generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include limited follow commercial performance current future product progress scope effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability administrative expense possibility acquire additional manufacturing capability office facility possibility acquire company new product cost associate settlement conversion convertible senior note relate warrant establishment additional collaborative relationship company cost associate defense settlement adverse result litigation government investigation future require additional funding form proceed equity debt financing fund require guarantee available favorable term critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement prepare accordance generally accept accounting principle preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate estimate include related revenue recognition allowance doubtful account valuation intangible asset contingent consideration liability result business combination tax provision base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery occur price fix determinable collectability reasonably assure record product sale net estimate mandatory supplemental discount government payer addition discount private payer relate charge generally refer grosstonet deduction record period relate sale occur government rebate chargeback represent majority grosstonet deduction require complex significant judgment management estimate assess period update reflect current information government rebate chargeback government rebate chargeback include amount pay payer healthcare providers united states include medicaid rebate adap veterans administration public health service discount rebate foreign government rebate rebate chargeback base contractual arrangement statutory requirement vary product payer individual payer plan qualified program purchase product wholesaler distributor low contractual price wholesaler distributor charge difference acquisition cost low contractual price consolidate allowance government chargeback payable direct customer classify reduction account receivable total million december million december consolidated allowance government rebate pay party direct customer record accrue government rebate consolidated balance sheet total billion december billion december allowance government rebate chargeback estimate base product sell historical utilization rate pertinent party industry information estimate patient population know market event trend channel inventory andor market datum consideration new information change program regulation guideline impact actual rebate andor expectation future utilization rate program believe methodology use estimate government rebate chargeback reasonable appropriate give current fact circumstance actual result differ significantly estimate year actual government rebate chargeback claim prior period vary estimate follow table summarize consolidated activity government rebate chargeback account million balance balance begin decreaseincrease end accrue government rebate chargeback year product sale payment year year end december activity relate sale activity relate sale prior total year end december activity relate sale activity relate sale prior total allowance doubtful account maintain allowance doubtful account estimate loss result inability customer require payment allowance base analysis factor include limited contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding geographic region review local economic environment potential impact government funding reimbursement practice financial condition customer economic environment operate deteriorate result inability payment additional allowance require believe allowance doubtful account adequate significant deterioration factor materially change expectation result increase allowance doubtful account december allowance doubtful account million million respectively valuation intangible asset conjunction business combination record intangible asset primarily relate iprd project total intangible asset billion december billion december identifiable intangible asset measure respective fair value acquisition date model value intangible asset require use significant estimate assumption include limited estimate revenue operate profit relate product product candidate probability success unapproved product candidate consider stage development time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain fda regulatory approval risk relate viability potential alternative treatment future target market believe fair value record intangible asset acquire connection business combination base reasonable estimate assumption give fact circumstance relate valuation date intangible asset relate iprd project consider indefinitelive completion abandonment associate effort development complete generally occur regulatory approval market product obtain associate asset deem finitelived amortize base respective estimate useful life point time period asset consider indefinite live amortize test impairment annual basis annual test aware event change indicate likely fair value iprd project respective carrying amount fair value indefinite live intangible asset dependent assumption expect timing probability achieve specify milestone change project revenue change discount rate significant judgment employ determine assumption change assumption significant impact result operation give period intangible asset finite useful life amortize estimate useful life primarily straightline basis intangible asset finite useful life review impairment fact circumstance suggest carry value asset recoverable valuation contingent consideration liability result business combination conjunction business combination consolidation variable interest entity primary beneficiary record contingent consideration liability payable achievement specify development regulatory approval salesbase milestone event financial result contingent consideration liability measure respective fair value acquisition initial consolidation date model value contingent consideration liability require use significant estimate assumption include limited estimate revenue operate profit relate product product candidate probability success unapproved product candidate consider stage development time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain fda regulatory approval risk relate viability potential alternative treatment future target market revalue contingent consideration obligation report period record change fair value expense consolidated statement income change fair value contingent consideration liability result update multiple assumption expect timing probability achieve specify milestone change project revenue change discount rate significant judgment employ determine assumption acquisition date subsequent reporting period update assumption significant impact result operation give period actual result differ estimate total contingent consideration liabilitie million december million december tax provision estimate income tax provision include defer tax asset liability base significant management judgment evaluate realization portion defer tax asset quarterly basis record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination subject income taxis unite states foreign jurisdiction include ireland economic political condition country actively consider change exist tax law predict form time potential legislative change material adverse impact result operation addition significant judgment require determine worldwide provision income taxis record liability relate uncertain tax position accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return believe uncertain tax position currently pende material adverse effect consolidated financial statement adverse resolution uncertain tax position period material impact result operation period december total federal state foreign unrecognized tax benefit million million respectively total unrecognized tax benefit million million december respectively recognize reduce effective tax rate period recognition december believe reasonably possible unrecognized tax benefit decrease approximately million month expect clarification irs tax authority uncertain tax position respect remain unrecognized tax benefit currently unable reasonable estimate period cash settlement respective tax authority file federal state foreign income tax return jurisdiction unite states abroad federal income tax purpose statute limitation open onwards certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year california income tax purpose statute limitation open onwards income tax return audit federal state foreign tax authority currently examination irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position brand prescription drug fee pharmaceutical manufacturer brand drug product require pay portion bpd fee calculate base select government sale calendar year percentage total industry government sale fee determine estimate total sale government agency assumption total pharmaceutical industry sale government agency estimate base past history expectation future brand drug sale activity pharmaceutical company judgment employ determine assumption update assumption impact result operation adjustment estimate past material irs issue final regulation relate bpd fee indicate entity obligation pay portion bpd fee give calendar year trigger qualifying sale previous year instead qualify sale current calendar year result final irs regulation require recognize fee million fee million consolidated statement income bpd fee approximately million million million respectively irs expect communicate final bpd fee amount sale quarter sale quarter bpd fee accrual total million december million december balance sheet arrangement balance sheet arrangement define item aii regulation contractual obligation contractual obligation consist debt obligation operating lease capital commitment purchase obligation active pharmaceutical ingredient inventoryrelate item clinical trial contract follow table summarize significant enforceable legally bind obligation future commitment obligation relate contract likely continue regardless fact certain obligation cancelable december million payment period contractual obligation total year year year year debt operating lease obligation capital commitment purchase obligation clinical trial total debt obligation include convertible senior note senior unsecured note interest payment incur calculate base term relate note information item note debt credit facility consolidate financial statement include annual report form december firm capital project commitment approximately million primarily relate construction new building december firm purchase commitment relate active pharmaceutical ingredient certain inventoryrelate item amount include minimum purchase requirement addition commit potential future milestone payment party license collaboration development arrangement payment agreement generally payable achievement certain developmental regulatory andor commercial milestone achievement milestone probable reasonably estimable contingency record consolidated balance sheet include table december clinical study clinical trial phase significant clinical trial expenditure contract research organization cro material contract cro cancelable historically cancel contract amount reflect commitment base exist contract reflect future modification termination exist contract anticipate potential new contract total gross unrecognized tax benefit liability include interest penalty million december believe reasonably possible unrecognized tax benefit decrease approximately million month expect clarification irs tax authority uncertain tax position respect remain unrecognized tax benefit currently unable reasonable estimate period cash settlement respective tax authority unrecognize tax benefit include current longterm income taxis payable longterm defer tax asset consolidate balance sheet include table recent accounting pronouncement information require item include item note organization summary significant accounting policy consolidate financial statement include annual report item quantitative qualitative disclosure market risk expose market risk result change foreign currency exchange rate interest rate credit risk reduce certain risk enter type foreign currency interest rate derivative hedging transaction follow investment guideline monitor outstanding receivables risk management program foreign currency exchange risk operation include manufacture sale activity united states canada ireland sale activity country outside united states include europe asia pacific result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change foreign currency exchange rate dollar foreign currency significant euro dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business approximately product sale denominate foreign currency partially mitigate impact change currency exchange rate net cash flow foreign currency denominate sale enter foreign currency exchange forward option contract hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay general market risk contract offset correspond gain loss transaction hedge december open foreign currency forward contract notional amount billion billion respectively hypothetical adverse movement foreign currency exchange rate compare dollar relative exchange rate december resulted reduction fair value contract approximately million date realize negatively affect earning remain life contract hypothetical movement foreign currency exchange rate compare dollar relative exchange rate december resulted reduction fair value contract approximately million date realize negatively affect earning remain life contract analysis consider impact hypothetical change foreign currency exchange rate anticipated transaction foreign currency sensitive instrument design offset interest rate risk portfolio availableforsale marketable security fix variable rate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base credit rating maturity industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate interestgenerate asset fix interestbeare liability december millions percentage expect maturity total fair value december total asset available forsale debt security average interest rate liabilitie debt average interest rate december issue senior unsecured note december register offering note pay interest fix annual rate range march issue senior unsecured note april register offering note pay interest fix annual rate march november issue april note february note respectively interest rate range july issue note private placement pursuant rule securities act amend note issue par bear interest rate convert share common stock subject certain circumstance connection acquisition pharmasset enter credit agreement subject variable interest rate portion interest expense relate variable interest total million credit risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe december account receivable southern europe specifically greece italy portugal spain total approximately million million great day past million great day past december account receivable southern europe specifically greece italy portugal spain total approximately million million great day past million great day past date experience significant loss respect collection account receivable believe allowance doubtful account adequate december item financial statement supplementary datum gilead sciences inc consolidated financial statement year end december content report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement income consolidate statement comprehensive income consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement report independent register public accounting firm board director stockholder gilead sciences inc audit accompany consolidated balance sheet gilead sciences inc december relate consolidated statement income comprehensive income stockholder equity cash flow year period end december audits include financial statement schedule list index item financial statement schedule responsibility company management responsibility express opinion financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statement refer present fairly material respect consolidate financial position gilead sciences inc december consolidate result operation cash flow year period end december conformity generally accept accounting principle opinion relate financial statement schedule consider relation basic financial statement take present fairly material respect information set forth audit accordance standard public company accounting oversight board united states gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework report date february express unqualified opinion thereon ernst young llp redwood city california february gilead sciences inc consolidated balance sheet million share amount december asset current asset cash cash equivalent shortterm marketable security account receivable net allowance december december inventory defer tax asset prepay taxis prepaid expense current asset total current asset property plant equipment net longterm portion prepay royalty longterm defer tax asset longterm marketable security intangible asset net goodwill longterm asset total asset liability stockholder equity current liability account payable accrue government rebate accrue compensation employee benefit income taxis payable accrue liability defer revenue current portion longterm debt obligation net total current liability longterm debt net longterm income taxis payable longterm defer tax liability longterm obligation commitment contingency note equity component currently redeemable convertible note stockholder equity prefer stock par value share share authorize outstanding common stock par value share share authorize december december share issue outstanding december december additional paidin capital accumulate comprehensive income loss retain earning total gilead stockholder equity noncontrolle interest total stockholder equity total liability stockholder equity accompany note gilead sciences inc consolidated statement income million share amount year end december revenue product sale royalty contract revenue total revenue cost expense cost good sell research development expense sell general administrative expense total cost expense income operation interest expense income expense net income provision income taxis provision income taxis net income net loss attributable noncontrolle interest net income attributable gilead net income share attributable gilead common stockholdersbasic share share calculationbasic net income share attributable gilead common stockholdersdilute share share calculationdilute accompany note gilead sciences inc consolidated statement comprehensive income million year end december net income comprehensive income loss net foreign currency translation gain loss net tax availableforsale security net unrealize gain net tax impact reclassification net income net tax impact net change cash flow hedge net unrealized gain loss net tax impact reclassification net income net tax impact net change comprehensive income loss comprehensive income comprehensive loss attributable noncontrolle interest comprehensive income attributable gilead accompany note gilead sciences inc consolidated statement stockholder equity millions gilead stockholder equity common stock accumulate additional total paidin comprehensive retain noncontrolle stockholder share capital income loss earning interest equity balance december contribution noncontrolle interest net income loss comprehensive income net tax issuance employee stock purchase plan issuance equity incentive plan tax benefit employee stock plan stockbase compensation repurchase common stock convertible note settlement convertible notes hedge settlement reclassification equity component currently redeemable convertible note balance december contribution noncontrolle interest net income loss comprehensive income net tax issuance employee stock purchase plan issuance equity incentive plan tax benefit employee stock plan stockbase compensation repurchase common stock warrant settlement convertible note settlement convertible notes hedge settlement reclassification equity component currently redeemable convertible note balance december change noncontrolle interest net income loss comprehensive income net tax issuance employee stock purchase plan issuance equity incentive plans tax benefit employee stock plan stockbase compensation repurchase common stock warrant settlement convertible note settlement convertible note hedge settlement purchase convertible note hedge reclassification equity component currently redeemable convertible note balance december accompany note gilead sciences inc consolidated statement cash flow millions year end december operating activity net income adjustment reconcile net income net cash provide operating activity depreciation expense amortization expense stockbase compensation expense excess tax benefit stockbase compensation tax benefit exercise vest stockbased award defer income taxis change fair value contingent consideration change operate asset liability account receivable net inventory prepaid expense asset account payable income taxis payable accrue liability defer revenue net cash provide operating activity invest activity purchase marketable security proceed sale marketable security proceed maturitie marketable security investment acquisition net cash acquire capital expenditure net cash investing activity financing activity proceed debt finance net issuance cost proceed convertible note hedge purchase convertible note hedge proceed issuance common stock repurchase common stock repayment debt longterm obligation payment settle warrant excess tax benefit stockbase compensation payment contingent consideration contribution noncontrolle interest net cash provide financing activity effect exchange rate change cash cash equivalent net change cash cash equivalent cash cash equivalent begin period cash cash equivalent end period supplemental disclosure cash flow information interest pay net amount capitalize income taxis pay accompany note gilead sciences inc note consolidated financial statement organization summary significant accounting policy overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world gilead primary area focus include human immunodeficiency virus hiv liver disease chronic hepatitis virus hcv infection chronic hepatitis virus hbv infection oncology inflammation cardiovascular respiratory condition operation country worldwide headquarters foster city california continue add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy product portfolio comprise sovaldi atripla truvada harvoni compleraeviplera stribild viread letairis ranexa ambisome zydelig cayston hepsera emtriva tybost vitekta global commercial sale operation marketing subsidiary north south america europe asiapacific addition sell distribute certain product corporate partner royaltypaye collaborative agreement basis presentation accompany consolidated financial statement include account gilead whollyowne subsidiary certain variable interest entity primary beneficiary consolidate entity expose economic record net income loss attributable noncontrolle interest consolidate statement income equal percentage economic ownership interest retain entity respective noncontrolle party intercompany transaction eliminate consolidated financial statement include result company acquire date acquisition applicable reporting period january complete twoforone stock split form stock dividend stockholders record january declare december accordingly share share amount period present consolidated financial statement note adjust retroactively reflect stock split significant accounting policy estimate judgment preparation consolidated financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis management evaluate significant accounting policy estimate base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate estimate assess period update reflect current information actual experience revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery occur price fix determinable collectability reasonably assure recognition revenue product sale provision government rebate medicaid reimbursement customer incentive cash discount prompt payment distributor fee expect return expire product appropriate item deduct gross product sale rebate chargeback estimate reduction revenue amount pay payer healthcare providers united states include medicaid rebate adap veterans administration public health service discount rebate foreign government rebate rebate chargeback base contractual arrangement statutory requirement vary product payer individual payer plan estimate base product sell historical utilization rate available pertinent party industry information estimate patient population know market event trend product sale channel inventory datum obtain major wholesaler accordance inventory management agreement consideration available new information change program regulation guideline impact actual rebate andor expectation future utilization rate program government chargeback payable direct customer classify reduction account receivable consolidated balance sheet government rebate invoice directly record accrue government rebate consolidated balance sheet cash discount estimate cash discount base contractual term historical utilization rate available expectation future utilization rate distributor fee inventory management agreement significant wholesaler pay wholesaler fee primarily compliance certain contractually determine covenant maintenance agree inventory level distributor fee base contractually determine fix percentage sale product return provide customer general right product return typically permit return product damage defective receive customer case product sell united states certain country outside united states product expire accept return product expire month expire year expiration date estimate expect return expire product base primarily ongoing analysis historical return pattern historical industry information report return rate similar product contractual agreement intend limit inventory maintain wholesaler royalty contract revenue royalty revenue sale product generally recognize receive generally quarter follow quarter correspond sale occur month follow month correspond sale occur revenue nonrefundable upfront license fee milestone payment development collaboration obligation supply product recognize performance occur obligation complete accordance specific term obligation arrangement revenue recognize obligation fulfil ratably development manufacturing period revenue associate substantive atrisk milestone recognize base achievement milestone set forth respective agreement advance payment receive excess amount earn classified defer revenue consolidated balance sheet research development expense research development expense consist primarily personnel cost include salary benefit stockbase compensation clinical study perform contract research organization cro material supply license fee milestone payment collaboration arrangement overhead allocation consist support facilityrelate cost charge cost include clinical study cost expense incur clinical study cost significant component expense clinical study perform thirdparty cro monitor level performance significant contract include extent patient enrollment activity communication cro accrue cost clinical study perform cro service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro material cro contract terminable write notice generally liable actual service complete cro certain noncancelable expense incur point termination amount pay advance relate uncompleted service refund contract terminate advertising expense expense cost advertising include promotional expense incur advertising expense million million million stockbased compensation utilize share base compensation form type equitybase award include restrict stock unit rsus performancebase restrict stock unit psus stock option compensation expense recognize consolidated statement income base estimate fair value grant date estimate fair value rsus base closing price common stock psus estimate fair value base monte carlo valuation methodology stock price date grant stock option award estimate fair value base blackschole option valuation model cash cash equivalent consider highly liquid investment insignificant interest rate risk original maturity month purchase date cash equivalent eligible instrument investment policy include cash equivalent include commercial paper money market fund overnight repurchase agreement repos major bank authorize dealer bank obligation marketable nonmarketable security determine appropriate classification marketable security consist primarily debt security time purchase reevaluate designation balance sheet date marketable security consider availableforsale carry estimate fair value report cash equivalent shortterm marketable security longterm marketable security unrealize gain loss availableforsale security exclude net income report accumulate comprehensive income loss separate component stockholder equity income expense net include interest dividend amortization purchase premium discount realize gain loss sale security otherthantemporary decline fair value security cost security sell base specific identification method regularly review investment otherthan temporary decline fair value review include consideration cause impairment include creditworthiness security issuer number security unrealize loss position severity duration unrealize loss intent sell security likely require sell security recovery amortize cost basis determine decline fair value investment accounting basis decline otherthantemporary reduce carry value security hold record loss decline result enter collaboration time time hold investment nonpublic company record nonmarketable security cost longterm asset amount otherthantemporary impairment regularly review security indicator impairment investment nonmarketable security material period present concentration risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe december account receivable southern europe specifically greece italy portugal spain total approximately million million great day past million great day past date experience significant loss respect collection account receivable believe allowance doubtful account adequate december certain raw material component utilize operation obtain single supplier certain raw material utilize operation facility supplier key component raw material name new drug application nda file food drug administration fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship commercial product supply product candidate clinical trial account receivable trade account receivable record net allowance wholesaler chargeback relate government program cash discount prompt payment doubtful account estimate wholesaler chargeback government program cash discount base contractual term historical trend expectation utilization rate program estimate allowance doubtful account determine base exist contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding geographic region review local economic environment potential impact government funding reimbursement practice historically amount uncollectible account receivable write insignificant consistent management expectation inventory inventory record low cost market cost determine firstin firstout basis periodically review composition inventory order identify obsolete slowmoving unsaleable item unsaleable item observe alternate use inventory record writedown net realizable value period impairment recognize future commercialization consider probable future economic benefit expect realize base management judgment capitalize prelaunch inventory cost prior regulatory approval number factor take consideration include current status regulatory approval process potential impediment approval process safety efficacy anticipate research development initiative impact indication compound viability commercialization marketplace trend december prelaunch inventory consolidate balance sheet significant property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straight line method repair maintenance cost expense incur estimate useful life year follow description estimate useful life building improvement laboratory manufacturing equipment office computer equipment leasehold improvement short useful life lease term office computer equipment include capitalize software unamortize capitalize software cost consolidate balance sheet million december million december leasehold improvement amortize short lease term asset useful life capitalize interest construction inprogress include property plant equipment interest capitalize significant goodwill intangible asset goodwill represent excess consideration transfer estimate fair value asset acquire liability assume business combination intangible asset indefinite useful life relate purchase inprocess research development iprd project measure respective fair value acquisition date amortize goodwill intangible asset indefinite useful live intangible asset relate iprd project consider indefinitelive completion abandonment associate effort development complete generally occur regulatory approval market product obtain associate asset deem finitelive amortize base respective estimate useful life point time test goodwill indefinitelive intangible asset impairment annual basis annual test aware event change indicate fair value asset carry amount intangible asset finite useful life amortize estimate useful life primarily straightline basis review impairment fact circumstance suggest carry value asset recoverable impairment longlive asset carry value longlive asset review regular basis existence fact circumstance internally externally suggest impairment specific potential indicator impairment include significant decrease fair value asset significant change extent manner asset significant physical change asset significant adverse change legal factor business climate affect value asset adverse action assessment fda regulator accumulation cost significantly excess originally expect acquire construct asset operate cash flow loss combine history operate cash flow loss projection forecast demonstrate continue loss associate income produce asset indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset asset group eventual disposition carry asset asset group excess carrying value asset asset group estimate fair value recognize impairment loss valuation contingent consideration result business combination connection certain business combination require pay future consideration contingent achievement specify development regulatory approval salesbase milestone event record contingent consideration result business combination fair value acquisition date connection consolidation variable interest entity primary beneficiary record contingent consideration relate future earnout payment base percentage gross margin entity report period revalue obligation record change fair value consolidated statement income record change fair value relate future milestone payment expense time relate product candidate receive marketing approval change fair value contingent consideration liability result update assumption expect timing probability achieve specify milestone change project revenue change discount rate significant judgment employ determine assumption acquisition consolidation date subsequent period update assumption significant impact result operation give period actual result differ estimate foreign currency translation transaction gain loss hedge contract nonus entity operation record functional currency entity result operation nonus dollar functional currency entity translate dollar average currency rate asset liability translate currency rate period end foreign currency translation adjustment record component comprehensive income loss stockholder equity foreign currency transaction gain loss record income expense net consolidated statement income net foreign currency transaction gain total million loss total million million hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition seek limit risk counterpartie contract unable perform seek limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract contract positive fair value date default enter derivative contract trading purpose hedge net investment foreign subsidiary fair value financial instrument apply fair value account financial asset liability nonfinancial asset liability recognize disclose fair value financial statement recur basis define fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine fair value measurement asset liability require record fair value consider principal advantageous market transact marketbase risk measurement assumption market participant use price asset liability risk inherent valuation technique transfer restriction credit risk derivative financial instrument recognize derivative instrument asset liabilitie fair value consolidate balance sheet change fair value derivative record period current earning accumulate comprehensive income loss depend derivative designate hedge transaction type hedge transaction classify cash flow instrument category cash flow hedge item hold issue derivative instrument trade speculative purpose assess inception ongoing basis derivative hedging transaction highly effective offset change cash flow fair value hedge item assess hedge ineffectiveness quarterly basis record gain loss relate ineffective portion current earning extent significant determine forecast transaction long probable occur discontinue hedge accounting affect portion hedge instrument relate unrealized gain loss contract recognize current earning income taxis income tax provision compute liability method defer tax asset liability determine base difference financial statement tax basis asset liability enact tax rate effect year difference expect reverse significant estimate require determine provision income taxis estimate base interpretation exist tax law regulation record liability relate uncertain tax position accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return believe uncertain tax position currently pende material adverse effect consolidated financial statement adverse resolution uncertain tax position period material impact result operation period brand prescription drug fee pharmaceutical manufacturer brand drug product require pay portion bpd fee calculate base select government sale calendar year percentage total industry government sale internal revenue service irs issue final regulation relate bpd fee indicate entity obligation pay portion bpd fee give calendar year trigger qualifying sale previous year instead qualify sale current calendar year result final irs regulation require recognize fee million fee million consolidated statement income irs expect communicate final bpd fee amount sale quarter sale quarter bpd fee accrual total million december million december consolidated balance sheet recent accounting pronouncement financial accounting standard board jointly international accounting standard board issue comprehensive new standard revenue recognition contract customer standard core principle report entity recognize revenue transfer promise good service customer reflect consideration entity expect entitled exchange good service apply new guidance contract scope entity identify contract customer identify performance obligation contract determine transaction price allocate transaction price performance obligation contract recognize revenue entity satisfie performance obligation additionally new guidance require significantly expand revenue recognition disclosure guidance effective begin quarter early application permit entity option retrospective modify retrospective approach adopt new guidance currently evaluate impact adoption standard consolidated financial statement fair value measurement determine fair value financial nonfinancial asset liability fair value hierarchy establish level input measure fair value follow level input include quote price active market identical asset liability level input include observable input level input quote price similar asset liability quote price identical similar asset liability market active input observable corroborate observable market datum substantially term asset liability marketable security review trading activity pricing measurement date sufficient quote price identical security available use market pricing observable market input similar security obtain thirdparty datum provider input represent quote price similar asset active market derive observable market datum level input include unobservable input support little market activity significant fair value underlie asset liability level asset liability include fair value measurement determine pricing model discount cash flow methodology similar valuation technique significant management judgment estimation financial instrument consist principally cash cash equivalent marketable security account receivable foreign currency exchange contract account payable shortterm longterm debt cash cash equivalent marketable security foreign currency exchange contract hedge account receivable forecast sale report respective fair value consolidate balance sheet shortterm longterm debt report amortize cost consolidated balance sheet remain financial instrument report consolidated balance sheet amount approximate current fair value follow table summarize asset liability record fair value respective fair value classification level input fair value hierarchy million december december level level level total level level level total asset money market fund corporate debt security treasury security residential mortgage assetbacke security government agency security municipal debt security foreign currency derivative contract defer compensation plan liabilitie contingent consideration defer compensation plan foreign currency derivative contract maintain deferred compensation plan director key employee defer compensation income tax purpose amount defer participant deposit rabbit trust periodically adjust reflect earning loss base participant investment election select group investment fund consist money market fund mutual fund level input estimate fair value government relate debt corporate debt residential mortgage assetbacked security take consideration valuation obtain thirdparty pricing service pricing service utilize industry standard valuation model include income marketbase approach significant input observable directly indirectly estimate fair value input include report trade brokerdealer quote similar security issuer credit spread benchmark security prepaymentdefault projection base historical datum observable input substantially foreign currency derivative contract maturity primarily month time horizon counterpartie minimum credit rating equivalent standard poor moody investors service inc fitch inc estimate fair value contract take consideration valuation obtain thirdparty valuation service utilize incomebase industry standard valuation model significant input observable directly indirectly input include foreign currency rate london interbank offer rate libor swap rate input applicable commonly quote interval fair value convertible senior note senior unsecured note determine level input base quote market value follow table summarize carry value fair value convertible senior note senior unsecured note million december december type borrowing description carry value fair value carry value fair value convertible senior note convertible senior note senior unsecured april note senior unsecured december note senior unsecured december note senior unsecured december note senior unsecured december note senior unsecured april note senior unsecured april note senior unsecured april note senior unsecured february note senior unsecured february note senior unsecured february note level input december asset liability measure level input contingent consideration liability policy recognize transfer level classification actual date event change circumstance cause transfer contingent consideration liability connection certain acquisition require pay future consideration contingent achievement specify development regulatory approval salesbase milestone event financial result estimate fair value contingent consideration liability acquisition date initial consolidation date report period probabilityweighte income approach reflect probability time future payment fair value measurement base significant level input anticipate timeline probability achieve development regulatory approval salesbase milestone event project revenue result probabilityweighte cash flow discount creditrisk adjust interest rate report period revalue obligation perform review assumption list record increase decrease fair value contingent consideration obligation consolidated statement income record fair value relate future milestone payment expense time relate product candidate receive marketing approval change fair value future earnout payment record sell general administrative sga expense absence significant change key assumption quarterly determination fair value contingent consideration obligation primarily reflect passage time significant judgment employ determine level input fair value measurement acquisition date initial consolidation date subsequent period update assumption significant impact result operation give period actual result differ estimate example significant increase probability achieve milestone project revenue result significantly high fair value measurement significant decrease estimate probability achieve milestone project revenue result significantly low fair value measurement significant increase discount rate anticipate timeline result significantly low fair value measurement significant decrease discount rate anticipate timeline result significantly high fair value measurement potential contingent consideration payment require achievement development regulatory approvalbased milestone relate acquisition cgi pharmaceuticals inc calistoga pharmaceuticals inc calistoga range payment milestone achieve estimate maximum million undiscounted july receive fda approval zydelig certain regulatory approvalbased milestone relate calistoga acquisition meet result contingent consideration payment total million quarter december december accrue million million respectively relate acquisition remainder contingent consideration liability december primarily relate potential future payment result acquisition arresto biosciences inc royalty obligation future sale specify salesbased milestone achieve follow table provide rollforward contingent consideration liability record accrue liability longterm obligation consolidate balance sheet million year end december balance beginning period milestone payment calistoga net change valuation addition consolidation variable interest entity balance end period availableforsale security estimate fair value availableforsale security generally base price obtain commercial pricing service follow table summary availableforsale security record cash cash equivalent marketable security consolidate balance sheet million december december gross gross gross gross amortize unrealize unrealized estimate amortize unrealize unrealized estimate cost gain loss fair value cost gain loss fair value money market fund corporate debt security treasury security residential mortgage asset back security government agency security municipal debt security total follow table summarize classification availableforsale security consolidate balance sheet million december december cash cash equivalent shortterm marketable security longterm marketable security total cash cash equivalent table exclude cash billion december million december follow table summarize portfolio availableforsale security contractual maturity million december amortize cost fair value year great year year great year year great year total follow table summarize gross realize gain loss relate sale marketable security million year end december gross realize gain sale gross realize loss sale follow table summarize availableforsale debt security continuous unrealized loss position deem otherthan temporarily impair million month month great total gross gross gross unrealize estimate unrealized estimate unrealized estimate loss fair value loss fair value loss fair value december debt security corporate debt security residential mortgage assetbacke security treasury security government agency security municipal debt security total december debt security corporate debt security residential mortgage assetbacke security treasury security government agency security municipal debt security total hold total position december position december unrealize loss position unrealize loss immaterial individually aggregate base review security believe otherthantemporary impairment security december intend sell security believe likely require sell security recovery amortize cost basis derivative financial instrument operate foreign country expose market risk associate foreign currency exchange rate fluctuation dollar foreign currency significant euro order manage risk hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition seek limit risk counterpartie contract unable perform seek limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract contract positive fair value date default enter derivative contract trading purpose hedge exposure foreign currency exchange rate fluctuation certain monetary asset liability foreign subsidiary denominate nonfunctional currency derivative instrument use hedge exposure designate hedge result change fair value record income expense net consolidated statement income hedge exposure foreign currency exchange rate fluctuation forecast product sale denominate nonfunctional currency derivative instrument use hedge exposure designate cash flow hedge maturity date month execute hedge contract quarterly assess prospective hedge effectiveness regression analysis calculate change cash flow result hedge instrument monthly basis assess retrospective hedge effectiveness dollar offset approach exclude time value effectiveness testing recognize change time value hedge income expense net effective component hedge record unrealized gain loss hedge instrument accumulate comprehensive income oci stockholder equity hedge forecast transaction occur hedge dedesignate unrealized gain loss reclassify product sale majority gain loss relate hedged forecast transaction report accumulate oci december reclassify product sale month cash flow effect derivative contract year end december include net cash provide operating activity consolidate statement cash flow notional amount foreign currency exchange contract outstanding billion december billion december derivative contract allow right offset asset liability present amount gross basis international swap dealers association inc master agreement respective counterpartie foreign currency exchange contract subject applicable requirement allow net settle transaction currency single net payable party follow table summarize classification fair value derivative instrument consolidate balance sheet million december asset derivative liability derivative fair classification fair value classification value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative december asset derivative liability derivative fair classification fair value classification value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative december december material derivative designate hedge follow table summarize effect foreign currency exchange contract consolidate financial statement millions year end december derivative designate hedge gain loss recognize accumulate oci effective portion gain loss reclassify accumulated oci product sale effective portion gain loss recognize income expense net ineffective portion amount exclude effectiveness testing derivative designate hedge gain loss recognize income expense net time time discontinue cash flow hedge result record relate amount income expense net consolidated statement income material amount record income expense net year end december result discontinuance cash flow hedge december hold type financial instrument derivative contract relate foreign currency exchange contract follow table summarize potential effect offset derivative type financial instrument consolidated balance sheet million december offset derivative assetsliabilitie gross amount offset consolidated balance sheet amount assetsliabilitie gross amount offset present gross amount consolidate balance consolidate derivative financial cash collateral net description recognize assetsliabilitie sheet balance sheet instrument receivedpledge legal offset derivative asset derivative liability december offset derivative assetsliabilitie gross amount offset consolidated balance sheet gross amount offset amount assetsliabilitie gross amount consolidated balance present consolidated derivative financial cash collateral net description recognize assetsliabilitie sheet balance sheet instrument receivedpledge legal offset derivative asset derivative liability acquisition biosciences inc february complete acquisition biosciences inc base canada total consideration transfer million time whollyowne subsidiary gilead drug development company primarily focus advance momelotinib orally administer daily candidate hematologic cancer acquisition account business combination fair value acquire asset assume liability primarily include iprd million goodwill million defer tax asset million unrecognized tax benefit defer tax liability million cash acquire million pro forma result operation acquisition present acquisition material consolidated result operation note intangible asset goodwill description iprd acquire pharmasset inc january complete acquisition pharmasset inc pharmasset publiclyheld clinicalstage pharmaceutical company commit discover develop commercialize novel drug treat viral infection pharmasset primary focus development oral therapeutic treatment hcv infection pharmasset lead compound sofosbuvir nucleotide analog december approve fda sovaldi oncedaily oral regimen treatment hcv patient genotype infection include hepatocellular carcinoma meeting milan criterion await liver transplantation hcvhiv coinfection october harvoni combine nsa inhibitor ledipasvir sofosbuvir receive approval fda treatment chronic hcv genotype infection adult acquisition pharmasset allow advance effort develop alloral regimen treatment hcv acquire outstanding share common stock pharmasset share cash tender offer subsequent merger term agreement plan merger enter november aggregate cash payment acquire outstanding share common stock billion finance transaction approximately billion cash hand billion senior unsecured note issue december billion bank debt issue january pharmasset acquisition account business combination result operation pharmasset include consolidated statement income january date acquire approximately outstanding share common stock pharmasset follow table summarize component cash pay acquire pharmasset millions total consideration transfer stockbase compensation expense total cash pay billion cash payment consist billion cash payment outstanding common stockholder million cash payment option holder pharmasset stock option plan billion cash payment outstanding common stockholder million cash payment vested option holder pharmasset stock option plan account consideration transfer remain million cash payment account stockbase compensation expense result accelerate vest pharmasset employee option immediately prior acquisition follow table summarize acquisition date fair value asset acquire liability assume consideration transfer million identifiable intangible asset cash cash equivalent asset acquire liability assume net total identifiable net asset goodwill total consideration transfer identifiable intangible asset acquire intangible asset primarily comprise sofosbuvir iprd compound estimate fair value billion date acquisition fair value asset determine probabilityweighte income approach discount expect future cash flow present value estimate net cash flow discount discount rate base estimate weightedaverage cost capital company profile similar pharmasset rate comparable estimate internal rate return acquisition represent rate market participant value intangible asset project cash flow sofosbuvir base key assumption estimate revenue operate profit relate project consider stage development acquisition date time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain marketing approval fda regulatory agency risk related viability potential alternative treatment future target market intangible asset relate iprd project consider indefinitelive asset completion abandonment associate effort december billion purchase iprd project sofosbuvir complete reclassify finitelived intangible asset amortize asset estimate useful life utilize straightline method goodwill million goodwill represent excess consideration transfer fair value asset acquire liability assume attributable synergy expect combine operation pharmasset operation goodwill expect deductible income tax purpose stockbase compensation expense stockbase compensation expense recognize accelerate vest employee option immediately prior acquisition report consolidated statement income follow millions year end december research development expense sell general administrative expense total stockbase compensation expense cost cost incur connection acquisition include millions year end december transaction cost investment advisory legal accounting fee bridge financing cost restructure cost total cost follow table summarize cost line item consolidate statement income cost recognize millions year end december research development expense sell general administrative expense interest expense total cost pro forma information follow unaudited pro forma information present combine result operation gilead pharmasset acquisition pharmasset complete january adjustment effect pro forma event directly attributable acquisition unaudite pro forma result reflect operating efficiency potential cost saving result consolidation operation gilead pharmasset accordingly unaudite pro forma result present informational purpose necessarily indicative actual result operation combine company acquisition occur begin period present indicative future result operation millions year end december total revenue net income attributable gilead unaudited pro forma consolidated result include nonrecurre pro forma adjustment assume acquisition occur january stock base compensation expense million incur include net income attributable gilead year end december cost million incur year end december include net income attributable gilead year end december inventory inventory summarize follow million december raw material work process finish good total recognize inventory longterm asset total amount report longterm asset comprise entirely raw material december december prior period amount reclassify conform current presentation joint venture form gilead sciences llc bristolmyers squibb bm note collaborative arrangement include consolidated financial statement hold efavirenz active pharmaceutical ingredient inventory efavirenz inventory purchase bms bms estimate net selling price efavirenz total million december billion december property plant equipment property plant equipment summarize follow million december property plant equipment net building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment construction progress subtotal accumulate depreciation amortization include relate capitalize lease equipment subtotal land total intangible asset goodwill intangible asset follow table summarize carry intangible asset million december finitelive intangible asset indefinitelive intangible asset total intangible asset finitelive intangible asset follow table summarize finitelive intangible asset millions december december gross carry accumulate gross carry accumulate amortization amortization intangible asset sofosbuvir intangible asset ranexa total fda approval commercial launch sovaldi december reclassify iprd relate sofosbuvir finitelive intangible asset amortization expense relate finitelived intangible asset include primarily cost good sell consolidated statement income total million million million december estimate future amortization expense associate finitelive intangible asset succeed fiscal year follow millions fiscal year total indefinitelive intangible asset complete acquisition total million fair value acquire asset assume liability attribute million iprd relate momelotinib consolidated balance sheet follow table summarize indefinitelive intangible asset million december indefinitelive intangible asset momelotinib cyt indefinitelive intangible asset foreign currency translation adjustment total goodwill follow table summarize change carry goodwill million balance december foreign currency translation adjustment balance december collaborative arrangement enter collaboration arrangement party development commercialization certain product party active participant operating activity collaboration expose significant risk reward depend commercial success activity collaboration arrangement assess inception reporting date determine primary beneficiary entity determine vie require consolidate party vie require consolidate entity contractual term arrangement essentially provide control entity majority voting interest assess primary beneficiary vie base power direct activity vie significantly impact vie economic performance obligation absorb loss right receive benefit vie potentially significant vie consolidate entity consolidated financial statement december material vie joint venture bms describe bristolmyers squibb company north america enter collaboration arrangement bms develop commercialize single tablet regimen contain truvada bms sustiva efavirenz united states combination approve use united states sell brand atripla bms structure collaboration joint venture operate limited liability company name bristolmyers squibb gilead sciences llc consolidate bms grant royaltyfree sublicense joint venture use respective company own technology return grant license joint venture use intellectual property result collaboration bms amend joint venture collaboration agreement allow joint venture sell atripla canada economic interest joint venture hold bms include share revenue outofpocket expense base portion net selling price atripla attributable efavirenz truvada net selling price truvada change time relative net selling price efavirenz bms respective economic interest joint venture vary annually bms share marketing sale effort start second quarter limited number activity jointly manage party long coordinate detail promotional activity united states party reduce joint promotional effort launch complera august stribild august party continue collaborate activity manufacture regulatory compliance pharmacovigilance daily operation joint venture govern primary joint committee form bms gilead responsible accounting financial reporting tax reporting manufacturing product distribution joint venture party provide respective bulk active pharmaceutical ingredient joint venture approximate market value agreement continue terminate mutual agreement party addition party terminate party participation collaboration day launch generic version party single agent product double agent product terminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination december joint venture hold efavirenz active pharmaceutical ingredient purchase bms bms estimate net selling price efavirenz market amount include inventory consolidate balance sheet december total asset hold joint venture billion consist primarily cash cash equivalent million account receivable million inventory billion total liability billion consist primarily account payable million accrue expense million december total asset hold joint venture billion consist primarily cash cash equivalent million account receivable million inventory billion total liability billion consist primarily account payable million accrue expense million asset liability amount reflect impact intercompany elimination include consolidated balance sheet consolidate joint venture legal structure joint venture limit recourse creditor general credit asset similarly asset hold joint venture settle obligation joint venture europe gilead sciences ireland unlimited company whollyowne subsidiary know gilead science limited bms enter collaboration agreement bms set forth term condition bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory party form limited liability company consolidate manufacture atripla distribution european territory efavirenz purchase bms bms estimate net selling price efavirenz european territory responsible manufacturing product distribution inventory management warehouse local subsidiary primary responsibility order fulfillment collection receivables customer relation handle sale return territory bms promote atripla general party share revenue outofpocket expense proportion net selling price component atripla truvada efavirenz start limited number activity jointly manage party long coordinate detail promotional activity region responsible accounting financial reporting tax reporting collaboration december efavirenz purchase bms bms estimate net selling price efavirenz european territory include inventory consolidate balance sheet party form limited liability company hold marketing authorization atripla europe primary responsibility regulatory activity major market country party agree independently continue use commercially reasonable effort promote atripla agreement terminate expiration lasttoexpire patent afford market exclusivity atripla component european territory addition december party terminate agreement reason termination effective calendar quarter notice termination nonterminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination event continue party decide sell atripla effective date termination date atripla withdraw country date party assume distribution atripla whichever early december party elect terminate agreement japan tobacco inc japan tobacco inc japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right agreement responsible seek regulatory approval territory require use diligent effort commercialize elvitegravir treatment hiv infection bear cost expense associate commercialization effort receive approval stribild elvitegravircontaine product fda august european commission capitalized million related milestone incur connection fda approval stribild million related milestone incur connection european commission approval milestone amortize useful patent life elvitegravir approximately year expiring agreement obligation pay royalty japan tobacco terminate productbyproduct basis patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement reason case license grant japan tobacco terminate party terminate agreement response material breach party janssen enter license collaboration agreement janssen sciences ireland janssen tibotec pharmaceutical develop commercialize fixeddose combination truvada janssen nonnucleoside reverse transcriptase inhibitor rilpivirine combination approve united states european union sell brand complera united states eviplera european union original agreement janssen grant exclusive license compleraeviplera worldwide exclude certain middle income develop world country japan amend agreement include distribution compleraeviplera rest world amend agreement expand collaboration include product contain janssen rilpivirine emtricitabine tenofovir alafenamide rftaf amend agreement janssen grant exclusive license compleraeviplera rftaf worldwide retain right distribute combination product country include mexico russia japan party restrict combine drug drug product similar component compleraeviplera rftaf responsible manufacturing compleraeviplera rftaf lead role registration distribution commercialization product country janssen distribute janssen exercise right codetail combination product country gilead sell party initial agreement price compleraeviplera expect sum price truvada price rilpivirine purchase separately cost rilpivirine purchase janssen compleraeviplera approximately market price rilpivirine specified percentage major market amendment effective enable sell party set price combine product party share revenue base ratio net selling price party component subject certain restriction adjustment gilead continue retain specify percentage janssen share revenue major market party terminate collaboration agreement respect product country product withdraw market country respect product country party materially breach agreement respect product agreement party obligation share revenue expire productbyproduct countrybycountry basis janssen patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement cause respect country sell product case janssen right sell party country product launch market few year debt credit facility financing arrangement follow table summarize carry borrowing financing arrangement million interest december type borrowing description issue date date rate convertible senior note july convertible senior note july senior unsecured april note march april senior unsecured december note december december senior unsecured december note december december senior unsecured december note december december senior unsecured december note december december senior unsecured april note march april senior unsecured april note march april senior unsecured april note march april senior unsecured february note november february senior unsecured february note november february senior unsecured february note november february credit facility fiveyear revolver january january variable total debt net current portion total longterm debt net convertible senior note july issue billion convertible senior note note billion convertible senior note note collectively note note private placement pursuant rule securities act amend note note issue par note bore annual interest rate note bear annual interest rate debt issuance cost million record longterm asset amortize interest expense contractual term note aggregate principal note sell reflect exercise initial purchaser option purchase additional note cover overallotment initial conversion rate note share principal represent initial conversion price approximately share initial conversion rate note share principal represent initial conversion price approximately share conversion rate subject customary antidilution adjustment note convert prior april follow circumstance calendar quarter commence september closing price common stock trading day consecutive period consecutive trading day end trading day precede calendar quarter great applicable conversion price applicable trading day business day period measurement period consecutive trading day trading day period trading price principal note product report sale price common stock applicable conversion rate trading day occurrence specify corporate transaction distribution certain stock right cash amount asset shareholder occurrence change control april case note holder convert note time regardless forego circumstance generally conversion holder receive cash equal less principal note conversion value note measure indenture govern relevant note conversion value exceed principal deliver option cash common stock combination cash common stock conversion value excess principal year end december note mature portion note convert year end december repay million principal balance relate note pay billion cash relate conversion spread note represent conversion value excess principal receive billion cash convertible note hedge relate note december note classify current give conversion criterion meet december give maturity date note classified current result relate unamortized discount million million december respectively classified equity component currently redeemable convertible note consolidated balance sheet note convert connection change control require provide premium form increase conversion rate subject state maximum addition event change control holder require purchase portion note purchase price equal principal plus accrue unpaid interest december ifconverte value note exceed principal amount note billion concurrent issuance note purchase convertible note hedge private transaction cost million tax deductible life note sell warrant private transaction acquire million share common stock receive net proceed million sale warrant convertible note hedge warrant intend reduce potential economic dilution future conversion note effectively increase conversion price share note share note net cost million convertible note hedge warrant transaction record stockholder equity consolidated balance sheet addition contract classify stockholder equity index common stock account derivative convertible note hedge cover subject customary antidilution adjustment million share common stock strike price initially correspond initial conversion price note subject adjustment similar applicable conversion price relate note market value share common stock time conversion note strike price applicable convertible note hedge entitle receive counterpartie transaction share common stock extent correspond election respect relate convertible note cash combination cash share common stock option excess market value common stock strike price convertible note hedge convertible note hedge terminate maturity note note remain outstanding conversion million share common stock underlie warrant subject customary antidilution adjustment warrant strike price share warrant expire share warrant expiring warrant expire warrant expire term exercisable respective expiration date market value common stock time exercise applicable warrant exceed respective strike price require net settle cash share common stock option respective counterpartie value warrant excess warrant strike price year end december exercise option settle cash warrant expire warrant relate note result pay billion settle warrant market value common stock time exercise warrant exceed strike price million share common stock underlie warrant strike price share expire tradingday period commence august end september warrant settle option cash share common stock relate contract meet applicable criterion equity classification settlement record reduction additional paidin capital consolidate balance sheet current accounting guidance bifurcated conversion option note debt instrument classified conversion option equity accrete result debt discount interest expense contractual term note follow table summarize information equity liability component note million carry value net carrying unamortized discount equity component liability component liability component december december december note note total note recognize million million million interest expense relate contractual coupon rate amortization debt discount issuance cost note effective interest rate liability component note note respectively net proceed general corporate purpose include repayment exist indebtedness repurchase share common stock april senior unsecured note march issue senior unsecured note april april note register offering aggregate principal billion april note pay interest fix annual rate debt issuance cost incur connection issuance debt total approximately million amortize interest expense contractual term april note recognize million interest expense relate contractual coupon rate amortization debt discount issuance cost april note april note redeem option time time time redemption price equal great principal note redeem sum determine independent investment banker present value remain schedule payment principal interest note redeem exclusive interest accrue date redemption discount redemption date semiannual basis treasury rate plus basis point plus case accrue unpaid interest note redeem date redemption time january redeem april note principal note redeem plus accrue unpaid interest date redemption addition event occurrence change control downgrade rating april note investment grade standard poor rating service moody investors service inc holder require purchase portion note price equal principal plus accrue unpaid interest net proceed general corporate purpose include repayment exist indebtedness repurchase share common stock december senior unsecured note december issue senior unsecured note december december december december december note december note december note december note respectively collectively december note register offer million million billion billion respectively aggregate principal billion december note pay interest fix annual rate mature december remain note mature december respectively pay interest fix annual rate respectively debt issuance cost incur connection issuance debt total approximately million amortize interest expense contractual term respective note recognize million million million interest expense relate contractual coupon rate amortization debt discount issuance cost december note outstanding december note redeem option time time time redemption price equal great principal note redeem sum determine independent investment banker present value remain schedule payment principal interest note redeem exclusive interest accrue date redemption discount redemption date semiannual basis treasury rate plus basis point case december note basis point case december note december notes plus case accrue unpaid interest note redeem date redemption time date month prior maturity date december note redeem december note principal note redeem plus accrue unpaid interest date redemption time date month prior maturity date december note redeem december note principal note redeem plus accrue unpaid interest date redemption event occurrence change control downgrade rating series outstanding december note investment grade standard poor rating service moody investors service inc remain holder series require purchase portion note series price equal aggregate principal note repurchase plus accrue unpaid interest date repurchase net proceed december notes fund acquisition pharmasset complete january note april senior unsecured note march issue senior unsecured note april april april april note april notes april note respectively collectively april note register offering total aggregate principal billion issue april note million pay interest fix annual rate april note billion pay interest fix annual rate april note billion pay interest fix annual rate debt issuance cost incur connection issuance debt total approximately million amortize interest expense contractual term respective note recognize million interest expense relate contractual coupon rate amortization debt discount issuance cost april note april note redeem option time time time redemption price equal great principal note redeem sum determine independent investment banker present value remain schedule payment principal interest note redeem exclusive interest accrue date redemption discount redemption date semiannual basis treasury rate plus basis point case april note basis point case april note basis point case april notes plus case accrue unpaid interest note redeem date redemption time date month prior maturity date april note redeem april note principal note redeem plus accrue unpaid interest date redemption time date month prior maturity date april note redeem april note principal note redeem plus accrue unpaid interest date redemption event occurrence change control downgrade rating april note investment grade standard poor rating service moody investors service inc holder require purchase portion note price equal aggregate principal note repurchase plus accrue unpaid interest date repurchase net proceed general corporate purpose include repayment exist indebtedness repurchase common stock february senior unsecured note november issue senior unsecured note february february february february notes february note february note respectively collectively february note register offer million billion billion respectively aggregate principal billion february note february note february note pay interest fix annual rate respectively debt issuance cost incur connection issuance debt total approximately million amortize interest expense contractual term respective note recognize million interest expense relate contractual coupon rate amortization debt discount issuance cost february note february note redeem option time time time redemption price equal great principal note redeem sum determine independent investment banker present value remain schedule payment principal interest note redeem exclusive interest accrue date redemption discount redemption date semiannual basis treasury rate plus basis point case february note basis point february note basis point february notes case accrue unpaid interest redeem date redemption time date month prior maturity date february note redeem february note principal note redeem plus accrue unpaid interest date redemption time date month prior maturity date february note redeem february note principal note redeem plus accrue unpaid interest date redemption event occurrence change control downgrade rating february note investment grade standard poor rating service moody investors service inc holder require purchase portion february note price equal aggregate principal note repurchase plus accrue unpaid interest date repurchase use net proceed general corporate purpose include repayment exist indebtedness repurchase common stock credit facility january conjunction acquisition pharmasset enter fiveyear billion revolve credit facility credit agreement year revolve credit agreement million shortterm revolve credit facility credit agreement shortterm revolve credit agreement billion term loan facility term loan credit agreement borrow million fiveyear revolve credit agreement million shortterm revolve credit agreement billion term loan credit agreement close acquisition fully repay outstanding debt term loan credit agreement shortterm revolve credit agreement time agreement terminate repay million fiveyear revolve credit agreement repay remain balance million outstanding fiveyear revolve credit agreement fiveyear revolve credit agreement contain customary representation warranty affirmative negative financial maintenance covenant event default loan bear interest eurodollar rate plus applicable margin base rate plus applicable margin define credit agreement reduce commitment prepay loan time premium penalty require comply certain covenant credit agreement note indenture december violation covenant fiveyear revolve credit agreement inclusive million swing line loan subfacility million letter credit subfacility fiveyear revolve credit agreement terminate amount owe agreement shall payable january contractual maturity finance obligation base contractual date aggregate maturity finance obligation subsequent december follow million maturity date total commitment contingency lease arrangement enter longterm noncancelable operating lease equipment facility lease facility foster city fremont verne palo alto rancho cucamonga san dimas california branford connecticut seattle washington dublin cork areas ireland london area united kingdom dubai united arab emirates operate lease sale marketing administrative facility europe canada south america asiapacific lease expire date lease contain option renew certain facility lease contain rent escalation clause significant rent escalation clause lease relate facility seattle washington expire year term lease provide consecutive right extend term lease contain annual percent rent escalation clause lease require pay additional amount operating expense maintenance lease corporate aircraft vary term renewal option expiration initial lease term lease expense operating lease approximately million million million aggregate noncancelable future minimum rental payment operating lease follow million total legal proceeding party legal action significant describe possible determine outcome matter reasonably estimate maximum potential exposure range possible loss litigation relate sofosbuvir january acquire pharmasset acquisition acquire sofosbuvir nucleotide analog act inhibit replication hcv december receive fda approval sofosbuvir know commercially sovaldi october receive approval fixeddose combination ledipasvir sofosbuvir know commercially harvoni patent patent application claim sofosbuvir sovaldi chemical entity metabolite fixeddose combination ledipasvir sofosbuvir harvoni party obtain right patent allegedly prevent attempt prevent commercialize sovaldi harvoni example aware patent patent application own party allege party cover use sovaldi harvoni predict ultimate outcome intellectual property claim relate sovaldi harvoni spend continue spend significant resource defend claim party successfully obtain valid enforceable patent successfully prove infringement patent sovaldi andor harvoni prevent sell sofosbuvir able obtain license patent license available commerciallyreasonable term predict ultimate outcome intellectual property claim relate sofosbuvir spend significant resource enforce defend patent range loss estimate time current legal proceeding significance sofosbuvir include arbitration hoffmanla roche ltd hoffmanla roche inc collectively roche gilead successor pharmasset party collaboration agreement roche agreement grant roche right develop psi cytidine analog prodrug treatment hcv infection collaborative research effort agreement end march roche serve arbitration pharmasset predecessor gilead pharmasset llc arbitration demand roche assert exclusive license sofosbuvir pursuant collaboration agreement sofosbuvir prodrug uridine analog allegedly prodrug psi cytidine analog roche claim exclusive right sofosbuvir exclusive license patent cover sofosbuvir infringe patent selling offer sale product contain sofosbuvir gilead gilead pharmasset llc file response roche arbitration demand april arbitration hearing hold june august arbitration panel determine roche fail establish claim rule favor result roche entitle damage relief interference proceeding litigation idenix pharmaceuticals inc february receive notice patent trademark office uspto declare interference idenix interference patent patent idenix pende patent application interference administrative proceeding uspto design determine invent subject matter claim party patent cover metabolite sofosbuvir idenix attempt patent class compound include metabolite purpose idenix interference determine invent compound entitle patent claim compound march uspto patent trial appeal board board determine idenix entitle benefit early application filing date patent application include application grant idenixs patent patent teach compound dispute board determine entitle filing date early application file patent application compound dispute senior party idenix interference january board determine pharmasset idenix invent compound dispute accordingly gilead prevail idenix interference decision board hold idenix fail prove conceive compound dispute specifically idenix fail prove idenix inventor identify structure method make use dispute compound board go conclude idenix fail work diligently make testing compound dispute relevant time period idenix appeal board decision district court district delaware december receive request uspto declare interference second idenix interference pende patent application patent patent include claim direct method treat hcv nucleoside compound similar involved idenix interference second idenix interference determine invent claim method treat hcv january board issue decision favor gilead phase second idenix interference board decide file patent application dispute method treat hcv designate gilead senior party second idenix interference invalidated patent claim idenix patent involve second idenix interference senior party presume invent dispute method treat hcv idenix fail teach use invention patent board invalidate idenix claim involve second idenix interference lack enablement board place idenix order cause require idenix explain judgment enter second idenix interference base decision board idenix interference decision second idenix interference consistent board early ruling march january idenix interference gilead declare senior party invent certain fluoro methyl nucleoside compound compound relevant method treat hcv issue second idenix interference believe idenix claim involve second idenix interference similar foreign patent claim compound metabolite use thereof invalid result file impeachment action federal court canada invalidate idenix canadian patent patent canadian patent correspond patent idenix patent application subject idenix interference idenix assert commercialization sovaldi canada infringe patent canadian patent correspond patent involve idenix interference invalid trial issue commence january file similar legal action norway oslo district court seek invalidate idenix norwegian patent correspond patent september idenix file invalidation action norwegian proceeding norwegian patent patent correspond patent march norwegian court find claim idenix norwegian patent invalid upheld validity claim challenge gilead patent april idenix appeal march decision norwegian court appeal idenixs obligation pay attorney fee stay pendency appeal appeal march decision schedule commence february january file legal action federal court australia seek invalidate idenixs australian patent correspond patent april idenix assert commercialization sovaldi australia infringe australian patent correspond patent trial issue schedule commence september sydney march european patent office epo grant idenix european patent patent correspond patent day patent grant file opposition epo seek revoke patent day idenix initiate infringement proceeding gilead united kingdom germany france allege commercialization sovaldi country infringe respective national counterparts patent united kingdom trial hold october determine issue infringement validity idenix patent december high court justice england wale court invalidate claim patent multiple ground specifically court hold patent lack novelty early file patent application teaching compound patent lack inventive step add knowledge exist time disclosure idenixs patent application insufficient teach compound claim compound activity virus like hepatitis virus court grant idenix permission appeal december judgment february german court dsseldorf hold hearing determine issue infringement idenix german patent trial date french lawsuit idenix award patent correspond patent japan china event patent issue expect challenge proceeding similar invoke country december idenix universita degli studi cagliari udsg centre national recherche scientifique luniversit montpellier sue district court district delaware allege commercialization sofosbuvir infringe patent interference exist patent patent december idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos june court massachusetts grant request transfer massachusetts litigation district court district delaware believe idenixs patent invalid infringe commercialization sofosbuvir sole right commercialize sofosbuvir district court set trial date october december resolution issue decision district court appeal party court appeal federal circuit cafc idenix acquire merck august acquisition change view lack merit claim idenix merck great resource idenix choose fund litigation high level idenix litigation merck inc august merck contact request pay royalty sale sofosbuvir obtain license patent nos coown isis pharmaceuticals inc believe merck patent invalid infringe commercialization sofosbuvir sole right commercialize sofosbuvir august file lawsuit district court northern district california seek declaratory judgment merck patent invalid infringe merck patent nos cover compound include relate sofosbuvir patent prosecution merck amend patent application attempt cover compound relate sofosbuvir apparent goal ultimately extract royalty payment sofosbuvir commercialization eliminate competition exclude market court determine merck patent valid infringe claim require obtain license pay royalty merck commercialize sofosbuvir party appeal decision district court cafc court set trial date march lawsuit litigation abbvie inc abbvie abbvie obtain patent nos abbvie patent purport cover use combination ledipasvirsofosbuvir harvoni treatment hcv gilead aware abbvie pende patent application united states country publish pende patent application direct use combination treatment hcv specifically combination ledipasvir sofosbuvir certain application file abbvie patent reason believe abbvie patent invalid accordingly december file lawsuit district court district delaware seek declaratory judgment abbvie patent invalid unenforceable relief believe abbott laboratories inc abbvie conspire eliminate competition hcv market falsely represent uspto gilead invent method treat hcv combination ledipasvirsofosbuvir february march abbvie respond lawsuit file lawsuit district court district delaware allege fixeddose combination ledipasvirsofosbuvir infringe patent lawsuit consolidate single action united states party appeal decision district court cafc abbvie patent block delayed commercialization combination product united states europe expect foreign patent block delay commercialization world court determine abbvie patent valid infringe claim require obtain license pay royalties abbvie commercialize sofosbuvir combination product litigation generic manufacturer approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug sale generic version product early patent expiration significant negative effect revenue result operation current legal proceeding significance generic manufacturer include mylan inc mylan april receive notice mylan submit anda fda request permission manufacture market generic version truvada notice mylan allege patent associate emtricitabine patent associate fixeddose combination emtricitabine tenofovir disoproxil fumarate invalid unenforceable andor infringe mylan manufacture use sale generic version truvada june file lawsuit mylan district court northern district west virginia infringement patent june receive notice mylan inc submit petition inter parte review ipr board allege patent associate tenofovir disoproxil fumarate invalid oppose mylan petition december uspto patent trial appeal board ptab issue decision deny mylan petition ipr tenofovir disoproxil fumarateassociate patent ground mylan establish reasonable likelihood success prevail challenge patent mylan request rehear basis believe ptab decision wrong apotex corp apotex june receive notice apotex submit and canadian minister health request permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate separate and request permission manufacture market generic version viread notice apotex allege patent associate truvada patent associate viread invalid unenforceable andor infringe apotex manufacture use sale generic version truvada viread august file lawsuit apotex federal court canada seek order prohibition approval ands teva pharmaceutical teva receive notice teva submit andss canadian minister health request permission manufacture market generic fixeddose combination atripla truvada viread teva file impeachment action federal court canada seek invalidation certain patent associate atripla truvada viread december court issue request order prohibit canadian minister health issuing notice compliance tevas generic version viread truvada atripla product expiry patent july teva appeal decision decision rule validity patent accordingly issue appeal minister health prohibit issue notice compliance tevas product separately court determine validity patent pende impeachment action trial impeachment action schedule september teva successful invalidating patent teva able launch generic version viread truvada atripla products canada prior expiry patents department justice investigation june receive subpoena attorney office northern district california request document relate manufacture relate quality distribution practice complera atripla truvada viread emtriva hepsera letairis cooperate government inquiry april united states department justice inform follow investigation decline intervene false claim act lawsuit file employee april employee serve amend complaint january federal district court issue order grant entirety prejudice motion dismiss amend complaint february employee serve second amend complaint dismiss second amend complaint matter party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation commitment normal course business enter firm purchase commitment primarily relate active pharmaceutical ingredient certain inventory relate item december commitment year approximately billion million million million million amount relate active pharmaceutical ingredient represent minimum purchase requirement actual payment purchase relate active pharmaceutical ingredient billion billion billion stockholder equity stock repurchase programs january board authorize threeyear billion stock repurchase program program program spend total million repurchase retire million share common stock average purchase price share million repurchase retire million share common stock average purchase price share billion repurchase retire million share common stock average purchase price share quarter complete program board director authorize new stock repurchase program program billion common stock program spend total billion repurchase retire million share common stock average purchase price share december remain authorize stock repurchase program billion spend billion repurchase million share common stock total average price use par value method accounting stock repurchase par value method common stock charge par value share involve excess cost share acquire par value allocate additional paidin capital apic base estimate average sale price issue share excess amount charge retain earning addition repurchase stock repurchase program repurchase share common stock withhold employee restrict stock award satisfy applicable tax withholding obligation follow table summarize reduction common stock apic charge retain earning result stock repurchase millions year end december reduction common stock apic charge retain earning prefer stock million share authorize preferred stock issuable series board authorize determine designation power preference right series prefer stock outstanding december right plan september terminate right plan provide distribution prefer stock purchase right dividend share common stock accumulate comprehensive income follow table summarize change accumulate oci component net tax million unrealize gain loss unrealize gain foreign currency availableforsale loss cash item security flow hedge total balance december comprehensive income loss reclassification amount reclassify accumulated comprehensive income net current period comprehensive income loss balance december comprehensive income loss reclassification amount reclassify accumulated comprehensive income net current period comprehensive income loss balance december amount reclassify gain loss cash flow hedge record product sale consolidate statement income amount reclassify unrealized gain loss availableforsale security record income expense net consolidated statement income employee benefit equity incentive plan stockholder approve adopt gilead sciences inc equity incentive plan plan plan broad base incentive plan provide grant equitybase award include stock option restrict stock unit restrict stock award performance award employee director consultant plan authorize issue maximum million share fullvalue award restrict stock restrict stock unit performance share performance unit extent settle common stock phantom share term plan plan authorize issuance total million share common stock december total million share remain available future grant plan stock option plan provide option grant designate nonqualifie incentive stock option prior january grant nonqualified incentive stock option stock option grant january nonqualified stock option plan employee stock option grant prior generally vest year stock option grant start generally vest year option exercisable period exceed contractual term year date stock option issue grant price fair market value common stock grant date stock option exercise settle common stock plan previously authorize available pool share follow table summarize activity relate information stock option plan option grant present table exercise price fair value underlie common stock grant date weight weightedaverage average remain share exercise price contractual term aggregate intrinsic thousand dollar year value millions outstanding december grant forfeit expired exercise outstanding december exercisable december expect vest net estimate forfeiture december aggregate intrinsic value represent value company close stock price trading day period excess weightedaverage exercise price multiply number option outstanding exercisable total intrinsic value option exercise billion million million weightedaverage grant date fair value stock option grant share share share december million unrecognized compensation cost relate stock option expect recognize estimate weightedaverage period year performancebase restrict stock unit plan grant psus vest achievement specify market performance goal include achieve total shareholder return compare predetermine peer group achieve revenue target actual number common share ultimately issue calculated multiplying number psus payout percentage range award generally vest committee subcommittee board determine specify market performance goal achieve fair value psu estimate date grant performance objective define grant depend term award fair value date grant determine base monte carlo valuation methodology stock price date grant addition grant psus certain employee plan vest award subject achievement specify individual performance goal typically year period fair value award equal closing price common stock grant date follow table summarize activity relate information psus weight average grantdate fair value share share thousand dollar outstanding december grant vest forfeited outstanding december weightedaverage grantdate fair value share exclude share relate grant currently grantdate fair value performance objective define weightedaverage grant date fair value psus grant share share share total fair value psus vest million million million recognize stockbased compensation expense million million million related psus december million unrecognized compensation cost relate psus expect recognize estimate weighted average period year restrict stock unit grant timebase rsus certain employee annual employee equity compensation review program new hire employee nonemployee members board rsus share awards entitle holder receive freely tradable share common stock vest award grant prior employee rsus vest ratably annual basis year date grant start january rsus vest year date grant fair value rsu equal closing price common stock grant date follow table summarize rsu activity relate information weight average grantdate fair value share share thousand dollar outstanding december grant assume vested forfeited outstanding december weightedaverage grant date fair value rsus grant share share share total fair value rsus vest million million million december million unrecognized compensation cost relate unvested rsus expect recognize weightedaverage period year employee stock purchase plan employee stock purchase plan amend international employee stock purchase plan espp employee purchase share common stock base percentage compensation subject certain limit purchase price share equal low fair market value common stock offering date purchase date espp offer twoyear lookback feature automatic reset feature provide offer period reset new lowerpriced offering offer price new offering period current offering period espp purchase settle common stock espp previously authorize available pool share million share issue espp million total million share common stock reserve issuance espp million share available issuance espp december december million unrecognized compensation cost relate espp expect recognize estimate weightedaverage period year stockbase compensation follow table summarize stockbase compensation expense include consolidated statement income million year end december cost good sell research development expense sell general administrative expense stockbase compensation expense include total cost expense income tax effect stockbase compensation expense net tax capitalize stockbased compensation cost inventory total million million million capitalize stockbased compensation cost remain inventory million december million december million december total stockbase compensation year end december include million million sga expense respectively relate acceleration unvested stock option connection acquisition pharmasset close quarter stockbase compensation recognize expense requisite service period consolidate statement income grade vest expense attribution approach unvested stock option grant prior january straightline expense attribution approach stock option grant adoption new guidance sharebase payment employee director january stockbase compensation expense relate stock option recognize adoption new guidance base award ultimately expect vest gross expense reduce estimate forfeiture guidance require forfeiture estimate time grant revise necessary subsequent period actual forfeiture differ estimate estimate forfeiture base historical experience prior adoption guidance pro forma information require disclose include forfeiture occur result guidance adopt january recognize tax benefit stockbase compensation apic incremental tax benefit realize tax attribute currently available utilize addition elect account indirect benefit stockbase compensation research tax credit extraterritorial income deduction consolidate statement income apic valuation assumption fair value option grant plan purchase espp estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility expect award life follow assumption calculate estimate fair value award year end december expect volatility stock option espp expect term year stock option espp riskfree interest rate stock option espp expect dividend yield fair value stock option grant calculate single option approach use blend historical volatility imply volatility trade option common stock determine expect volatility expect term stockbase award represent weightedaverage period award expect remain outstanding estimate weightedaverage expect term base historical cancellation historical exercise datum relate stock option contractual term vest term award riskfree interest rate base observe interest rate appropriate term stockbase award dividend yield base history expectation dividend payout defer compensation maintain retirement saving plan eligible employee defer compensation income tax purpose section internal revenue code gilead plan certain foreign subsidiary maintain define benefit plan require local regulatory requirement total matching contribution expense gilead plan define benefit plan million million million net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding period dilute net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding dilutive security outstanding period potential dilutive share common stock result assume exercise outstanding stock option psus assume exercise warrant relate convertible senior note include note note note determined treasury stock method principal note note note settle cash conversion spread relate respective note include calculation dilute net income share attributable gilead common stockholder common stock result assume settlement conversion spread note note dilutive effect average market price common stock period exceed conversion price note note warrant relate note note dilutive effect average market price common stock period exceed warrant exercise price note note note note mature result include impact period outstanding net income share calculation period show common stock result assume settlement conversion spread note note dilutive effect average market price common stock period exceed conversion price note note warrant relate note note settle result include impact period outstanding net income share calculation relate warrant dilutive effect average market price common stock period exceed warrant exercise price note note exclude stock option purchase approximately million weightedaverage share common stock outstanding million weightedaverage share million weightedaverage share computation dilute net income share attributable gilead common stockholder effect antidilutive follow table reconciliation numerator denominator calculation basic diluted net income share attributable gilead common stockholder million year end december net income attributable gilead share share calculation basic effect dilutive security stock option equivalent conversion spread relate note conversion spread relate note conversion spread relate note warrant relate note share share calculation dilute net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder dilute segment information product sale operate business segment primarily focus discovery development commercialization innovative medicine area unmet medical need product include segment majority product similar economic characteristic include nature product production process type customer distribution method regulatory environment product sale consist follow millions year end december antiviral product sovaldi atripla truvada harvoni compleraeviplera stribild viread antiviral total antiviral product product letairis ranexa ambisome zydelig total product sale follow table summarize total revenue external customer collaboration partner geographic region million product sale productrelate contract revenue attribute region base shipto location royalty nonproduct relate contract revenue attribute region base location collaboration partner year end december revenues united states europe countrie total revenue follow table summarize revenue customer individually account total revenue percentage total revenue year end december amerisourcebergen corp mckesson corp cardinal health inc longlive asset december net book value property plant equipment office computer equipment united states ireland canada billion million million respectively december net book value property plant equipment office computer equipment united states ireland canada million million million respectively income taxis provision income taxis consist follow millions year end december federal current deferred state current defer foreign current defer provision income taxis foreign pretax income billion million million cumulative unremitted foreign earning consider indefinitely reinveste foreign subsidiary taxis provide approximately billion december billion december residual tax liability amount remit approximately billion december billion december reconciliation federal statutory tax rate apply income taxis effective tax rate summarize follow year end december federal statutory rate state taxis net federal benefit foreign earning different rate research credit net unbenefitted stock compensation effective tax rate defer income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability follow million december defer tax asset net operating loss carryforward stockbase compensation reserve accrual currently deductible defer revenue depreciation relate research credit carryforward net total defer tax asset valuation allowance valuation allowance total defer tax asset defer tax liability intangible unremitted foreign earning total defer tax liability net defer tax asset valuation allowance million december december december conclude base standard set forth financial accounting standard board accounting standard codification relate income taxis likely realize benefit defer tax asset relate certain state net operating loss credit carryforward december federal net operating loss carryforward approximately million federal net operating loss carryforward start expire utilize federal tax credit carryforward approximately million start expire utilize addition state net operating loss tax credit carryforward approximately billion million respectively state net operating loss tax credit carryforward start expire utilize utilization net operating loss tax credit subject annual limitation ownership change limitation provide internal revenue code amend similar state provision annual limitation result expiration net operating loss credit utilization file federal state foreign income tax return jurisdiction unite states abroad federal income tax purpose statute limitation open onwards certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year california income tax purpose statute limitation open onwards income tax return audit federal state foreign tax authority currently examination irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position total federal state foreign unrecognized tax benefit million december million december total unrecognized tax benefit million million december respectively recognize reduce effective tax rate period recognition continue classify interest penalty relate unrecognized tax benefit income tax provision consolidate statement income accrue interest penalty relate unrecognized tax benefit million december december believe reasonably possible unrecognized tax benefit decrease approximately million month expect clarification irs tax authority uncertain tax position respect remain unrecognized tax benefit currently unable reasonable estimate period cash settlement respective tax authority follow rollforward total gross unrecognized tax benefit liability year end december million december balance beginning period tax position relate current year addition reduction tax position relate prior year addition reduction settlement lapse statute limitation balance end period subsequent event february announce board director authorize new billion fiveyear share repurchase program initiate completion program february announce initiation quarterly dividend share begin second quarter subject declaration board director quarterly dividend equivalent share annual basis select quarterly financial information unaudite follow amount million share amount quarter quarter quarter quarter total revenue gross profit product sale net income net income attributable gilead net income share attributable gilead common stockholdersbasic net income share attributable gilead common stockholdersdilute total revenue gross profit product sale net income net income attributable gilead net income share attributable gilead common stockholdersbasic net income share attributable gilead common stockholdersdilute gilead sciences inc schedule valuation qualifying account million balance additionscharged balance end beginning period expense deduction period year end december account receivable allowance sale return allowance valuation allowance defer tax asset year end december account receivable allowance sale return allowance valuation allowance defer tax asset year end december account receivable allowance sale return allowance valuation allowance defer tax asset allowance doubtful account cash discount chargeback valuation allowance defer tax asset include million million december respectively relate acquisition item change disagreement accountant account financial disclosure applicable item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness disclosure control procedure define rule securities exchange act amended exchange act control procedure company design ensure information require disclose company report file submit exchange act record process summarize report time period specify securities exchange commission rule form information accumulate communicate company management include chief executive officer chief financial officer appropriate allow timely decision require disclosure base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective december management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule exchange act internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include chief executive officer chief financial officer conduct evaluation effectiveness internal control financial reporting base criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework base evaluation conclude internal control financial reporting effective december independent register public accounting firm ernst young llp audit consolidated financial statement include annual report issue report internal control financial reporting december report audit internal control financial reporting appear change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting report independent register public accounting firm board director stockholder gilead sciences inc audit gilead sciences inc internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission framework coso criterion gilead sciences inc management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle company internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion gilead sciences inc maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states consolidated financial statement gilead sciences inc report date february express unqualified opinion thereon ernst young llp redwood city california february item information applicable iii item director executive officer corporate governance information require item concern director executive officer incorporate reference section definitive proxy statement file securities exchange commission pursuant regulation connection annual meeting stockholder proxy statement heading nominee board committee meeting executive officer section beneficial ownership reporting compliance write code ethic apply director employee include executive officer include limitation principal executive officer principal financial officer principal accounting officer controller person perform similar function code ethic available website httpwwwgileadcom investor section corporate governance change waiver code ethic disclose website intend satisfy disclosure requirement item form amendment waiver provision code ethic disclose information website item executive compensation information require item incorporate reference section proxy statement heading executive compensation compensation committee interlock insider participation compensation committee report compensation nonemployee board member item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference section proxy statement heading security ownership certain beneficial owner management security authorize issuance equity compensation plan item certain relationship relate transaction director independence information require item incorporate reference section proxy statement heading nominee certain relationship relate party transaction item principal accountant fee service information require item incorporate reference section proxy statement head principal accountant fee service item